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Abstract 
Crohn’s disease (CD) is now recognised to be due to defective host 
responses to bacteria in genetically susceptible individuals. Others in our 
research group previously found defective neutrophil recruitment, bacterial 
clearance and monocyte-derived macrophage (MDM) proinflammatory 
cytokine secretion in CD. To investigate the defective cytokine secretion, we 
performed transcriptomic analysis and identified reduced MDM optineurin 
(OPTN) expression in 10% CD patients. Here, I show that macrophages 
stimulated with E. coli, bacterial Toll-like and NOD-like receptor ligands 
upregulate OPTN, a Golgi complex protein that regulates vesicle transport. In 
vitro, Optn-/- bone marrow-derived macrophages (BMDM) stimulated with E. 
coli secrete significantly lower levels of proinflammatory TNF and IL6 
cytokines, which is normalised to wildtype levels on addition of lysosomal 
function inhibitors. In vivo, Optn-/- mice develop a more severe Citrobacter 
colitis with greater mortality, an early defective neutrophil recruitment to the 
bowel and lower levels of serum proinflammatory cytokines. The Optn-/- mice 
also demonstrated a similar phenotype of defective neutrophil recruitment 
and lower serum proinflammatory cytokines in an E. coli-induced peritonitis. 
These results indicate that the low OPTN expression originally identified in 
CD macrophages has likely contributed to an attenuated antibacterial 
response, which potentially led to the development of bowel inflammation. 
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• siRNA  small interfering RNA 
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• TACE  Tumour necrosis factor-α converting enzyme 
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Chapter 1 Introduction  
Idiopathic inflammatory bowel disease (IBD) is a chronic relapsing systemic 
inflammatory disorder, primarily affecting the gastrointestinal tract (GI) but is 
associated with extraintestinal manifestations as well as other inflammatory 
diseases [1]. IBD consists of two predominant phenotypes, Crohn’s disease 
(CD) and ulcerative colitis (UC), which are differentiated by their distinct 
inflammatory pattern and distribution of disease [2]. 
1.1 Diagnosis and natural history of inflammatory bowel disease 
The diagnosis of CD or UC in patients with symptoms of bowel disease is 
dependent on the clinical history, disease presentation on endoscopy and 
imaging as well as biopsy histology. Crohn’s disease presents with 
transmural inflammation of the GI mucosa that can affect the entire GI tract 
from the mouth to the anus [3] (Figure 1.1). By contrast, ulcerative colitis 
presents with superficial to deep ulceration and inflammation of the GI 
mucosa that affects only the colon to varying extents from the distal rectum 
to the proximal caecum [4].  
1.1.1 Natural history of Crohn’s disease 
CD most commonly presents with patchy discontinuous inflammatory skip 
lesions that affects the terminal ileum only (45% patients), colon (32%) or 
ileum and colon i.e. ileocolonic (19%) (Figure 1.1) [5]. The majority of 
patients are diagnosed between the ages of 17 to 40 (56%), with a smaller 
percentage diagnosed above 40 (32%) and below 17 years of age (11%). In 
the majority of CD patients (81%), the mucosal disease is purely 
inflammatory, with a minority having more severe stricturing (5%) or 
penetrating/fistulating disease (19%) [3].  
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Endoscopically, the inflamed CD bowel presents on a spectrum from small 
discrete aphthous ulcers, patchy well demarcated skip lesions to deep 
serpiginous and linear cobblestone ulcers (Figure 1.1). One of the hallmarks 
of CD is the finding of granulomas on bowel biopsy, which are collections of 
macrophages and lymphocytes.  
The clinical presentation is largely dependent on disease location and 
behaviour, which may include symptoms of diarrhoea, abdominal pain, 
vomiting, bowel obstruction, weight loss, haematochezia and mucochezia. 
Whilst the anatomical location affected by CD remains relatively 
unchanged [6], the behaviour of the disease can change substantially with 
time. Three months after diagnosis, almost a fifth (19%) of patients and at 20 
years, more than half (51%) developed a more aggressively behaving 
disease [5]. In a different cohort, over a 10 year period, 27% of patients with 
purely inflammatory CD developed stricturing disease whilst 29% developed 
penetrating disease over a median of 6 years [7].  
After the first year, only 55–65% achieve remission, 15–25% continue 
with low levels of disease activity whilst the remaining 10–30% develop a 
further exacerbation. In the long term, only 10–13% remain in remission for 
several years, 13–20% continue to have active disease whilst the vast 
majority, 67–73% have a chronic intermittent disease course [8].  
The life expectancy of CD patients today is no different from the general 
population. This is in contrast to older studies and is likely due to improved 
treatment options available now [9, 10]. 
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Figure 1.1 The various manifestations of Crohn’s disease. (a) Burrill B. 
Crohn who presented a case series of patients with terminal ileitis, whom the 
disease has been named after, (b) resection specimen of the terminal ileum 
showing cobblestoning and ulceration of the mucosa, (c) endoscopic view of 
patchy ulcerated mucosa, (d) barium follow through of the small bowel 
showing stricturing of the terminal ileum (arrow), (e) H&E stain showing 
transmural inflammation and a non-caseating granuloma in CD, (f) drugs 
used in the treatment of Crohn’s disease, clockwise from top left 
corticosteroids, adalimumab anti-TNF, mesalazine, azathioprine, (g) Montreal 
classification of Crohn’s disease, (h) pictorial representation of location and 
behaviour of Crohn’s disease, (i) extraintestinal manifestations of Crohn’s 
disease, namely uveitis, (j) pyoderma gangrenosum, (k) magnetic resonance 
image of sacroiliac joints showing sacroiliitis (arrows) and (l) oral Crohn’s 
disease (See Image references). 
 
1.1.2 Natural history of ulcerative colitis 
By contrast, UC presents with inflammation in the distal rectum that 
extends continuously to varying extents to involve just the rectum (proctitis, 
32% patients), rectum, sigmoid and descending colon (left-sided colitis, 31%) 
or the whole colon including the transverse, ascending colon and caecum 
(pancolitis, 31%) [11, 12]. The clinical presentation in UC is largely 
dependent on the extent and severity of the disease, with symptoms and 
signs of bloody diarrhoea, abdominal cramps, weight loss, passage of pus 
and mucus, proximal constipation, toxic megacolon and bowel perforation in 
the extreme. Most patients present with mild (no signs of systemic toxicity 
and up to 4 bloody stools daily, 51% patients) and moderate UC (more than 
4 bloody stools daily, 40%). Only a minority present with severe UC (signs of 
systemic toxicity and more than 6 bloody stools daily, 9%) [11]. 
Endoscopically, the bowel in UC presents on a spectrum from mild 
erythema, oedema and loss of vascular markings, mucosal granularity, 
friability and spontaneous bleeding, erosions to large ulcers. Histologically, in 
contrast to CD, there is marked involvement of the mucosal crypts with 
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visible crypt architectural distortion, cryptitis and crypt abscesses in the UC 
mucosa but no granulomas, suggesting a different aetiology.  
The natural history of UC over 10 years is good, with the majority of 
patients (55%) achieving remission, 37% having intermittent exacerbations 
and only 6% developing chronic continuous symptoms [13]. One fifth of 
patients with proctitis or left-sided colitis at diagnosis progressed to pancolitis 
over a 10-year period. Conversely, the probability of regression of the 
pancolitis over 25 years was calculated to be 75% in another study [14]. The 
overall colectomy rate in UC over 10 years was 9.8% and overall mortality 
risk was not increased compared to the general population.  
1.2 Epidemiology and burden of inflammatory bowel disease 
1.2.1 Healthcare cost of inflammatory bowel disease 
The natural history of CD and UC highlight the potential impact of these two 
inflammatory diseases on the population. It inflicts a chronic recurrent 
debilitating illness on a relatively young population affecting physical growth 
and education in children [15], work productivity and fertility in adults [16] and 
mortality in the elderly [17]. The healthcare cost of IBD was calculated to be 
£500 million in 2000 and £720 million per year in 2006 for the UK National 
Health Service, C$753 million in 2008 and C$1.2 billion per year in 2012 in 
Canada, €4.6 to 5.6 billion per year in 2012 in Europe and US$1.4 billion in 
1990 and US$6.3 billion in 2008 in USA [18-22]. The total economic burden 
for CD and UC is estimated to be US$10.9-15.5 billion and US$3.4-8.6 billion 
in USA and €2.1-16.7 billion and €5.4-12.6 billion in Europe [23, 24]. 
 The trend of rising healthcare and total costs is made worse by the 
increasing incidence of IBD with time and also geographical location [25, 26]. 
The highest annual incidence for CD was 12.7, 5.0 and 20.2 per 100,000 
person-years and for UC was 24.3, 6.3 and 19.2 per 100,000 person-years in 
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Europe, Asia and North America respectively. The prevalence for CD was 
322 and 319 per 100,000 persons and for UC was 505 and 249 per 100,000 
persons in Europe and North America. 75% and 60% of CD and UC 
epidemiological studies identified a rising disease incidence with an average 
annual percentage rise of 1.2% to 23.3% in CD and 2.4% to 18.2% in UC. By 
contrast, no CD and only 6% of UC studies showed decreasing incidence 
[26].   
1.2.2 Rising incidence and prevalence of IBD 
 CD and UC was traditionally a disease of the western developed 
world. However, with globalisation and westernisation of lifestyle, IBD is 
rising in Asia [27].  In developing countries where CD and UC were 
previously rarely reported, IBD has also emerged. IBD in Asia and these 
developing countries seems to be following a similar pattern of progression in 
developed countries in the 20th century with an initial rise in UC incidence 
that stabilises followed by a rise in CD incidence 15 to 20 years later [26-28].  
By example, in Asia the prevalence of CD in Japan has risen from 2.9 
to 13.5 per 100,000 persons over 12 years and from 1.3 to 7.2 per 100,000 
persons over 14 years in Singapore. The prevalence of UC has quadrupled 
from 7.6 to 30.9 per 100,000 over 8 years in South Korea, tripled from 2.3 to 
6.3 per 100,000 over 9 years in Hong Kong and quadrupled over 10 years in 
China. Due to its recent emergence in developing countries, currently there is 
little time lapse data to confirm this trend. Incidence and prevalence is still 
low relative to developed Western countries. The prevalence of CD and UC 
was 1.2 and 5.3 per 100,000 persons in 2008 in Sri Lanka, 16.7 and 44.3 per 
100,000 persons in 2004 in Barbados and 15 and 76 per 100,000 persons in 
2009 in Argentina [29-31].  
The prevalence of UC was 3.7 in Malays, 11.2 in Chinese and 17.9 in 
Indians per 100,000 persons in Malaysia and 44.3 per 100,000 persons in 
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India [32, 33]. The disparity in prevalence amongst different ethnic groups in 
a single location and of a single ethnic group i.e. Indians in different locations 
reflects the contribution of genetic susceptibility and the environment to the 
development and prevalence of disease. Unfortunately, genetic data from 
patients in developing countries is not currently available. 
1.3 Environmental effects on IBD 
1.3.1 Smoking 
To date, the strongest associated environmental factor in IBD is 
smoking. In Caucasians, smoking is detrimental in CD and protective in UC, 
increasing the risk of CD (OR 1.76) and decreasing the risk of UC (0.58) [34]. 
However, the increased risk of CD with smoking has not been reproduced in 
Israeli Jews and the Chinese although the protective effect of smoking has 
been reproduced in the Japanese. It is postulated that smoking may not 
cause but modulate disease via immunosuppressive effects on immune cells 
such as macrophages and T cells, further strengthening the case for a 
macrophage defect in IBD immunopathogenesis [35].  
1.3.2 Diet 
The association of diet and IBD has been around since the time of 
Bonnie Prince Charlie (1720-1788), who likely suffered from ulcerative colitis. 
He treated himself by adopting a milk free diet in 1745 [36]. More recently 
two meta-analyses looking at dietary intake and IBD identified a higher risk of 
CD and UC with high fat and meat intake, whilst a high intake of fruit and 
fibre was protective for CD and a high vegetable intake was protective for UC 
[37, 38]. It is unclear how these dietary antigens may increase the risk of 
disease or be protective but may alter the expression of transcription factors 
that regulate inflammation, affect mediators of inflammation such as short 
chain fatty acids or alter the gut microflora [38]. Additionally, whilst these 
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results may be important in the development of disease, the effect of diet on 
disease progression is not clear. 
The role of probiotics and prebiotics in modulating the gut microflora in 
IBD is discussed below. It is well accepted that enteral nutrition can be used 
as first-line therapy in children with CD to induce remission, which adds to 
the argument that dietary content can influence the mucosal inflammatory 
process [39-42]. Although enteral therapy is widely used in children, its 
mechanism of action is not known and in adults there is limited efficacy [43]. 
It has always been argued that the lack of effect in adults is due to poorer 
compliance with an exclusive enteral therapy regimen but this difference in 
effect may be due to differences in the inflammatory process in adults vs 
children, although this has not been conclusively shown. 
1.4 Treatment of inflammatory bowel disease 
The rise in healthcare costs of IBD is in part due to the rising cost of drug 
treatment and the availability of endoscopic as well as surgical therapies. 
Endoscopy does not just have a role in diagnosis of the disease but in the 
monitoring of remission, surveillance of cancer, diagnosis of disease 
exacerbations and treatment of strictures. Surgery has a role not just when 
drug treatment has failed and bowel resection is required but also in the 
treatment of fistulae and insertion of feeding lines. However, the mainstay of 
IBD treatment is with drug therapy to modulate inflammation (Figure 1.1). 
1.4.1 5-Aminosalicylates 
 5-Aminosalicylates (5-ASA) in the form of sulphasalazine were first 
used in the early 1950s and forms the mainstay of treatment in induction and 
maintenance of remission in mild to moderate UC. Its exact mechanism of 
action is unknown but it is thought to exert a topical effect on the bowel via a 
combination of inhibition of cytokine, prostaglandin and leukotriene synthesis, 
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inhibition of leukocyte adhesion and function, macrophage chemotaxis [44] 
and prevention of clonal expansion of T and B cells. Many formulations of 
mesalazine exist with long acting single dose varieties as well as topical 
enemas and suppositories for distal proctitis. There is less evidence for the 
use of 5-ASA in CD except in ileal and right sided colonic disease [45].  
1.4.2 Corticosteroids 
 Corticosteroids form the main acute therapeutic option in a flare of UC 
or CD and was first used in the 1950s to treat UC and reduced mortality from 
24% to 7% [46]. Steroids function by switching off proinflammatory genes 
that encode cytokines, chemokines and adhesions molecules via NF-κB and 
switching on anti-inflammatory genes. In UC, steroids will successfully induce 
a remission in up to 70% patients. Steroids are twice as effective in inducing 
remission in CD compared to placebo and more than one and half times 
more effective than 5-ASA [47]. 
1.4.3 Thiopurine analogues 
 The main drug treatment to maintain remission in moderate to severe 
UC and CD are the thiopurine analogues azathioprine (AZA) and 6-
mercaptopurine (6-MP). The thiopurine analogues are generally used as 
steroid-sparing agents in maintaining the remission achieved by steroids and 
ciclosporin thereby preventing the long term complications associated with 
steroid and ciclosporin toxicity. They act as purine antimetabolites that are 
falsely incorporated into dividing immune cells, hence has a slow mode of 
action taking months to be efficacious. They have been shown to reduce the 
number of lamina propria plasma cells and impair intracellular replication of 
E. coli in macrophages [48]. 
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1.4.4 Anti-TNF therapy 
 The newest class of drugs in IBD are the biologics that target specific 
cytokines, receptors or molecules with antibodies. The most widely used 
biologics in CD are the anti-TNF antibodies infliximab and adalimumab. The 
exact mechanism of action of anti-TNFs in CD is unknown but may be 
through direct blockade of TNF or the induction of apoptosis in immune cells 
[49-52]. It is important to note that although anti-TNF therapy is efficacious in 
the setting of chronic CD inflammation there have been reports of new onset 
CD during anti-TNF therapy for ankylosing spondylitis and juvenile arthritis 
[53-61]. As such, whilst anti-TNFs may have a therapeutic role in the chronic 
inflammation of CD in inducing apoptosis of immune cells that perpetuate the 
inflammation [62], in the acute setting, TNF may be important in bacterial 
clearance in the bowel and its blockade then results in CD.  
1.5 Pathogenesis of Crohn’s disease 
The earliest description of Crohn’s disease was by the anatomical pathologist 
Giovanni Battista Morgagni who described an eroded and ulcerated ileum in 
1769 in De sedibus et causis morborum per anatomen indagatis or ‘Of the 
seats and causes of disease investigated through anatomy’ [63, 64]. 
However, the most widely quoted description that gave name to the disease 
was in 1932 by Burrill Crohn (Figure 1.1), together with Leon Ginzburg and 
Gordon Oppenheimer, who presented a case series of patients with terminal 
ileitis to the Gastroenterological and Pathology section of the American 
Medical Association meeting in New Orleans [65, 66]. 
1.5.1 Infectious aetiology 
Although the disease was first described more than 200 years ago, the 
cause of Crohn’s disease is still not known [67]. There have been many 
proposed theories of causation including bacterial and viral agents, diet, poor 
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nutrition, imbalances in gut microflora, dysfunctional mucosal barrier, 
allergies, autoimmunity or immunodeficiency. Whilst there is evidence to 
support each theory there is no overwhelmingly proven hypothesis identifying 
a single cause of CD. It is likely that the cause of CD is complex and that as 
a syndrome, the collective signs and symptoms of CD may be the 
manifestation of multiple different defective processes resulting in a common 
expression of dysfunctional physiology that is the phenotype of CD. It is 
therefore plausible that different factors may play a role in different patients 
but result in the same phenotype of CD. 
CD commonly affects the terminal ileum. This area of the bowel 
constitutes the area with the largest change in the number of intraluminal 
bacteria from the relatively sterile proximal small bowel (104 bacteria) to the 
colon (1012 bacteria) [68]. Antibiotics have had a beneficial role in the 
induction and maintenance of remission in CD albeit to only a limited extent 
further supporting a role for intraluminal bacteria in the pathogenesis and 
maintenance of inflammation in CD [69]. Additionally, diversion of the faecal 
stream results in improvement of CD inflammation [70], which all point to a 
role for bacteria in the aetiopathogenesis of CD. 
An association between Mycobacterium avium subspecies 
paratuberculosis (MAP) and CD was made in the early 20th century by Dr T. 
K. Dalziel who noted the similarity between bovine Johne’s disease caused 
by MAP and human CD although no visible mycobacterium were seen in CD 
tissue unlike in cattle [71]. Unfortunately, the causal association remains 
controversial and is unsupported due to clinicopathological differences 
between Johne’s disease and CD [72], the inability to find MAP in bowel 
biopsies and in CD granulomas [73], and the lack of difference between 
relapse rates in MAP treated vs. placebo treated CD patients [74]. 
By contrast, stronger evidence is available for the role of adherent 
invasive E. coli (AIEC) in CD. The most convincing evidence for this is the 
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discovery of AIEC in 21.7% of CD chronic inflamed ileum versus only 6.2% in 
controls [75]. The invasion of AIEC is with its type 1 pili [76] that bind and 
invade the mucosal epithelium via CEACAM6, a carcinoembryonic antigen 
upregulated by proinflammatory cytokines and AIEC itself [77, 78] or via long 
polar fimbriae binding to M cells and invasion into Peyer’s patches [79]. AIEC 
was also able to survive in macrophages and initiate inflammation [80]. 
Additionally, E. coli DNA has been found on PCR from microdissected CD 
granulomas [81]. 
1.5.2 Dysbiosis 
Recently the focus has been on the changes in diversity of the bowel 
microflora that may be associated with CD causation [82]. Dysbiosis of the 
gut microflora has become a major focus of investigation in an attempt to 
identify qualitative and quantitative changes in gut microflora diversity, 
metabolic activity and distribution [83].  These findings identified a reduced 
complexity in the Fermicute phylum in CD patients [84, 85]. Twins with CD 
were found to have microbial compositions that were different from healthy 
controls (HC) and were different depending on whether the ileum or colon 
was affected by CD [86]. Additionally, a reduction in the abundance of 
Faecalibacterium prausnitzii was associated with a higher risk of post-
operative recurrence of ileal CD and was anti-inflammatory in mouse models 
of colitis [87]. Of note there is evidence that diet can modify the gut 
microflora, which may be the mechanism by which diet modifies the risk of 
developing CD [88].  
1.6 Genetic factors in Crohn’s disease 
Whilst the rising incidence of CD points to an environmental factor in 
causation, family and racial aggregation of CD points to a genetic 
contribution to aetiology. In first-degree relatives, the age-adjusted relative 
risk of developing the same type of IBD is 5 to 10 in CD and 2 to 8 for UC 
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[89-91].  IBD concordance rates in monozygotic twins was 20% to 50% for 
CD and 14% to 19% in UC but less than 7% in dizygotic twins for both CD 
and UC [92-96]. Finally, Jews have a two-fold increase risk of developing CD 
if they have affected family members compared to non-Jews [91]. 
The investigation into the genetic causation of CD has seen an 
unprecedented explosion in discovery over the past decade, beginning with 
the discovery of an association with CARD15/NOD2 [97, 98] till the more 
recent discoveries of genome wide association studies (GWAS) that has 
identified single nucleotide polymorphisms (SNP) within 163 different gene 
susceptibility loci [99-102].  
1.6.1 NOD2 
Nucleotide-binding oligomerisation domain-containing protein 2 (NOD2) was 
the first gene to be associated with CD and to date confers the greatest risk 
of developing CD. Using positional cloning and candidate gene approaches, 
two groups identified NOD2 as a susceptibility gene in CD [97, 98]. NOD2 is 
a cytosolic receptor protein that recognises the ubiquitous bacterial 
peptidoglycan muramyl dipeptide (MDP), a pathogen associated molecular 
pattern. Unlike NOD1, NOD2 expression is more restricted to haematopoietic 
cells such as myeloid and lymphoid cells, as well as intestinal epithelium 
[103] and Paneth cells [104]. Expression of NOD2 is upregulated on 
exposure to lipopolysaccharide (LPS), tumour necrosis factor α (TNF) and 
interferon γ (IFNγ).  
 The NOD2 protein has a leucine-rich repeat (LRR) region that senses 
MDP, which results in oligomerisation at the central nucleotide-binding 
domain (NBD) and interaction of its multiple caspase-recruitment domains 
(CARD) with downstream adaptors such as receptor-interacting protein-2 
(RIP2) [105]. This results in downstream nuclear factor-κB (NF-κB) and 
mitogen-activated protein kinase (MAPK) dependent gene transcription. Of 
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note, only loss of function variants in NOD2 are associated with CD, whilst 
gain of function variants in NOD2 are associated with Blau syndrome, a 
granulomatous disease with arthritis, uveitis and dermatitis. The three NOD2 
loss of function variants associated with CD are 2104C>T/Arg702Trp (SNP8, 
in exon 4), 2722G>C/Gly908Arg (SNP12, in exon 8) and 
3020insC/Leu1007fsinsC (SNP13, in exon 11. All three CD variants result in 
loss of function and impaired induction of pro-inflammatory cytokines [106-
109]. Individuals who are heterozygous for one of the variants have a two to 
four fold risk of developing CD, whilst individuals who are homozygous or 
compound heterozygous have a 20 to 40 fold risk [110].  
 Despite this, the overall effect of NOD2 variants on inflammation and 
CD remains controversial. It is unclear if the NOD2 variants act via intestinal 
Paneth cells or myeloid cells or what the mechanism of action that results in 
increased CD risk is. NOD2 variants have been shown to regulate Toll-like 
receptor 2-mediated T helper type 1 responses, transcription of IL10 and 
expression of α-defensins [111-114]. Additionally, NOD2 variants are 
associated with increased ileal permeability, ileal only CD, penetrating and 
stenosing disease and acts as a marker of severity and need for surgery 
[115-117]. Whilst NOD2 confers the highest heritable risk of developing CD, 
the allele frequency in the healthy Caucasian population for SNP8, SNP12 
and SNP13 are 4.3%, 1.2% and 2.3% implying that NOD2 alone may not be 
sufficient to result in CD but interacts with other as yet unknown risk factors 
[118]. Finally, whilst NOD2 increases the risk of developing CD, it is 
protective in UC, indicating that CD and UC may be pathophysiologically 
different [100]. 
1.6.2 ATG16L1 
A nonsynonymous SNP resulting in a threonine to alanine substitution 
(1338A>G/Thr300Ala) in the autophagy-related 16-like 1 (ATG16L1) gene 
was also identified on GWAS to be associated with CD [102, 119]. The 
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1338A/A homozygous genotype of the risk allele has been reported to confer 
a 1.65-fold risk of developing CD, with a 2.2-fold risk of ileal disease [120]. 
However, similar to NOD2, the ATG16L1 disease conferring allele frequency 
in the healthy Caucasian population is 50.4% vs. 58.1% in the CD cohort, 
indicating that the ATG16L1 disease conferring allele is not sufficient to result 
in CD alone [121]. 
 Autophagy, or simply self-eating, is the term used to describe the 
intracellular processes that degrade and recycle unwanted macromolecules, 
organelles and cellular components via lysosomes. There are at least three 
main types of autophagy, microautophagy, macroautophagy and chaperone-
mediated autophagy [122]. Microautophagy is the uptake and degradation of 
cytoplasm by invagination of the lysosome, whilst chaperone-mediated 
autophagy is the import and degradation of cytosolic proteins by chaperones 
that are directly translocated across the lysosomal membrane independent of 
autophagosome [123]. Macroautophagy, commonly referred to as just 
autophagy is the sequestration of cytoplasm into double or multiple-
membrane autophagosomes and its subsequent degradation by lysosomes. 
A specific subtype of autophagy is xenophagy, which is the selective 
degradation of microbes through an autophagy related mechanism.  
Macroautophagy, here on just referred to as autophagy involves the 
initiation, elongation, completion steps of the double membrane 
autophagosome, then fusion and cargo degradation with lysosomes. After 
induction of autophagy, the ULK1 complex (ULK1-ATG13-FIP200-ATG101) 
in the endoplasmic reticulum recruits phosphatidylinositol-3-OH kinase 
(PI(3)K) complex, which forms phosphatidylinositol-3-phosphate that recruits 
double membrane vesicles containing ATG18, ATG12-ATG5-ATG16L1 and 
LC3 (Figure 1.2). The induction of starvation autophagy results in the 
inclusion of organelles and macromolecules for recycling. By contrast, LC3 
present on the double membrane autophagosome can bind adaptor 
molecules such as p62, neighbour of BRCA1 gene 1 (NBR1), nuclear dot 
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protein 52 (NDP52) and optineurin (OPTN) carrying cargo such as 
ubiquitinated bacteria in selective autophagy (Figure 1.3) [124, 125].  
Completion of the autophagosome occurs, which then fuses with lysosomes 
to form autophagolysosomes where contents are degraded. Autophagy is 
likely to have evolved as a response to nutrient starvation and allows 
unicellular organism to recycle damaged organelles and misfolded proteins, 
hence is upregulated upon starvation, endoplasmic reticulum (ER) stress and 
also infection [122, 123]. 
 
Figure 1.2 Induction of starvation autophagy. Induction of starvation 
autophagy results in the inclusion of organelles and macromolecules from 
the cytoplasm for degradation in double membrane autophagosomes. 
 
Whilst autophagy was initially discovered in yeast cells as a response 
to starvation, autophagy has been linked to phagocytosis and bacterial 
handling. Particles that stimulate Toll-like receptors (TLR) whilst it is 
phagocytosed by murine macrophages recruit LC3 to the phagosome, which 
was associated with enhanced killing of phagocytosed microbes [126]. The 
discovery of an association between ATG16L1 and CD identifies autophagy 
as a process that may be defective in CD but the exact mechanism by which 
ATG16L1 increases the risk of CD remains unanswered. Human intestinal 
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cells with the T300A variant or that had ATG16L1 knocked down were found 
to have impaired autophagy of internalized Salmonella within 
autophagosomes [102, 127], while ATG16L1 deficient murine macrophages 
stimulated with LPS were found to secrete high levels of the inflammasome 
associated pro-inflammatory cytokines IL1β and IL18 [128]. ATG16L1 
hypomorphic mice were found to exhibit abnormalities in the granule 
exocytosis pathways in Paneth cells, which secrete antimicrobial peptides 
into the intestine, findings that were replicated in humans carrying the T300A 
variant [129]. However, the findings in the mice were later found to be 
associated with coinfection with murine norovirus [130].  
 
Figure 1.3 Selective autophagy and the role of adaptors in bringing cargo to 
autophagosomes. OPTN, optineurin; Ub, ubiquitin; p62/SQSTM1, protein 
62/sequestosome1; NDP52, nuclear dot protein 52.   
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More recently, an association between NOD2 and ATG16L1 has been 
found. NOD2 stimulation by MDP induced autophagy in dendritic cells and 
was required for MHC Class II CD4+ T cell responses whilst NOD2 
stimulation in peripheral blood mononuclear cells from humans with the 
ATG16L1 T300A variant produced more inflammasome associated IL1β 
[131, 132].   
1.6.3 The missing heritability in CD 
GWAS are powered with large numbers of healthy versus affected 
individuals to identify disease susceptibility genes using the hypothesis that 
common complex diseases are due to relatively few common variants of 
small effect [133]. However, as discussed above, the collective signs and 
symptoms that make up the phenotypic syndrome of CD may be the result of 
multiple different rare variant-causing pathophysiological pathways. Given 
the GWAS limitation and the heterogeneity of the phenotype of CD it is 
therefore not surprising that the GWAS CD associated variants is calculated 
to account for only 23% of the total CD heritability and the recent discussion 
of the missing heritability unaccounted for in GWAS of complex diseases [99, 
134]. 
1.7 Innate immunity in the gastrointestinal tract 
Acute inflammation is the bodies’ immediate reaction to trauma or infection 
and involves the classic signs of calor, dolor, rubor, tumor and functio laesa 
i.e. heat, pain, redness, swelling and loss of function first described by 
Celsus in De Medicina in the 1st century BC [135]. This acute inflammatory 
response is mediated by ‘wandering cells’ first identified by the Nobel 
laureate and Father of Cellular Innate Immunity, Elie Metchnikoff who had 
observed phagocytic cells in starfish larvae [136]. These phagocytes would 
later make up cells of the innate immune system consisting monocytes and 
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macrophages of the mononuclear phagocyte system as well as 
polymorphonuclear leukocytes or neutrophils. 
1.7.1 Macrophages and neutrophils in gut mucosa 
When bacteria breach our mucosal barrier they come into contact with 
tissue-resident macrophages, which are sentinels positioned and 
programmed to detect and deal with invading organisms [137]. Macrophages 
are specialised cells that are equipped with a wide range of pattern 
recognition receptors (PRR) that detect microbes. These PRR include the 
TLR that recognise pathogen associated molecular patterns (PAMP), which 
were discovered by Jules Hoffmann in fruit flies and Bruce Beutler in human 
macrophages, who were jointly awarded the Nobel Prize in 2011 [138, 139]. 
The Nod-like receptor NOD2 recognises muramyl dipeptide (MDP) as 
discussed earlier whilst the TLR recognise other PAMP such as the 
lipopeptide Pam3CSK4 by TLR2, double-stranded RNA by TLR3, 
lipopolysaccharide (LPS) by TLR4, flagellin by TLR5, single-stranded RNA 
by TLR7 and single-stranded DNA by TLR9 (Figure 1.4) [140].  
The TLR are divided into two groups, TLR 2, 4 and 5 that are 
expressed on the cell surface and recognise mainly bacterial PAMP and TLR 
3, 7 and 9 that are expressed on intracellular vesicles and mainly recognise 
microbial nucleic acids. The TLR are type 1 transmembrane proteins with an 
extracellular/intravesicular LRR domain that recognises PAMP, a 
transmembrane domain and an intracellular Toll-interleukin 1 receptor (TIR) 
domain for downstream signalling. Signalling of TLR occur via the TIR 
domain-containing adaptor molecules MyD88 and TIRAP down the MyD88-
dependent pathway or via TRAM and TRIF, down the MyD88-independent 
pathway. For example, TLR4 in complex with MD2 binds LPS and recruits 
the adaptors TIRAP and MyD88, which activates a MyD88-dependent early 
NF-κB mediated inflammatory cytokine pathway. The internalised TLR4-
MD2-LPS complex can then recruit TRAM and TRIF that activates the 
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IRF3/TRIF-dependent type I interferon pathway as well as a TRIF-dependent 
late NF-κB inflammatory cytokine pathway. In contrast to TLR4, TLR2, 5, 7 
and 9 only activates the MyD88-dependent inflammatory cytokine pathway 
and TLR3 the TRIF pathway. 
 
Figure 1.4 TLR and NLR activation by PAMP in macrophages. Activation of 
the NF-κB and IRF-3 pathway results in induction of pro-inflammatory 
cytokine gene transcription. 
 
NF-κB activation is rapid and results in the transcription of 
proinflammatory cytokines, chemokines and adhesion molecules whilst type I 
interferon responses are aimed at limiting the spread of infectious agents 
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such as intracellular viruses, promoting antigen presentation and activating 
the adaptive immune system [141]. The resulting TLR activation of 
macrophages by bacterial PAMP is the release of proinflammatory cytokines 
such as TNF and chemokines such as CXCL1 that mediate acute 
inflammation and the recruitment of neutrophils. Blood flow to the site of 
infection increases and TNF results in increased expression of cellular 
adhesion molecules on endothelial cells. Initial capture and rolling adhesion 
is facilitated by transitory adhesion between selectins on neutrophils and 
endothelial cells, which is then reinforced by tighter adhesion between 
integrins CD11a/lymphocyte function-associated antigen-1 (LFA-1), 
CD11b/macrophage antigen 1 (Mac-1) and LPAM-1 (integrin α4β7) with 
intercellular cell adhesion molecule-1 (ICAM-1), vascular cell adhesion 
molecule-1 (VCAM-1) and mucosal vascular addressin cell adhesion 
molecule-1 (MAdCAM-1). Transmigration through the endothelium then 
occurs through the interaction of platelet-endothelial cell adhesion molecules 
(PECAM) on neutrophils and endothelial cells [142].  
Neutrophils are recruited to sites of infection within minutes and 
response peaks at 24 to 48 hours [143]. Neutrophils are the army of first 
responders that are efficient phagocytes at killing microbes using the NADPH 
oxidative burst as well as its arsenal of antimicrobial peptides such as 
myeloperoxidase, Cathepsin G, elastase and defensins [144, 145]. It has 
been shown that neutrophil depletion worsens the colitis in a DSS, TNBS and 
T cell transfer model of colitis, reinforcing the importance of neutrophils in the 
containment of infection and prevention of subsequent intestinal inflammation 
[146-148]. Additionally, mice lacking the neutrophil chemokine CXCL1 are 
more susceptible to a DSS colitis [149]. Finally, as discussed above, patients 
with monogenic deficiencies of neutrophil function commonly manifest 
intestinal inflammation that is similar to CD. 
Tissue resident neutrophils have a short lifespan of a few days, 
undergo apoptosis and are cleared by macrophages to allow for resolution of 
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inflammation and wound healing. Indeed, the depletion of intestinal 
mononuclear phagocytes alone in contrast to depletion of neutrophils and 
mononuclear phagocytes has been shown to worsen a DSS induced colitis, 
suggesting that mononuclear cells have a role in the resolution of neutrophil-
led inflammation [150]. Finally, it is important to note that the origin of tissue 
resident macrophages remains controversial. It was widely accepted for a 
long time that all tissue resident macrophages originated from peripheral 
blood monocytes [151]. However, more recent fate mapping studies in mice 
show that resident macrophages in the liver, lung, spleen and peritoneum are 
established from the primitive yolk sac prior to birth and subsequently 
maintain themselves independent of blood monocytes [152], whilst intestinal 
macrophages during inflammation derive from blood Ly6C+ monocytes [153]. 
Whilst there is agreement on the origins of tissue resident macrophages in 
some organs, their origins in other organs particularly during inflammation 
remains hotly debated [154-157]. 
1.7.2 Cytokine trafficking in macrophages 
Whilst extensive work has been done on the stimulation, signalling pathways 
and transcriptional mechanisms that result in the release of cytokines from 
macrophages as well as the effect of these cytokines on target receptors and 
cells, only recently has more been discovered about the pathways and 
mechanisms that control cytokine trafficking and vesicle fusion within cells. 
These discoveries earned James Rothman, Randy Schekman and Thomas 
Sudhof the Nobel Prize in 2013 for their role in identifying the function of 
SNARE proteins as well as the genes that control and time vesicle fusion.  
1.7.2.1 TNF 
The intracellular trafficking of cytokines in macrophages is most widely 
studied in TNF, which has shed light on the complex and tightly regulated 
trafficking of cytokines from the trans-Golgi network (TGN) to the plasma 
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membrane [158]. TNF secretion is non-constitutive and is tightly regulated at 
the transcriptional and translational levels to deliver a large bolus when 
macrophages are activated [159, 160], but unlike other cytokines is trafficked 
as a transmembrane precursor. On LPS stimulation, membrane-bound TNF 
can be found at the Golgi complex by 20 minutes and TNF secreted by 40 
minutes [161]. After processing through the Golgi complex, TNF is packaged 
in tubulo-vesicular carriers and transported to the recycling endosome en 
route to the plasma membrane [162]. The packaging of TNF into tubulo-
vesicular carriers at the Golgi complex is controlled by golgin-245/p230, a 
member of the golgin family of proteins that function in membrane fusion 
events and structural support at the Golgi [163]. The exact role of p230 in 
TNF exit from the Golgi is still unclear, but live imaging indicates that p230 
largely remains at the Golgi suggesting that p230 has a role in TNF sorting 
but not vesicle scission.  Similarly, Rab6 that localises to the TGN may have 
a role in stabilising p230 on the tubule-vesicular carriers and when depleted, 
like p230 resulted in attenuated TNF secretion [164]. By contrast, scission of 
these carriers at the Golgi is controlled by phosphoinositide-3-kinase (PI3K) 
p110δ isoform and dynamin 2 [165]. The TGN is a complex dynamic 
structure and major sorting centre at the crossroads of the endocytic and 
exocytic pathways, utilising numerous molecular machineries and proteins to 
correctly direct cytokines and cellular products to their destination [166]. 
 TNF carriers exit the TGN and fuse with the recycling endosomes 
[162]. TNF carriers contain the SNARE complex, Stx6/Stx7/Vti1b that pairs 
with its R-SNARE partner VAMP3 on recycling endosomes for carrier-
endosome fusion [167]. The final fusion step for delivery of TNF to the 
plasma membrane is facilitated by pairing of VAMP3 on the recycling 
endosome and Q-SNARE complex, Stx4/SNAP23 on the plasma membrane 
[168]. Syntaxin 4 (Stx4) and ADAM17/TACE (TNF converting enzyme) are 
sequestered to cholesterol-rich lipid rafts that result in the delivery of TNF 
carriers to these discrete punctae and their subsequent rapid cleavage into 
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soluble TNF and release into the extracellular environment [169, 170]. 
Interestingly, if an activated macrophage is phagocytosing a microbe, TNF 
and VAMP3 positive endosomes are delivered to the phagocytic cup 
providing membrane for an expanding cup and release of TNF [162]. 
1.7.2.2 IL6 
IL6 is also a proinflammatory cytokine secreted by macrophages on 
stimulation with LPS. The trafficking of IL6 share many similarities with TNF 
[171]. Newly synthesised IL6 exits the TGN in transport vesicles either alone 
or together with TNF, and like TNF utilises similar SNAREs to fuse with 
recycling endosomes. It is within the endosomal compartment that their paths 
separate with TNF directed to phagocytic cups but not IL6, suggesting an 
important role for the endosomal system in sorting cargo for delivery to the 
plasma membrane. The location or nature of the cell surface sites that IL6 
are directed to is still unclear. As such, IL6 can be transported in two distinct 
pathways that diverge at the endosomal compartment. 
1.7.2.3 IL10 
By contrast, the anti-inflammatory cytokine IL10 is secreted in two 
distinct pathways in macrophages, which are either endosome dependent or 
independent [172]. On LPS stimulation, a significant proportion of IL10 is 
trafficked in similar pathways to TNF and IL6, exiting the Golgi in p230 
dependent carriers. The IL10 is then delivered to the endosomal 
compartment where sorting occurs then release. Another portion of IL10 exits 
the TGN in golgin-97 positive carriers, which bypasses the endosomal 
compartment.   
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1.7.3 The innate immune system and Crohn’s disease 
The GWAS discovery of NOD2, ATG16L1 as well as the autophagy gene 
IRGM as well as smaller studies that found associations with variants in 
CD14, TLR4, 5, 9 and 10 all suggest a role of the innate immune system and 
acute inflammation in CD [173-177]. In addition to GWAS, congenital 
monogenic innate immunodeficiencies affecting neutrophils have also 
provided strong evidence to support a role for defective innate immunity in 
CD.  Failure of neutrophils to accumulate in sufficient numbers (leukocyte 
adhesion deficiency) [178], impaired vesicle trafficking and fusion (Chediak-
Higashi and Hermansky-Pudlak syndromes) [179, 180] or poor digestion of 
bacteria within excessively acidic phagolysosomes (chronic granulomatous 
disease and glycogen storage disease-1b) [181-184] commonly develop 
granulomatous bowel inflammation that is indistinguishable from CD [185, 
186]. These findings provide further evidence to support the hypothesis that 
defective innate immunity and acute inflammation increases the probability of 
developing CD. 
1.8 Defective innate immunity in Crohn’s disease 
Following from the observation that patients with congenital neutrophil 
immunodeficiencies present with a CD-like colitis, others in our research 
group investigated neutrophil recruitment in the bowel of CD patients and 
found impaired neutrophil recruitment at sites of trauma [107]. This was 
associated with lower levels of the neutrophil chemokine CXCL8 in skin 
windows of CD patients. To investigate the effects of this impaired neutrophil 
recruitment, others in our group investigated bacterial clearance by injecting 
heat-killed E. coli (HkEc) subcutaneously into the forearm of CD patients and 
HCs [187]. Local blood flow at the injection site determined by laser Doppler 
scanning and accumulation of radioactively labelled autologous neutrophils 
as markers of acute inflammation was significantly attenuated in CD patients. 
The clearance rate of radioactively labelled heat-killed E. coli from the site of 
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injection was significantly reduced in CD patients but not in UC patients 
(inflammatory disease control) or healthy controls, with an extrapolated total 
clearance time of 44.3 days in CD versus 10.2 days in healthy controls. The 
local blood flow and bacterial clearance rates were dose dependent and was 
similar below 107 HkEc but significantly attenuated in CD patients above 107 
HkEc.  
 To investigate this common phenotype of impaired bacterial clearance 
in CD, others in our group stimulated CD macrophages with HkEc and 
looked at cytokine and chemokine secretion [187]. The secretion of 
proinflammatory cytokines TNF, IL4, IL5, IL13, IL15 and IFNγ were lower in 
the HkEc stimulated ileal and colonic CD macrophages whilst IL6, IL12p70, 
GCSF and GMCSF were only lower in colonic CD and IL17 in ileal CD. By 
contrast, proinflammatory cytokine secretion in UC macrophages were 
similar to or greater than healthy controls. Secretion of chemokines CCL5, 
CXCL10, CCL2 and CXCL8 and anti-inflammatory cytokines IL1Ra and IL10 
were similar in CD macrophages compared to healthy controls. The defective 
TNF secretion was replicated in a further cohort of 101 CD patients [188]. 
 This defective TNF secretion on HkEc stimulation was not due to 
impaired cytokine gene transcription or mRNA stability [187]. Intracellular 
TNF levels were lower in HkEc stimulated CD macrophages which 
normalised to healthy control levels on addition of the ER to Golgi transport 
inhibitor brefeldin A, which indicated that TNF translation was also normal. In 
light of the normal TNF transcription and translation we stimulated CD 
macrophages with HkEc with and without the lysosomal function inhibitors 
monensin, chloroquine and NH4Cl and found that the intracellular TNF levels 
normalised to healthy control levels, suggesting that the low TNF levels were 
due to misdirected trafficking of TNF to lysosomes for destruction.  
 These findings have led us to propose a 3-stage model of Crohn’s 
disease pathogenesis, occurring in three temporally distinct but related 
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stages (Figure 1.5). Stage 1 involves the penetration of luminal contents 
such as bacteria and faeces into the normally sterile lamina propria that 
occur in the presence of an abnormal mucosal barrier. In stage 2, 
macrophages in healthy individuals mount a strong acute inflammatory 
cytokines response resulting in robust neutrophil recruitment, clearance of 
luminal contents and resolution of inflammation. However, CD macrophages 
mount an attenuated acute inflammatory response characterised by defective 
cytokine secretion resulting in poor neutrophil recruitment and inadequate 
bacterial clearance. The residual bacteria and faeces acts as a focus for the 
formation of granulomas and stage 3, which is a compensatory adaptive 
immune response exemplified by high levels of proinflammatory cytokines 
and the phenotype of CD that responds to immunosuppressive and anti-TNF 
therapy. 
To investigate this trafficking defect, myself and others in our group 
performed microarray analysis of macrophage gene expression in CD 
patients and HCs, using UC patients as an inflammatory disease control. 
Mean and standard deviation of expression in the healthy control cohort was 
used to detect under expressed genes in individual CD patients using 
customised software [189]. This approach of outlier gene expression analysis 
has been used in cancer studies to identify candidate genes of pathological 
relevance [190]. Using this approach, we identified seven CD patients with 
abnormally low expression of optineurin (OPTNlow) in their macrophages in 
our initial cohort [191]. A further cohort replicated these results and identified 
four further CD patients to a total of eleven OPTNlow CD patients out of 105 
CD patients, but none in the 75 healthy controls or 49 UC patients. 
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 Figure 1.5 Three-stage model of Crohn’s disease pathogenesis. Stage 1 is 
the penetration of faeces and bacteria into the bowel mucosa, stage 2 is the 
impaired proinflammatory cytokine secretion by macrophages and resultant 
attenuated neutrophil recruitment and stage 3 is the resulting compensatory 
adaptive immune response to uncleared bacteria and faeces [192]. 
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1.9 Optineurin 
1.9.1 Optineurin structure and function 
Optineurin (OPTN) was originally isolated in a yeast two-hybrid screen of a 
HeLa cell cDNA library as a binding partner of the adenoviral TNF inhibitor 
E3-14.7K and named FIP2 (14.7K interacting protein 2) [193]. In 2002, 
mutations in FIP2 were found to be associated with autosomal dominant 
adult-onset primary open angle glaucoma (POAG) in 54 different families and 
named optineurin (optic neuropathy inducing) [194]. 
 
Figure 1.6 Phylogenetic tree of optineurin protein in different species. 
Adapted from Ying et al, 2012 [195]. 
 
 OPTN homologs have been identified in many species including 
zebrafish and mice (Figure 1.6). In humans, OPTN is a 67 kD protein made 
up of 577 amino acids and the OPTN gene comprises 13 exons that spans 
37 kilobases on chromosome 10. In mice, OPTN is predicted to be a 67 kD 
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protein made up of 584 amino acids sharing 78% homology with human 
OPTN. The mouse Optn gene comprises 13 exons on chromosome 2 [196]. 
In zebrafish, Optn is predicted to be 60 kD and is made up of 524 amino 
acids. The zebrafish optn gene comprises 13 exons and is on chromosome 
4.  
 
Figure 1.7 OPTN protein domains, mutation and binding partner sites. (a) 
Diagram depicting mutation sites for glaucoma (above) and ALS (below). (b) 
OPTN amino acid binding partner sites. CC, coiled-coils; ZF, zinc-finger; 
UBD, ubiquitin-binding domain; LZ, leucine zipper; LIR, LC3-interacting 
region. Adapted from Ying et al, 2012 [195]. 
 
 The human OPTN protein is made up of multiple coiled-coil domains 
(CC), a zinc-finger (ZnF) domain, a ubiquitin-binding domain (UBD), a 
leucine-zipper (LZ) domain and an LC3-interacting region (LIR) (Figure 1.7). 
OPTN shares 53% similarity with NEMO (NF-κB essential modulator). Like 
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NEMO, OPTN is found in complexes with other interacting proteins [197] and 
is involved in multiple cellular functions beyond NF-κB signalling.  
OPTN is ubiquitously expressed in many different organs and is 
upregulated by TNF and LPS via NF-κB signalling [198-200]. OPTN’s main 
role is in vesicle trafficking and autophagy via its binding partners myosin VI, 
rab8, huntingtin (HTT) and LC3.  
1.9.2 Optineurin in vesicle trafficking 
OPTN was first identified as a binding partner of myosin VI using a yeast 
two-hybrid system (Figure 1.8) [201]. OPTN was found to bind myosin VI 
between amino acids 412 to 520 and together colocalise to the Golgi 
complex and vesicles at the plasma membrane in HeLa cells. RNA 
interference of OPTN resulted in loss of myosin VI from the Golgi complex 
and Golgi fragmentation. OPTN was also previously found to bind Rab8 
[202]. Overexpression of Rab8 alone results in recruitment of myosin VI to 
Rab8 vesicles but overexpression of Rab8 in the presence of OPTN RNAi 
blocked myosin VI recruitment, suggesting that OPTN links myosin VI to the 
Golgi complex and has a role in maintaining the Golgi structure.  
Additionally, OPTN in complex with myosin VI and Rab8 has a role in 
post-Golgi membrane trafficking since OPTN RNAi resulted in reduced 
transport of the VZV-G protein from the Golgi to the plasma membrane in 
nonpolarised HeLa cells and corrected aberrant transport introduced by a 
mutant C-terminal tail myosin VI in polarised MDCK kidney epithelial cells 
[203]. OPTN and its binding partners myosin VI and Rab8 were also shown 
to have a role in polarised delivery of EGFR to the leading edge of A549 
human alveolar epithelial cells resulting in impaired lamellipodia formation 
[204]. Finally, using live-cell fluorescence microscopy in HeLa cells, OPTN 
and myosin VI depletion was found to reduce secretory vesicle fusion events 
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at the plasma membrane but have no effect on vesicle formation events at 
the trans-Golgi network [205]. 
 
 
Figure 1.8 OPTN and its binding partners myosin VI, Rab8 and Htt.  
Illustration shows the binding of OPTN with its binding partners and how 
OPTN may act as a bridge binding vesicles to actin filaments via myosin VI 
to facilitate vesicle transport. Adapted from Sahlender et al, 2005 [201]. 
 
OPTN was also colocalised with huntingtin (HTT) to the Golgi complex 
in rat striatal cells that was dependent on expression of wildtype Htt in 
contrast to a 111Q polyglutamine Htt mutant [206]. RNAi of wildtype Htt and 
expression of mutant Htt resulted in impaired post-Golgi trafficking to 
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lysosomes, which was dependent on the expression of wildtype Rab8 and 
OPTN and resulted in the accumulation of the lysosome bound mannose-6-
phosphate receptor at the TGN and reduced lysosomal DQ-collagen VI 
proteolysis. By contrast, Htt RNAi in HeLa cells resulted in endosome and 
lysosome dispersion that was dynein dependent with minimal defects in 
intracellular trafficking [207].  
OPTN has also been shown to regulate endocytic trafficking of 
transferrin receptor at the recycling endosome in rat RGC5 retinal ganglion 
and human retinal pigment epithelial cells, a process impaired by expression 
of the glaucoma associated E50K mutation in the proximal NEMO-like TBK1 
binding site domain of OPTN [208, 209]. A consequence of OPTN RNAi in 
RGC5 cells is the reduced secretion of neurotrophin-3 (NT-3) and ciliary 
neurotrophic factor that resulted in increased apoptotic cell death, which was 
reversed with exogenous NT-3 [210].  
1.9.3 Optineurin and autophagy 
As discussed above, autophagy is the term used to describe the intracellular 
processes that degrade and recycle unwanted cytosolic macromolecules, 
organelles and cellular components via lysosomes. Autophagy involves the 
formation of double membrane autophagosomes covered with LC3 that bind 
cargo carrying molecules such as NDP52 and p62 in selective autophagy 
(Figure 1.3) or degrades cytosolic macromolecules and organelles in non-
selective autophagy under conditions of starvation (Figure 1.2). 
Optineurin was found to be associated with the LC3 autophagy protein 
using a yeast two-hybrid system and verified by pull-down assays. The LC3-
interacting region (LIR) in OPTN (Figure 1.7) was mapped to amino acids 
169 to 209 [125]. Phosphorylation of OPTN within the LIR at serine-177 by 
TANK binding kinase 1 (TBK1) enhanced binding of OPTN to LC3 and 
autophagic clearance of ubiquitin-coated cytosolic Salmonella enterica 
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(Figure 1.3). Conversely, OPTN with ubiquitin and LC3 binding domain 
mutations as well as silencing of OPTN or TBK1 resulted in impaired 
Salmonella autophagy and intracellular bacterial proliferation. 
Additionally, in RGC5 cells endogenous OPTN is mainly turned over by 
the ubiquitin-proteosome pathway but when the OPTN E50K mutant is 
overexpressed in these cells, the ubiquitin-proteosome pathway is 
compromised and autophagy is induced [211]. 
1.9.4 Optineurin and the type I interferon response 
The type I interferon response aims to improve presentation and clearance of 
intracellular viruses. The OPTN type I interferon response involves TANK-
binding kinase 1 (TBK1), a member of the IκB-kinase family involved in 
activation of interferon regulatory factor 3 (IRF3) and production of interferon 
β (IFNβ) [212]. 
OPTN shares 53% homology with NEMO and contains a ubiquitin-
binding domain (UBD) (Figure 1.7), hence is also called NEMO-related 
protein (NRP). Mice containing a knockin defect at the UBD of OPTN were 
used to generate bone marrow derived macrophages (BMDM), which were 
stimulated with LPS. Defective pUb binding in these LPS stimulated BMDM 
containing UBD-mutant OPTN resulted in impaired phosphorylation of IRF3 
and production of IFNβ suggesting that OPTN binding to K63-pUb chains at 
its UBD is required for the activation of OPTN’s binding partner TBK1 [200, 
212, 213].  
By contrast, in another study OPTN was functioning as a negative 
regulator of the antiviral response. OPTN overexpression in human 
embryonic kidney cells inhibited Sendai virus triggered induction of IFNβ and 
conversely RNAi promoted viral induced IFNβ production and impaired 
Bunyamwera viral replication [214]. It is not clear why these results are 
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seemingly contradictory but may be related to variations in the response to 
viral infection in different cell types or non-specific effect of RNAi beyond just 
OPTN knock down. 
1.9.5 Optineurin and disease 
Mutations in OPTN have been associated with glaucoma, amyotrophic lateral 
sclerosis (ALS) and Paget’s disease of the bone. Mutations in OPTN was 
first associated with ALS in six affected subjects from consanguineous 
marriages in four different families [215]. Two affected siblings from a single 
family were found to have a deletion of exon 5, two unrelated subjects, one 
from a consanguineous marriage were found to be homozygous for a 
nonsense mutation 1502C>T/Q398X (exon 12) and two sibling pairs from 
unrelated families were heterozygous for a missense mutation 
1743A>G/E478G (exon 14). OPTN was colocalised with disease associated 
superoxide dismutase 1 (SOD1) and fused in sarcoma (FUS) in inclusion 
bodies of patients with ALS [215, 216]. Additionally, the Q398X and E478G 
ALS mutations were associated with impaired inhibition of IRF3, suggesting a 
viral aetiology [217]. A further six novel variants were identified in an Italian 
cohort and a further two in a Dutch cohort with familial and sporadic ALS 
[218, 219]. By contrast, three other studies in did not support the association 
of OPTN with ALS [220-222]. The involvement of OPTN in ALS therefore 
remains to be further elucidated. 
 Four mutations in OPTN were originally identified that were linked to 
POAG [194]. They are 458G>A/E50K (exon 4), which was the commonest 
variant affecting 13.5% of familial POAG patients, 691_692insAG/premature 
stop (exon 6), 1944G>A/R545Q (exon 16) and 603T>A/M98K (exon 5), 
which was only associated in South Asian families. Further disease 
associated variants have been found but only account for <1% of cases. 
Most of the OPTN associated mutations are missense mutations with one 
frameshift nonsense mutation and a silent mutation. 
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 The most widely studied OPTN mutant is the E50K mutation. Mice 
overexpressing OPTN with the E50K mutation had thinner retina with loss of 
RGCs [223]. OPTN was shown to translocate to the nucleus when exposed 
to an apoptotic stimulus in a Rab8 dependent manner in fibroblasts. 
Overexpression of wildtype OPTN protected cells from the apoptotic stimulus 
in contrast to E50K-OPTN that did not translocate to the nucleus or maintain 
mitochondrial membrane integrity resulting in decreased survival [224]. 
Additionally, E50K-OPTN has been shown to impair post Golgi trafficking in 
human retinal pigment epithelium and RGC as discussed above. 
 In 2010, a GWAS into Paget’s disease of the bone, a disease of 
increased and dysorganised bone remodelling in British patients identified 
three candidate loci, one of which was mapped to OPTN on chromosome 
10p13 [225]. The association of Paget’s with OPTN has since been validated 
in a French-Canadian cohort of patients [226]. Interestingly, the 10p13 
chromosomal region had already been linked to familial Paget’s disease in 
2008 although the candidate gene was not identified [227]. However, to date 
the disease associated variant in OPTN has not been identified nor the 
functional consequences that results in Paget’s disease. 
1.10 Outline of thesis 
1.10.1 Summary of background information 
CD is a chronic, relapsing, systemic inflammatory disorder that 
predominantly affects the GI tract. The incidence of CD is rising with time and 
in places previously unknown to have CD. The aetiology of CD is unknown, 
but recent GWAS studies have implicated NOD2, which detects 
intracytoplasmic pathogens and ATG16L1, a gene involved in autophagy, 
implicating the innate immune system in the pathogenesis of this disease. 
Furthermore, individual with inherited neutrophil immunodeficiencies 
commonly manifest in colitis that is indistinguishable from CD. 
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 Others in our research group previously identified an impaired acute 
inflammatory response in CD patients exposed to E. coli. CD patients had 
impaired neutrophil recruitment to sites of infection and delayed clearance of 
radioactively labelled E. coli. This defect was associated with impaired 
proinflammatory cytokine secretion in macrophages. This led our group to 
propose a 3-stage model for the pathogenesis of CD. The central causal 
phase of incomplete bacterial clearance by neutrophils follows the initial 
phase of faecal and bacterial penetration into the bowel wall. The incomplete 
clearance of bowel contents from the tissues results in the final phase 
involving a secondary adaptive immune response and the phenotype of CD. 
 Previous work from our group to investigate the defective 
proinflammatory cytokine secretion identified genes involved in vesicle 
trafficking. Myself and others in our group found optineurin expression in 
human macrophages to be significantly lower in 10% of CD patients in our 
cohort. Optineurin is an intracellular adaptor molecule that forms a complex 
with myosin VI, Rab8, HTT and LC3. It has been found to localise to the 
Golgi complex and plasma membrane in non-immune cells with a role in 
protein sorting at the Golgi and vesicle fusion at the membrane. This makes 
optineurin an exciting candidate for further investigation in macrophages to 
identify if optineurin has a role in bowel inflammation. 
1.10.2 Summary of investigations and hypothesis 
In this thesis, the discovery of abnormally low expression of OPTN in human 
macrophages is replicated and validated in a separate cohort of CD patients 
and healthy controls by myself and others in our group. Demographic data of 
the OPTNlow CD patients were analysed by myself to identify any 
predisposing factors that may be causal in the abnormal expression of 
OPTN. 
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 The role of OPTN in macrophages in vitro was studied by myself using 
bacteria and TLR stimulation assays to investigate gene transcription, 
cytokine secretion, vesicle trafficking, autophagy, ER stress, phagocytosis 
and killing whilst its intracellular location in macrophages elucidated using 
colocalisation analysis on confocal immunofluorescence microscopy. This 
was aided by studies using subcellular fractionation, immunoprecipitation and 
shotgun proteomics by others in our group. 
Finally, the role of OPTN in infection and colitis in vivo was 
investigated using optn knockdown zebrafish injected with Salmonella by our 
collaborators and an Optn-/- mouse model of intraperitoneal infection and 
Citrobacter rodentium colitis by myself to look at differences in susceptibility 
to infection, immune cell recruitment and cytokine secretion.  
The null hypothesis of this thesis is that there is no association 
between low OPTN expression in MDM and the development of CD. I 
investigated this hypothesis by exploring these statements: 
1. Low OPTN expression in human monocyte-derived macrophages is 
specific to CD patients and not in HC or UC patients (Chapter 3). 
2. Low or deficient OPTN in macrophages is important in proinflammatory 
cytokine secretion and trafficking (Chapter 4). 
3. In vivo, OPTN deficient mice developed a more severe colitis that is 
associated with impaired neutrophil recruitment to site of infection 
(Chapter 5).   
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Chapter 2 Materials and Methods 
2.1 CD patient and healthy control recruitment 
CD patients were recruited from the University College London Hospital 
Inflammatory Bowel Disease clinic. Patients had definitive diagnoses of CD, 
which were confirmed using standard diagnostic criteria and the Montreal 
classification for Crohn’s disease [228].  All CD patients were between 18 
and 75 years of age and were free of Hepatitis B, Hepatitis C and Human 
Immunodeficiency Virus (HIV). CD patients in the first cohort had quiescent 
disease (Harvey-Bradshaw index <3) [229] and on either no medication or a 
stable maintenance dose of 5-aminosalicylates for the previous 3 months. 
CD patients in the second cohort also had quiescent disease (Harvey-
Bradshaw index <3) but could be on any medication for their CD except 
treatment dose steroids at the time of venesection. CD patients who met the 
inclusion criteria were recruited to participate in the study.  
Matched HC from the Division of Medicine, University College London 
staff and student population were recruited. HCs were between 18 and 75 
years of age, did not have CD or UC and were not on immunosuppressants. 
No CD patient or HC was studies more than once in the 2 different cohorts.  
Details of CD patients and HCs are provided (Table 3-2). Signed 
informed consent was obtained from all participants at each meeting, which 
includes consent for venesection, release of tissue obtained at endoscopy or 
surgery and review of medical notes. Clinical details of CD patients and HCs 
were recorded in a password protected Excel spreadsheet, registered and 
covered by the Data Protection Act 1998. Clinical details include name, 
hospital number, date of birth, Montreal classification for Crohn’s disease, 
smoking status, family history, date of venesection, current and previous 
medication and Harvey-Bradshaw were obtained from the CD patients or 
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their clinical records.  
2.2 gDNA extraction, OPTN sequencing and SNP genotyping.  
Genomic DNA (gDNA) was extracted from peripheral venous blood using the 
QIAamp DNA blood Mini Kit (Qiagen). Sequencing of the OPTN gene in 
OPTNlow CD patients and genotyping of the rs12415716 SNP in HC and CD 
patients was performed as previously described [191]. 
2.3 Optn-/- mouse generation and verification 
2.3.1 Optn-/- mouse generation 
Optn+/- mice on a C57BL/6 background were obtained from the Wellcome 
Trust Sanger Institute (WTSI), Cambridge, UK. The C57BL/6NTac-
Optntm1a(EUCOMM)Wtsi mice were generated by targeted mutagenesis of the 
Optn gene on Chromosome 2 using a ‘knockout first’, conditional targeting 
allele strategy by insertion of an IRES/lacZ – promoter-driven Neo targeting 
cassette upstream of critical exon 3 [230]. 
2.3.2 Mouse husbandry 
Mice were bred to obtain Optn+/+ and Optn-/- mice in specific-pathogen free 
(SPF) cages in the Biological Sciences Unit, University College London. 
Colonies were generated by keeping Optn+/+ and Optn-/- breeding pairs to 
produce pure Optn+/+ and Optn-/- litters. Mouse stocks were fed with Harlan 
2018 Teklad Global 18% protein rodent diet whilst breeders were fed with 
Harlan 2019 Teklad Global 19% protein rodent diet. 
2.3.3 Mouse genotyping 
Mice were genotyped using Optn_47570_F, Optn_47570_R and 
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CAS_R1_Term_x primers (Appendix 1) provided by the WTSI from ear clip 
derived gDNA with the HotStar Taq Mastermix kit (Qiagen 203445). Mouse 
gDNA was extracted from ear clips by incubating the ear clips overnight at 55 
°C in 95 μl of DNA extraction buffer (Section 2.6 Reagents) containing 5 μl of 
4 mg/ml proteinase K (Qiagen).  The samples were vortexed at 1400 rpm at 
55 °C for 10 minutes in an Eppendorf Thermomixer comfort then centrifuged 
at 28,000 g for 10 minutes to pellet hair. The samples were transferred into 
new tubes and boiled at 95 °C for 5 minutes.  
The PCR reaction volume was made up of 12.5 μl HotStar Taq 
Mastermix, 1 μl forward primer, 1 μl reverse primer, 1 μl gDNA and 9.5 μl 
RNase-free water, to a total volume of 25 μl. The final concentration in the 
reaction volume was 2.5 U HotStar Taq DNA polymerase, 1× PCR buffer 
containing 1.5 mM MgCl2, 200 μM of each dNTP, 0.4 μM of each primer and 
a variable amount of gDNA. The PCR mix was activated at 95 °C for 15 
minutes, denatured at 95 °C for 45 s, annealed at 60 °C for 45 s, extended at 
72 °C for 45 s, for a total of 28 cycles, then extended for a final time at 72 °C 
for 10 minutes before being cooled to 4 °C on a DNA Engine Tetrad 2® 
Peltier Thermal Cycler (Bio-Rad). The annealing temperature of 60 °C was 
chosen after a temperature gradient was run for each primer pair. 5 μl 
Orange J was added to each 25 μl reaction mix and 15 μl was run on a 1% 
agarose gels then viewed with a ChemiDoc™ Imager (Bio-Rad). 
2.3.4 Optn-/- mouse verification 
Primers that spanned exon 2 to 4 of the Optn gene (Figure 4.12) were 
created using Primer 3 (Appendix 1). Stock primers were made up to 100 μM 
in RNase-free water as per manufacturer’s instructions (Eurofins and Sigma) 
and further diluted to 10 μM in RNase-free water for PCR.  Total RNA from 
Optn+/+ and Optn-/- mouse small bowel was harvested and converted into 
cDNA (Section 2.9 Quantitative Reverse Transcription PCR). RT-PCR was 
performed with 25 μl HotStar Taq Mastermix, 2 μl forward primer, 2 μl 
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reverse primer, 2 μl cDNA and 19 μl RNase-free water, to a total volume of 
50 μl and final concentration of 2.5 U HotStar Taq DNA polymerase, 1× PCR 
buffer containing 1.5 mM MgCl2, 200 μM of each dNTP, 0.4 μM of each 
primer and ~40 ng/μl of cDNA. The RT-PCR was activated at 95 °C for 15 
minutes, denatured at 95 °C for 30 s, annealed at 56 °C for 45 s, extended at 
72 °C for 60 s, for a total of 35 cycles, then extended for a final time at 72 °C 
for 10 minutes before being cooled to 4 °C on a DNA Engine Tetrad 2® 
Peltier Thermal Cycler (Bio-Rad), which revealed a larger amplicon in the 
Optn-/- small bowel (Figure 4.15). The annealing temperature of 56 °C was 
chosen after a temperature gradient was run for the primer pair. 
The RT-PCR reaction was repeated and the knockout Optn+ and 
wildtype amplicon were purified using QIAquick® PCR purification columns 
(Qiagen 28104) as per manufacturer’s instructions and sequenced with the 
same primers using a BigDye® Terminator v3.1 Cycle Sequencing kit on an 
Applied Biosystems 3730XL DNA Analyzer.  
Whole cell lysates of Optn+/+ and Optn-/- thioglycollate-induced 
peritoneal macrophages in Laemlli buffer were made and immunoblotted 
(Section 2.10 Immunoblot), which confirmed the absence of OPTN in the 
Optn-/- mice. 
2.3.5 Investigating the naïve Optn-/- phenotype 
2.3.5.1 Naïve Optn+/+ and Optn-/- organs 
Naïve Optn+/+ and Optn-/- large bowel, small bowel, spleen, kidney, liver, 
stomach, brain, heart, lung and thymus were harvested and fixed overnight in 
10% neutral buffered formalin (CellPath). The organs were embedded, 
sectioned and stained with haematoxylin and eosin (H&E) (Figure 4.19). 
To make H&E slides of the bone marrow, Optn+/+ and Optn-/- hind legs 
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were dislocated at the hip joint and removed, overlying muscle and tendons 
were cut off and hind leg bones were fixed in 10% neutral buffered formalin 
overnight.  Femurs and tibiae were decalcified in PBS containing 5% EDTA 
for 14 days on a Stuart SRT6 analogue rocker and roller mixer. The PBS 
containing 5% EDTA was made using tetrasodium EDTA (Sigma), which is 
more soluble and was changed daily. 
2.3.5.2 Flow cytometry of peripheral blood 
Naïve Optn+/+ and Optn-/- were culled with CO2 and cervical dislocation. A 
midline thoracotomy was performed and a cardiac puncture using a 1 ml 
syringe attached to a 26 G needle containing 100 μl of 0.3% citrate in PBS 
was carried out. Blood was transferred into Falcon tubes and kept on ice. 
 Red blood cells were lysed by adding 1 ml of red cell lysing solution 
(Sigma R7757) to citrated blood for 3 minutes at room temperature. Cells 
were washed in 10 ml of FACS buffer (PBS containing 1% BSA, 0.01% 
azide), centrifuged at 500 g for 5 minutes at 4 °C and resuspended in 200 μl 
of FACS buffer containing 2.0 µg/ml anti-CD16/CD32 Fc block for 20 
minutes. Cells were washed in 1 ml of FACS buffer then stained in 100 μl 
FACS buffer containing 0.5 µg/ml CD11b V450, 0.25 µg/ml Gr1 PE, 0.25 
µg/ml CD3 PE-Cy™7, 0.25 µg/ml CD19 PerCP-Cy™5.5, 0.25 µg/ml Ly-6C 
APC and 0.5 µg/ml F4/80 FITC antibodies for 30 minutes in the dark at room 
temperature then fixed in 1% formaldehyde in PBS for 10 minutes. 
Compensation particles (BD 552845) were prepared by adding each 
antibody above to 100 µl of FACS buffer containing 1 drop of positive 
particles (~60 µl) and 1 drop of negative particles (~60 µl) to the same final 
concentration of antibodies. Particles were incubated in the dark at room 
temperature for 20 minutes then washed with 1 ml FACS buffer, centrifuged 
at 500 g for 5 minutes and resuspended in 300 µl of FACS buffer. Cells were 
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run on a BD LSRFortessa after compensation with antibody labelled particles 
and analysed with FlowJo (Tree Star, Inc). 
2.3.5.3 Flow cytometry of blood and bone marrow 
Naïve Optn+/+ and Optn-/- were culled with CO2 and cervical dislocation. Their 
hind legs were dislocated at the hips, removed and transported on ice. The 
overlying muscle and tendons were cut off. The cleaned bones were cut at 
either end and the bone marrow cavity was flushed through with ice cold 
sterile PBS in a 10 ml syringe attached to a 26 G needle into sterile petri 
dishes. The bone marrow cells were transferred into 50 ml Falcon tubes and 
centrifuged at 500 g for 5 minutes at 4 °C. 
Red blood cells were lysed by adding 1 ml of red cell lysing solution 
(Sigma R7757) to citrated blood for 3 minute at room temperature. Cells 
were washed in 10 ml of FACS buffer (PBS containing 1% BSA, 0.01% 
azide), centrifuged at 500 g for 5 minutes at 4 °C and resuspended in 200 μl 
of FACS buffer containing 2.0 µg/ml anti-CD16/CD32 Fc block for 20 
minutes. Cells were washed in 1 ml of FACS buffer then stained in 100 μl 
FACS buffer containing 0.5 µg/ml CD11b V450, 0.25 µg/ml Gr1 PE, 0.25 
µg/ml CD3 PE-Cy™7, 0.25 µg/ml CD19 PerCP-Cy™5.5, 0.25 µg/ml Ly-6C 
APC and 0.5 µg/ml F4/80 FITC antibodies for 30 minutes in the dark at room 
temperature then fixed in 1% formaldehyde in PBS for 10 minutes. 
Compensation particles (BD 552845) were prepared by adding each 
antibody above to 100 µl of FACS buffer containing 1 drop of positive 
particles (~60 µl) and 1 drop of negative particles (~60 µl) to the same final 
concentration of antibodies. Particles were incubated in the dark at room 
temperature for 20 minutes then washed with 1 ml FACS buffer, centrifuged 
at 500 g for 5 minutes and resuspended in 300 µl of FACS buffer. Cells were 
run on a BD LSRFortessa after compensation with antibody labelled particles 
and analysed with FlowJo (Tree Star, Inc). 
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2.4 Optn-/-Nod2-/- mouse generation 
2.4.1 Nod2-/- mice 
Nod2-/- mice on a C57BL/6 background, B6.129S1-Nod2tm1Flv/J were 
obtained from The Jackson Laboratory and housed in SPF cages in the 
same animal unit as the Optn-/- mice. 
2.4.2 Optn-/-Nod2-/- mice 
Optn-/-Nod2-/- mice were generated by crossing Optn-/- and Nod2-/- mice to 
obtain Optn-/-Nod2-/- and Optn+/+Nod2+/+ mice, which were housed in SPF 
cages with the other mice. Mice were genotyped using primers provided by 
Jackson for genotyping the Nod2-/- mice (Appendix 1). Pure breeding pairs of 
Optn-/-Nod2-/- and Optn+/+Nod2+/+ mice were used to generate mice for 
experiments. 
2.5 Antibodies and stains 
2.5.1 Antibodies used in immunoblots 
The following antibodies were used for MDM and THP-1 immunoblots: OPTN 
(Sigma HPA003360; 1:2,000), actin (Sigma A5060; 1:2,000), EEA1 (Cell 
Signaling #3288; 1:1,000), LAMP1 (Abcam ab24170; 1:1,000), GM130 (BD 
610823; 1:250), Golgin-245 (Santa Cruz sc-102565; 1:250), GAPDH (Santa 
Cruz sc-51906; 1:2,000), anti-rabbit IgG-HRP (Cell Signaling #7074; 
1:2,000), anti-mouse IgG-HRP (GE Healthcare NA931; 1:2,000). The 
following antibodies were used for BMDM immunoblots: OPTN (Abcam 
ab101592; 1:2,000), TNF (Abcam ab9739; 1:2,000), CHOP (Affinity 
BioReagents MA1-250; 1:500), GRP78/BiP (Santa Cruz sc-1051; 1:250), 
GRP94 (Santa Cruz sc-11402; 1:250), LC3B (Sigma L7543; 1:1,000). 
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2.5.2 Antibodies used in confocal microscopy 
The following antibodies and stain were used for MDM confocal microscopy: 
GM130 (BD 610823, 1:100), OPTN (Gift from F. Buss, Cambridge, 1:100), 
EEA1 (BD 610456, 1:100), DAPI (Invitrogen D3571, 1:33,000), Alexa Fluor® 
488-TNF/adalimumab (Abbott, 1:1,000) made with Alexa Fluor® 488 antibody 
labelling kit (Invitrogen A20181), Alexa Fluor® 546 anti-rabbit IgG (Invitrogen 
A11010; 1:1,000), Alexa Fluor® 488 anti-mouse IgG (Invitrogen A11001; 
1:1000). The following antibodies were used for BMDM confocal microscopy: 
Alexa Fluor® 488-TNF (BD 557719, 1:100), EEA1 (Abcam ab2900; 1:100), 
GM130 (BD 610823; 1:100). 
2.5.3 Antibodies used in flow cytometry 
The following were used for flow cytometry: Compensation particles set (BD 
552845), LIVE/DEAD® fixable blue dead cell stain kit (Invitrogen L23105), 
CD16/CD32 Fc block (eBioscience 16-0161; 1:500), F4/80 FITC 
(eBioscience 11-4801; 1:1,000), CD3 PE-Cy™7 (BD 560591; 1:800), CD19 
PerCP-Cy™5.5 (BD 551001; 1:800), Gr1 PE (BD 553128; 1:800), Ly-6C 
APC (BD 560595, 1:800), CD11b-V450 (BD 560455, 1:400) CD19 PE (BD 
553786; 1:400), CD45 PerCP-Cy™5.5 (BD 550994, 1:200). 
2.5.4 Antibodies used in immunohistochemistry 
The following were used for immunohistochemistry: Myeloperoxidase (Dako 
A0398; 1:1,000), normal goat serum (Sigma G9023, 1:10), Bond Polymer 
Refine Detection (Leica DS9800), Bond DAB Enhancer (Leica AR9432), 
OPTN (Sigma HPA003360; 1:100). 
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2.6 Reagents 
2.6.1 Heat-killed E. coli (HkEc) stock 
The fully antibiotic sensitive clinical isolate, E. coli NCTC 10418 was cultured 
by adding 1 μl glycerol stock into 10 ml LB broth (Sigma L3022) and 
incubated at 37 °C, 250 rpm in an Innova™ 4000 incubator shaker (New 
Brunswick Scientific) overnight. E. coli was centrifuged at 3000 g for 20 
minutes, room temperature in a Heraeus Multifuge X1R (Thermo Scientific), 
washed once in 20 ml PBS, resuspended in 1 ml PBS and counted at 1:20 
dilution using a Cecil BioQuest™ CE2502 spectrophotometer. The E. coli 
optical density at 600 nm (OD600) of 1×108 bacteria/ml in PBS is 0.365. 
Concentration of E. coli in PBS was adjusted to 1×1010 bacteria/ml and 
incubated at 60 °C for 1 hour in a Grant GD100 circulating immersion bath 
and stored at -20 °C. Killing of E. coli was checked by plating 80 μl of HkEc 
onto LB agar plates with no antibiotics. 
2.6.2 MTT cell viability assay reagents 
2.6.2.1 MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrozolium 
bromide)  
0.2% MTT was made by dissolving 1 g of MTT (Sigma M2128) in 500 ml of 
PBS and stored at 4 °C in the dark. 
2.6.2.2 MTT lysis solution 
900 ml of isopropranol, 47 ml of dH2O, 50 ml of 10% SDS and 3 ml of 
concentrated HCl were added together, which was kept at room temperature. 
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2.6.3 Buffers 
2.6.3.1 DNA extraction buffer 
DNA extraction buffer was made by adding 1 ml 1M Tris pH 8 (VWR 
103156X), 100 μl 0.5 M EDTA (Sigma E6511), 2 ml 1M NaCl (Sigma S7653) 
and 50 μl 1% SDS (Sigma L3771) to 6.85 ml of dH2O. 
2.6.3.2 Laemmli sample buffer 
3× Laemmli sample buffer was made by adding together 2.4 ml 1M Tris-HCl 
pH 6.8 (VWR), 3 ml 10% SDS (Sigma), 3 ml 100% glycerol (BDH 101186M) , 
1.6 ml 2-mercaptoethanol (Sigma 63689) and 0.006 g bromophenol blue 
(Sigma B0126), and stored at 4 °C. 
2.6.3.3 10× Transfer buffer  
10× transfer buffer was made by dissolving 144 g glycine (Sigma G7126), 
3.74 g SDS (Sigma L3771) and 30.25 g Tris (VWR 103156X) to 800 ml dH2O 
using a magnetic stirrer then made up to 1L. 
2.6.3.4 Tris-buffered saline (TBS) and TBS-Tween 0.1% 
10× TBS was made by adding 800 g NaCl (Sigma), 20 g KCl (Sigma P4054) 
and 300 g Tris to dH2O, pH adjusted to 7.4 using HCl and made up to 10 
litres dH2O. 1× TBS-Tween 0.1% was made by adding 5 ml Tween-20 
(Sigma P1379) to 500 ml of 10× TBS, made up to 5 litres with dH2O. 
2.6.3.5 50× Tris-acetate-EDTA (TAE) buffer 
484 g of Tris, 114.2 ml of glacial acetic acid and 200 ml of 0.5 M EDTA pH 
8.0 was made up to 2 L of dH2O.  
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2.6.3.6 FACS buffer (PBS containing 1% BSA and 0.01% azide) 
5 g of bovine serum albumin (BSA)/albumin fraction V (VWR 1120180100) 
was added to a new bottle of 500 ml PBS pH 7.2 (Gibco 20012). 500 μl of 
10% sodium azide in dH2O (Sigma S8032) was added to the 500 ml of PBS 
and stored at 4 °C. 
2.6.3.7 Confocal buffer (PBS containing 0.5% BSA, 0.1% saponin, 
0.01% azide) 
2.5 g of BSA, 0.5 g of saponin (Sigma S4521) and 500 μl of 10% azide was 
added to a new bottle of 500 ml PBS and stored at 4 °C. 
2.6.4 Cell culture media 
2.6.4.1 THP-1 cell culture media (RPMI 10% FBS, 20 mM HEPES, 100 
U/ml penicillin/streptomycin, 20 µM BME) 
50 ml of foetal bovine serum (Sigma F9665), 10 ml of 1 M HEPES (Sigma 
H0887), 5 ml of 10,000 U/ml Penicillin/Streptomycin (Gibco 15140-122), 200 
μl of 50 mM 2-mercaptoethanol (Gibco 31350) were added to a new 500 ml 
bottle of RPMI-1640, GlutaMAX™ Supplement (Gibco 61870).  
2.6.4.2 BMDM cell culture media (DMEM 10% FBS, 25 mM HEPES, 100 
U/ml penicillin/streptomycin, 1 g/L D-glucose, 4 mM L-
glutamine, 1 mM pyruvate) 
50 ml of FBS (Sigma) and 5 ml of 10,000 U/ml Penicillin/Streptomycin 
(Gibco) were added to a 500 ml bottle of low-glucose Dulbecco’s Modified 
Eagle Medium (DMEM) (Gibco 22320) and stored at 4 °C. 
75 
 
2.6.4.3 Thioglycollate-induced peritoneal macrophage (TiPM) cell 
culture media (RPMI 10% FBS, 100 U/ml penicillin/streptomycin, 
20 mM HEPES) 
50 ml of FBS (Sigma), 10 ml of 1 M HEPES (Gibco) and 5 ml of 10,000 U/ml 
Penicillin/Streptomycin (Gibco) was added to a 500 ml bottle of RPMI-1640, 
GlutaMAX™ Supplement (Gibco) and stored at 4 °C. 
2.6.5 Bacterial culture broth 
2.6.5.1 3% thioglycollate broth 
30 g of thioglycollate broth (Merck 108191) was dissolved in 1 L of dH2O and 
autoclaved. Sterile 3% thioglycollate was aliquoted into sterile 50 ml Falcon 
tubes and aged at 4 °C for 1 year prior to use. 
2.6.5.2 Luria-Bertani (LB) broth and agar plates 
5 g bacto-peptone (BD 211677), 2.5 g bacto-yeast extract (Oxoid LP0021), 5 
g NaCl (Sigma), 7.5 g agar (Oxoid LP0011) were added to ~400 ml dH2O, 
mixed with a magnetic stirrer and made up to 500 ml then autoclaved and 
plated. LB broth was made up as above without the agar. 
2.6.6 Histology and microscopy reagents 
2.6.6.1 Desalted human IgG at 50 mg/ml, 0.01% azide 
Pooled human immune globulin/Vivaglobin® (CSL Behring) at 160 mg/ml was 
desalted through a PD-10 desalting column (GE Healthcare 17-0851-01) 
following manufacturer’s instructions and eluted with PBS. The eluted 
desalted human IgG was quantified using a BCA protein assay kit (Thermo 
Scientific 13276818) as per manufacturer’s instructions, then diluted to 50 
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mg/ml with PBS. Volume of human IgG was measured with a P1000 pipette 
and the required volume of 10% sodium azide was added to make a final 
concentration of 0.01% azide. 
2.6.6.2 Mowiol® mountant 
6 ml of glycerol, 2.4 g of Mowiol (Calbiochem 475904) and 6 ml dH2O were 
added together in a 50 ml Falcon tube, vortexed and shaken for 2 hours. 12 
ml of 200 mM Tris-HCl pH 8.5 was added and the mountant was incubated at 
50 °C on a shaker until Mowiol fully dissolves, which took 3 hours. The 
mountant was filtered through a 0.45 μm filter, aliquoted and stored at -20 °C. 
2.6.6.3 2.5% gum mastic in absolute ethanol 
10 g of gum mastic (Sigma G0878) was dissolved in 100 ml absolute alcohol 
overnight. The 10% gum mastic was filtered using a Whatman #1 filter paper 
in a funnel. 2.5% gum mastic was made by adding 25 ml 10% gum mastic to 
75 ml absolute alcohol and stored at 4 °C. 
 
2.6.6.4 Steiner Silver reducing solution 
The Steiner silver reducing solution was made by adding 60 ml of 2.5% gum 
mastic to 100 ml of freshly made 2% hydroquinone (Sigma 53960) in dH2O 
and 0.8 ml of 1% silver nitrate (0.005% AgNO3 final concentration). NB 
reducing solution will be milky. 
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2.7 Cell culture and stimulation 
2.7.1 Monocyte-derived macrophages (MDM) 
2.7.1.1 Isolation of monocytes and culture of MDM 
100 ml of peripheral venous blood was collected from CD patients and HC in 
5 U/ml heparin by adding 300 μl of 1,000 IU/ml heparin sodium (Wockhardt) 
to each 50 ml syringe. Peripheral blood monocytes were isolated using 
Lymphoprep™ (Axis-Shield) by layering 25 ml of blood onto 15 ml of 
Lymphoprep in 50 ml Falcon tubes. Tubes were centrifuged at 900 g for 30 
minutes at 20 °C with the brakes off. The lymphocyte-monocyte layer at the 
interface of the serum at the top and the Lymphoprep in the middle was 
harvested and pooled into two 50 ml Falcon tubes. The cell suspension was 
topped up with PBS and centrifuged at 575 g for 5 minutes at 20 °C with the 
brakes on. The cells were washed two further times with PBS but centrifuged 
at 500 g and 325 g respectively.  
The cell pellet was resuspended in 10 ml of RPMI-1640, GlutaMAX™ 
supplement (Gibco) containing 100 U/ml penicillin, 100 µg/ml streptomycin 
(PAA) and 20 mM HEPES (Sigma) and plated onto 92 mm Nunclon™ ∆ 
coated tissue culture plates (Nunc). The cells were incubated in a tissue 
culture incubator at 37 °C, 5% CO2 for 2 hours in a Heraeus BB15 incubator 
(Thermo Scientific) to allow for monocyte adherence induced by serum 
starvation. After 2 hours, the RPMI media was tipped off, cells were washed 
with PBS once to remove non adherent lymphocytes and fed with 10 ml of 
RPMI containing 10% FBS (Sigma), 100 U/ml penicillin, 100 µg/ml 
streptomycin and 20 mM HEPES. After 24 hours, cells were fed with a further 
10 ml of RPMI containing 10% FBS and incubated for a total of 5 days to 
obtain adherent monocyte-derived macrophages as previously described.  
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2.7.1.2 Stimulation of MDM 
After 5 days, MDM were washed in PBS, scraped, counted and cultured 
overnight in X-VIVO 15 medium (Lonza) at 1×106 cells on 35 mm × 10 mm 
Nunclon™ ∆ coated tissue culture plates (Nunc) for RNA collection, at 
2.5×105 cells/well in FALCON® 24-well tissue culture plates for immunoblots, 
at 1×105 cells/well in FALCON® 96-well tissue culture plates for cytokine 
assays or at 5×104 cells/coverslip in FALCON® 24-well tissue culture plates 
for confocal microscopy. 
After 24 hours, MDM were stimulated with 1 µg/ml muramyl dipeptide 
(MDP) (Sigma), 4 µg/ml Pam3CSK4 (Alexis Biochemicals), 200 ng/ml 
lipopolysaccharide (LPS) (Alexis Biochemicals) or heat-killed E. coli (HkEc) 
NCTC 10418 at a multiplicity of infection (MOI) of 20 and harvested for total 
RNA and whole cell lysates. 
2.7.2 THP-1 cells 
2.7.2.1 THP-1 cell culture 
THP-1 cells, an acute monocytic leukaemia cell line were maintained in 
RPMI/THP-1 culture media (see section 2.6 Reagents). Prior to being 
stimulated, THP-1 cells were passaged at 1:20 and left to grow for 3 days 
prior to being harvested and counted. 
2.7.2.2 THP-1 cell stimulation 
THP-1 cells were plated in THP-1 culture media in densities as described for 
MDM and stimulated with 1 µg/ml muramyl dipeptide (MDP) (Sigma), 4 µg/ml 
Pam3CSK4 (Alexis Biochemicals), 200 ng/ml lipopolysaccharide (LPS) (Alexis 
Biochemicals) or heat-killed E. coli (HkEc) NCTC 10418 at a multiplicity of 
infection (MOI) of 20 and harvested for total RNA and whole cell lysates. 
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2.7.3 Bone marrow-derived macrophages (BMDM) 
2.7.3.1 Bone marrow cell harvest and culture 
Naïve Optn+/+ and Optn-/- mice age 9 to 12 weeks were culled with CO2 and 
cervical dislocation. Their hind legs were dislocated at the hips, removed and 
transported in PBS on ice. The overlying muscle and tendons were cut off in 
a tissue culture hood, the bones cleaned briefly by dipping in 70% ethanol 
and kept in PBS on ice. The cleaned bones were cut at either end and the 
bone marrow cavity was flushed through with ice cold sterile PBS in a 10 ml 
syringe attached to a 26 G needle into sterile petri dishes. The bone marrow 
cells from both femurs and tibiae of one mouse were filtered through a sterile 
70 μm nylon filter into a 50 ml Falcon tubes and centrifuged at 500 g for 5 
minutes at 4 °C.  
Red blood cells were lysed by adding 1 ml of red cell lysing solution 
(Sigma R7757) to the bone marrow cell pellet for 3 minutes at room 
temperature. Cells were washed in 30 ml of PBS and centrifuged at 500 g for 
5 minutes at 4 °C. Bone marrow cells were resuspended in 4 ml of BMDM 
culture media (see section 2.6 Reagents) containing 20 ng/ml recombinant 
mouse M-CSF (Peprotech 315-02). 1 ml of resuspended bone marrow cells 
were added to each 92 mm × 17 mm Nunclon™ ∆ coated tissue culture 
plates (Nunc) and topped up with 9 ml of BMDM culture media containing 20 
ng/ml M-CSF. After 24 hours, a further 10 ml of BMDM culture media 
containing 20 ng/ml M-CSF was added to each plate. After 5 days, BMDM 
from both Optn+/+ and Optn-/- mice were ~96% CD11b+ F4/80+ on flow 
cytometry (Figure 4.18). 
2.7.3.2 BMDM cell stimulation 
After 5 days, BMDM were washed in PBS, scraped, counted and cultured 
overnight in BMDM culture media at 1×106 cells on 35 mm × 10 mm 
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Nunclon™ ∆ coated tissue culture plates (Nunc) for RNA collection, at 5×105 
cells/well in FALCON® 24-well tissue culture plates for immunoblots, at 1×105 
cells/well in FALCON® 96-well tissue culture plates for cytokine assays or at 
5×104 cells/coverslip in FALCON® 24-well tissue culture plates for confocal 
microscopy. 
After 24 hours, BMDM were stimulated with 1 µg/ml muramyl 
dipeptide (MDP) (Sigma), 4 µg/ml Pam3CSK4 (Alexis Biochemicals), 200 
ng/ml lipopolysaccharide (LPS) (Alexis Biochemicals) or heat-killed E. coli 
(HkEc) NCTC 10418 at a multiplicity of infection (MOI) of 20 and harvested 
for total RNA and whole cell lysates. 
2.7.4 Thioglycollate induced peritoneal macrophages (TiPM) 
2.7.4.1 TiPM cell induction and harvest 
1ml sterile aged 3% thioglycollate broth (see section 2.6 Reagents) was 
injected into the peritoneum of age-matched Optn+/+ and Optn-/- mice using a 
26 G needle. Mice were scruffed and held supine with their heads down at 45 
° to minimise accidental organ puncture. After 5 days, mice were culled with 
CO2 and cervical dislocation. Mice were laid supine and their external 
abdominal skin and hair was cleaned with 70% ethanol and a superficial cut 
in the midline lower abdominal skin was made. The hind legs and tail of the 
mice was firmly held down and the abdominal skin was pulled away by 
holding the skin where it was cut and pulling up towards the head to reveal 
the intact peritoneal cavity.  
 4 ml of cell dissociation buffer (Gibco 13151) and 1 ml of air was 
injected carefully into the peritoneal cavity with a 26 G needle. The peritoneal 
cavity was shaken by holding the head down and shaking the abdomen by its 
hind legs and tail to facilitate adequate cell collection from the whole cavity. 
The parietal peritoneum was held with forceps at the centre of the abdomen 
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and tented up and a small ~5 mm cut in the parietal peritoneum was made 
above the air pocket. Sterile plastic Pasteur pipettes were used to collect the 
cell dissociation buffer containing peritoneal cells from the whole peritoneal 
cavity including the flanks into 15 ml Falcon tubes on ice. The volume of 
buffer extracted was noted. Cells were centrifuged at 500 g for 5 minutes at 4 
°C. Red blood cells were lysed by adding 1 ml of red cell lysing solution 
(Sigma R7757) to the peritoneal cell pellet for 3 minutes at room 
temperature. Cells were washed in 10 ml of PBS and centrifuged at 500 g for 
5 minutes at 4 °C.  
2.7.4.2 TiPM cell stimulation 
Cells were counted and cultured overnight in TiPM culture media at 1×106 
cells on 35 mm × 10 mm Nunclon™ ∆ coated tissue culture plates (Nunc) for 
RNA collection, at 5×105 cells/well in FALCON® 24-well tissue culture plates 
for immunoblots, at 1×105 cells/well in FALCON® 96-well tissue culture plates 
for cytokine assays or at 5×104 cells/coverslip in FALCON® 24-well tissue 
culture plates for confocal microscopy 
After 24 hours, TiPM were stimulated with 1 µg/ml muramyl dipeptide 
(MDP) (Sigma), 4 µg/ml Pam3CSK4 (Alexis Biochemicals), 200 ng/ml 
lipopolysaccharide (LPS) (Alexis Biochemicals) or heat-killed E. coli (HkEc) 
NCTC 10418 at a multiplicity of infection (MOI) of 20 and harvested for total 
RNA and whole cell lysates. 
2.8 Macrophage Expression Microarray 
Total RNA was harvested from unstimulated MDM and after 4 hours of 
stimulation with Pam3, LPS and HkEc in Buffer RLT (Qiagen) using the 
RNeasy Mini Kit columns with RNase-free DNase treatment (Qiagen). 
Concentration of total RNA in RNase-free H2O (Qiagen) was measured with 
a NanoDrop ND-1000 spectrophotometer (Thermo Scientific). Additionally, 
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OD260/OD280 and OD260/OD230 was measured, which assessed protein and 
solvent contamination.  RNA integrity was analysed by measuring ribosomal 
RNA band 28S/18S ratios using high resolution electrophoresis on an Agilent 
Bioanalyzer (Agilent Technologies, Inc), which was >8.  
500 ng of total RNA was amplified using the Illumina TotalPrep-96 
RNA Amplification kit (Ambion) and normalised to 150 ng/µl. 750 ng was 
hybridised to Illumina Human-WG6 v3.0 Expression BeadChips (Illumina) for 
16 hours at 58ºC. Beadarrays were stained with streptavidin-Cy3 (GE 
Healthcare) and scanned using the Beadarray reader and processed with 
GenomeStudio® data analysis software (Illumina). 
 Gene expression outlier analysis was carried out on customised 
software developed in collaboration with Anna Lobley and Daniel Roden 
(Department of Computer Science, UCL). This software identifies outlier 
genes by comparing gene expression in individual CD patients with the 
cohort of HCs using both p-value significance of the standardised deviation 
of CD test sample expression levels compared to the mean expression in 
HCs and log2 fold-change between CD test sample expression levels 
compared to the mean expression in HCs. The p value was set at a threshold 
of p<0.005 and a minimum fold change of 1.5 compared to the mean 
expression in HCs. 
2.9 Quantitative reverse transcription PCR (qRT-PCR) 
2.9.1 Cell preparation and conversion into cDNA 
Total RNA from BMDM was collected by lysing cells in 350 μl of Buffer RLT 
(Qiagen) containing 10 μl of 2-mercaptoethanol (Sigma) per 1 ml Buffer RLT. 
The whole of the large bowel was cut into 4 segments, open longitudinally to 
remove faeces and weighed to ensure that each segment was <30 mg. 
Large bowel segments were placed in 600 μl of RNAlater (Qiagen) and 
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homogenised with a TissueLyser LT (Qiagen) for 5 minutes at 50 Hz. Tubes 
were centrifuged at 14,000 g for 3 minutes at 4 °C and supernatants were 
transferred into fresh tubes. 600 μl of 70% ethanol was added to each tube 
and sample was transferred to RNeasy® Mini kit columns (Qiagen) and 
processed following manufacturer’s instructions with no DNase digestion 
step. 
Total RNA was converted to complementary DNA (cDNA) using the 
QuantiTect® Reverse Transcription Kit (Qiagen) following the manufacturer’s 
instructions. 1 μg of total RNA was added to 2 μl of gDNA Wipeout Buffer 
(Qiagen), made up to 14 μl with RNase-free water and incubated for 2 
minutes at 42 °C then placed on ice. 6 μl reverse transcription-mix containing 
1 μl Quantiscript Reverse Transcriptase, 4 μl Quantiscript RT buffer, 5× and 
1 μl RT primer mix (Qiagen) was added to each RNA sample making a total 
volume of 20 μl. Samples were incubated at 42 °C for 15 minutes and 95 °C 
for 3 minutes on a DNA Engine Tetrad 2® Peltier Thermal Cycler (Bio-Rad), 
made up to 100 μl with buffer TE (10 mM Tris pH 8.0, 1 mM EDTA) and 
stored at -20 °C. 
2.9.2 qRT-PCR protocol 
qRT-PCR of Tnf, Il6, Il10 and Cxcl1 was performed using the 
QuantiFast SYBR® Green PCR kit (Qiagen), in duplicate on a Mastercycler® 
ep realplex (Eppendorf) with primers created using Primer3 (Appendix 1). 
Stock primers at 100 μM were diluted to 3 μM i.e. 30 μl per 1 ml of RNase-
free water for qRT-PCR and stored at -20 °C. The qRT-PCR reaction was 
made up of 12.5 μl 2× QuantiFast SYBR Green PCR Master Mix, 2.5 μl 
forward primer, 2.5 μl reverse primer, 2 μl cDNA and 5.5 μl RNase-free 
water, to a total volume of 25 μl. The final concentration in the reaction 
volume was 1× QuantiFast SYBR Green PCR Master Mix, 0.3 μM of each 
primer and ~400 ng cDNA/reaction. The PCR mix was activated at 95 °C for 
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15 minutes, denatured at 95 °C for 15 s and annealed/extended at 60 °C for 
60 s, for a total of 40 cycles, then a melting curve was performed. The 
annealing temperature of 60 °C was chosen after a temperature gradient was 
run for each primer pair.  
Normalized mean gene expression values ± SD were determined from 
duplicate cycle threshold (Ct) values for each gene and the housekeeping 
gene peptidylprolyl isomerase A (Ppia). Relative transcript levels were 
determined by the 2−ΔΔCt method [231]. 
2.10 Immunoblot 
2.10.1 Whole cell lysate preparation 
After stimulation, MDM and BMDM supernatants were removed then the 
adherent cells were washed once in 500 μl PBS then lysed in 200 μl Laemmli 
sample buffer (see section 2.6 Reagents) containing protease inhibitors 
(Roche 11697498001) and phosphatase inhibitors 2 & 3 (Sigma P5726 & 
P0044). Samples were scraped with sterile 24 cm cell scrapers (SLS 
99002T), transferred into eppendorfs and pipetted up and down 10 times to 
break DNA then boiled at 95°C for 5 mins on an Eppendorf Thermostat plus 
and stored at -20 °C. Stimulated THP-1 cells were transferred into 
eppendorfs then centrifuged at 500 g for 5 minutes at 20 °C with a Beckman 
Coulter Microfuge 22R. Supernatants were transferred into new eppendorfs. 
200 μl Laemmli sample buffer containing protease inhibitors and 
phosphatase inhibitors was added to wells to lyse any remaining cells then 
transferred to the eppendorfs to lyse the cell pellet and pipetted up and down 
10 times to break DNA then boiled at 95 °C for 5 mins and stored at -20 °C. 
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2.10.2 Semi-dry transfer 
SDS-PAGE gels were cast using the Mini-PROTEAN® System (Bio-Rad) with 
30% w/v Acrylamide/ProtoFLOWGel (SLS H16996), 1.5 M Tris-HCl pH 8.8 
(resolving gel), 1 M Tris-HCl pH 6.8 (stacking gel), dH2O, 10% SDS (Sigma 
L3771), freshly made 10% ammonium persulphate (Sigma A7460) and 
TEMED (Sigma T9281) (added in the order listed with TEMED last). 10% 
SDS-PAGE gels were used for all experiments except for TNF and LC3 
where 15% gels were cast. 10 μl of sample were loaded onto 10-well SDS-
PAGE gels and run in ~700 ml of 1× transfer buffer without methanol (see 
section 2.6 Reagents) at 30 mA per gel for 40 minutes. 
60 ml of 100% methanol was added to the remaining 300 ml of 1× 
transfer buffer to make a 1× transfer buffer containing 20% methanol. 
Hybond-P PVDF membranes (GE Healthcare/Amersham RPN303F) were 
cut into 9 cm × 6 cm rectangles and activated in 100 % methanol. Four 
sheets of 12 cm × 8 cm blotting paper were soaked in transfer buffer, layered 
onto a Trans-Blot® SD semi-dry transfer cell (Bio-Rad) and rolled with an 
empty FACS tube to remove trapped bubbles. The activated PVDF 
membrane was washed in transfer buffer than placed on the blotting paper. 
The SDS-PAGE gel was removed from its glass mould in the transfer buffer, 
the stacking gel was gently cut off with the edge of the glass plate and the 
gel was placed on top of the PVDF membrane. Four more sheets of blotting 
paper were layered on top of the gel and rolled to remove trapped bubbles. 
The transfer cell was run at 100 mA per gel for 60 minutes. 
Membranes were blocked in 5% Marvel non-fat skimmed milk 
(Premier Foods) for 1 hour then washed 3 times in TBS-Tween. Membranes 
were probed with primary antibody overnight at 4°C (see section 2.5 
Antibodies) then washed 3 times with TBS-Tween. Membranes were probed 
with secondary antibody for 1 hour at room temperature then washed 3 times 
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with TBS-Tween. Bound antibody was detected using 1 ml ECL Plus 
(Amersham) per membrane, which was made up as per manufacturer’s 
instructions. Membranes were exposed to Hyperfilm ECL (Amersham) in a 
film cassette and scanned in at 300 dpi. 
Band intensity was quantified and normalised to actin using ImageJ 
(National Institutes of Health). 
2.11 Immunoprecipitation  
THP-1 cells (107) were lysed in 50 mM HEPES pH 7.5 (Sigma), 100 mM 
NaCl (Sigma), 10% glycerol, 0.5% NP-40 (Sigma), 0.5% CHAPS (Sigma), 
protease inhibitors (Roche), phosphatase inhibitor cocktail 1, 2 (Sigma) and 
300 μg/ml PMSF (Sigma) then passed through a 21G needle. Insoluble 
material was removed by centrifugation and the supernatant pre-cleared with 
protein A-agarose (Sigma) for 2 hours at 4°C. Pre-cleared supernatant was 
then incubated with anti-OPTN antibody (Sigma, 1:50) for 30 minutes at 4°C. 
Protein A-agarose was added, incubated overnight at 4°C and then washed 
5 times with ice cold PBS. THP-1 supernatant was incubated with protein A-
agarose overnight at 4°C and then washed 5 times with ice cold PBS and 
used as a negative control. 
2.12 Mass spectrometry 
For liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis, 
proteins were separated by 10% SDS-PAGE under reducing conditions. 
Proteins were visualized by silver-staining with ProteoSilver Plus (Sigma), 
bands were excised from both the OPTN-IP and control-IP gel lanes and 
processed for in-gel digestion and LC-MS/MS with the LTQ-Orbitrap mass 
spectrometer (Thermo Fisher Scientific), as previously described [232]. Raw 
MS files were analysed by the Mascot search engine 2.3.02 (Matrix Science) 
and searched against a SwissProt human database 2013_10 (containing 
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39,696 entries including common contaminants). Mascot search analysis 
parameters included: trypsin enzyme specificity, allowance for 2 missed 
cleavages, peptide mass tolerance of 20 ppm for precursor ions and 
fragment mass tolerance of 0.8 Da. Oxidation (M) was selected as a variable 
modification and carbamidomethyl (C) was selected as a fixed modification. 
2.13 Subcellular fractionation 
2.13.1 Preparation of sucrose gradients 
A 50% sucrose solution containing 1 mM EDTA pH 7.4 and 5 U/ml heparin 
and a separate 1 mM EDTA pH 7.4 and 5 U/ml heparin were made. Nine 5% 
step dilutions of 50% sucrose were made (Table 2-1). 
Table 2-1 Sucrose gradient composition used for subcellular fractionation. 
% sucrose Volume of 50% sucrose solution used (ml) 
Volume of 1 mM EDTA pH 
7.4 added (ml) 
50 10 0 
45 9 1 
40 8 2 
35 7 3 
30 6 4 
25 5 5 
20 4 6 
15 3 7 
10 2 8 
 
1 ml of each sucrose gradient was added to a 15 ml Falcon tube sequentially 
starting from 50% to the 15% sucrose gradient and left overnight to 
equilibrate at 4°C.  
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2.13.2 Subcellular fractionation of THP-1 cells 
2×108 THP-1 cells were incubated in RPMI 1640 and stimulated with HkEc at 
a multiplicity of infection of 20 for 24 hours. THP-1 cells were harvested and 
made up in 10% sucrose 1 mM EDTA pH 7.4 with 5 U/ml heparin containing 
protease inhibitor (Roche 11697498001) then lysed on ice with a dounce 
homogeniser (GPE limited) and sonicated 3×5 s (MSE Soniprep 150) up to 
three times or until cells are visibly lysed on light microscopy. Lysed THP-1 
cells were centrifuged at 750 g for 10 minutes at 4 °C.  
The post-nuclear supernatant was layered onto the sucrose gradient 
and ultracentrifuged in a TST 41.14 Kontron swing-bucket rotor at 220,000 g 
for 3 hours at 4°C on a Beckman Optima™ LE-80K Ultracentrifuge with slow 
acceleration and deceleration. The nuclear pellet was resuspended in 50 μl 
10% sucrose and stored at -80 °C. After centrifugation, 1 ml fractions were 
removed. The pellet was also resuspended in 50 μl 10% sucrose and all 
fractions were stored at -80 °C. 
Fraction sucrose percentages were measured with a Bellingham + 
Stanley Abbe 60 Refractometer. 
2.14 Lysosomal inhibition and TNF production 
5×105 BMDM from Optn-/- and Optn+/+ mice were plated in FALCON® 24-well 
tissue culture plates in DMEM and stimulated for 4 hours with HkEc at a MOI 
of 20 plus either DMEM alone, or DMEM with 2.5 μM monensin (Sigma 
M5273), 10 mM NH4Cl (Sigma A4514), 100 μM chloroquine (Sigma C6628), 
2.5 μM brefeldin A (Merck 203729) or 200 nM bafilomycin A (Sigma B1793).  
1 μl of 5M NH4Cl in dH2O, 1 μl of 1.25 mM monensin in DMEM (1:80 
dilution from 0.1 M monensin in methanol stock), 1 μl of 50 mM chloroquine 
in DMEM, 1 μl of 1.25 mM brefeldin A (1:2 dilution from 2.5 mM brefeldin A in 
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methanol stock) or 1 μl of 100 μM bafilomycin A in 10% DMSO stock was 
added to the 500 μl DMEM containing BMDM and HkEc at the start of the 4 
hour experiment to obtain final concentrations above. After 4 hours, 
supernatants were removed and stored at -80 °C and BMDM were lysed in 
Laemlli buffer and immunoblotted for TNF (see section 2.10 Immunoblot). 
2.15 Intraperitoneal E. coli infection 
2.15.1 Live E. coli infection 
The fully antibiotic sensitive clinical isolate of E. coli NCTC 10418 was 
cultured overnight in 10 ml LB broth, washed once in PBS, resuspended in 1 
ml PBS and counted at 1:20 dilution using a Cecil BioQuest™ CE2502 
spectrophotometer. The E. coli optical density at 600 nm (OD600) of 1×108 
bacteria/ml in PBS is 0.365. Nine to twelve week old Optn-/- and Optn+/+ 
female mice were injected intraperitoneally with serially diluted E. coli at 
1×108, 5×107, 2.5×107 and 1×107 bacteria/ml in PBS. Mice were weighed 
daily and tail bleed serum was collected for cytokine analysis at 48 hours. To 
tail bleed, mice were restrained with a plastic mouse restraint, the distal 5 
mm of its tail was cut off with a blade and the tail was massaged repeatedly 
to collect drops of blood in an eppendorf. Eppendorfs were sat at room 
temperature for 3 hours to allow clotting then centrifuged to obtain serum. 
After 6 days, mice were culled using CO2. 
2.15.2 Killed E. coli infection 
To assess cellular recruitment to the peritoneum, 1 ml heat-killed E. coli was 
injected into nine to twelve week old Optn-/- and Optn+/+ mice at 1-5×108 
HkEc/ml in PBS. Naïve and day 1 peritoneal washouts were harvested in cell 
dissociation buffer (Gibco) and analysed using flow cytometry (see section 
2.7.4 TiPM and 2.29 Flow cytometry). 
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2.16 Zebrafish Study 
2.16.1 Optn in situ hybridisation 
Whole-mount in situ hybridization was carried out as previously described 
with optn target-specific probes (Appendix 1) [233]. Stained specimens were 
mounted in paraffin, sectioned and counterstained with Nuclear Fast Red 
(Vector Labs) prior to imaging with a Leica DMR compound microscope 
equipped with a DFC420C camera. 
2.16.2 Salmonella immersion and injection infection 
Salmonella enterica serovar Typhimurium was grown in LB broth at 37°C, 
200 rpm overnight. To prepare Salmonella for an immersion (bath) infection, 
the culture was diluted 1 in 10 with DMEM, grown at 37°C, 200 rpm for a 
further 3 hours, washed once and resuspended in E3. Groups of 20 zebrafish 
larvae at 4 dpf were exposed to Salmonella at a final concentration of 5×108 
CFU/ml at 28.5°C. Salmonella injection was carried out using a method 
adapted from Prajsnar et al [234]. Salmonella was grown as above, washed 
and resuspended (1:1 ratio) in PBS. Injection doses were prepared by 
diluting the resuspended Salmonella 1:100 with PBS. 1 nl of this solution 
(approximately 200 CFU) was microinjected into the yolk sac of anesthetized 
2 dpf embryos mounted in methylcellulose. Immersion and injection doses 
were verified by plating onto LB agar. Embryos were recovered to E3, 
washed to remove excess methylcellulose and incubated for observations at 
28°C. Total RNA was isolated from zebrafish embryos using Trizol 
(Invitrogen). cDNA was synthesized from 2 μg of total RNA with the High 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems). qRT-PCR 
and primer used (Appendix 1) was as previously described [235].  
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2.16.3 Optn morpholino knockdown 
Morpholinos (GeneTools, LLC) were designed to target the splice donor site 
after exon 1 of the optn gene (Appendix 1). Primers that spanned introns 
were used for RT-PCR of the targeted junctions (Appendix 1). Morpholinos 
were injected into one- to four-cell stage embryos at 1.0 pmol per embryo as 
previously described [236]. Embryos were then injected with Salmonella at 2 
dpf as above and incubated for observations at 28°C. 
2.17 Dextran sodium sulphate (DSS) colitis 
2.17.1 DSS colitis protocol 
Optn+/+ and Optn-/- mice age 9 to 12 weeks were given 2% DSS (MW 36,000-
50,000) (MP Biomedicals 160110) in their drinking water for 7 days as 
described [237]. The normal drinking water in the animal unit was used to 
make up the 2% DSS to minimise the effect of alteration in water taste on 
consumption of the DSS that results from autoclaving water. The DSS was 
changed with fresh DSS after 2 days and 5 days from the start of the 
experiment and was changed back to fresh drinking water in a new water 
bottle after 7 days (Figure 2.1). 
2.17.2 DSS colitis clinical score 
Mice were weighed and faeces collected daily to calculate the disease 
activity score (Table 2-2) and guaiac faecal occult blood test slides 
(immunostics, inc HS-100). At set time points, mice were culled with CO2 and 
cervical dislocation and bowel and blood was harvested. 
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 Figure 2.1 Acute DSS colitis protocol. Protocol involves 7 days of DSS in the 
drinking water. Adapted from Wirtz et al, 2007 [237]. 
 
Table 2-2 DSS clinical disease activity score [238]. 
Score 0 1 2 3 4 
% Weight loss No weight loss 1 to 5 6 to 10 10 to 20 >20 
Stool consistency Well-formed pellets  Pasty stools  Watery stools 
Bleeding No blood on hemoccult   Positive hemoccult   Gross bleeding 
 
2.18 Citrobacter rodentium colitis 
2.18.1 Preparation of C. rodentium 
C. rodentium strain ICC169 was kindly provided by Gad Frankel (Division of 
Cell and Molecular Biology, Imperial College London, UK). C. rodentium was 
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cultured overnight by adding 1 µl glycerol stock to 10 ml LB broth medium 
containing 50 µg/ml nalidixic acid and incubated at 37°C 250 rpm in a 
shaker-incubator. C. rodentium was washed once in 10 ml phosphate-
buffered saline (PBS), pH 7.2 then made up in 1 ml PBS per 10 ml original 
LB broth, pooled and counted at an optical density of 600 nm (OD600), which 
is 0.161 for 1×108 bacteria/ml in PBS.  
2.18.2 Induction of C. rodentium colitis 
Nine to twelve week old Optn-/- and Optn+/+ littermate female mice were orally 
gavaged with 200 µl of C. rodentium in PBS using a 1 ml syringe attached to 
a curved 1 inch 20G stainless steel 2 mm ball-tipped gavage needle, giving 
each mouse 2.5 – 4.5 x 109 CFU of C. rodentium. Mice were scruffed firmly 
and held head up to minimize movement that may cause oesophageal or 
gastric perforation. 
Mice were weighed daily. Faeces collected for C. rodentium excretion 
and tail bleeds for serum cytokine analysis. After 2, 3 or 9 days, mice were 
culled with CO2 and cervical dislocation and cardiac punctures for blood was 
performed. Large bowel was collected for histology (see section 2.20 
Histology) and livers and spleens for bacterial culture. 
2.18.3 Sample preparation for C. rodentium culture 
Spleens and liver from C. rodentium infected mice were also harvested to 
check if there was a bacteraemia. Organs were homogenised in sterile 5 ml 
bijous containing 1 ml PBS using a 5 ml syringe plunger. 20 μl of supernatant 
was plated in each sector of a 4-sector 90 mm Petri Star™ dish (VWR 710-
3519) containing LB agar with 50 µg/ml nalidixic acid and incubated 
overnight at 37 °C  in a LEEC MkII dry incubator.    
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Fresh faeces was collected from individual mice, weighed dry then 
dispersed in 500 µl PBS using sterile pipette tips. The faeces was vortexed 
for 30 seconds then centrifuged at 500g for 30 seconds to pellet solid faeces. 
Serial dilutions were plated on LB agar plates as above and counted the next 
day. 
2.19 Lamina propria cell isolation 
Mice were culled with CO2 and cervical dislocation. Large bowels were cut 
longitudinally and washed in ice cold PBS containing 100 U/ml penicillin, 100 
µg/ml streptomycin (PAA) to remove faeces. Epithelial cells were removed by 
incubation of each large bowel in 20 ml of predigestion solution (HBSS 
(Gibco) containing 10% FBS, 100 U/ml penicillin, 100 µg/ml streptomycin and 
2 mM EDTA) in 50 ml Falcon tubes at 37°C, 250 rpm for 1 hour in an 
Innova™ 4000 incubator shaker [239]. Epithelial cells were passed through a 
70 μm filter. The remaining lamina propria tissue was cut into 1 mm pieces 
and washed with PBS to remove EDTA. Lamina propria tissue was incubated 
in 20 ml digestion solution (HBSS containing 10% FBS, 100 U/ml penicillin, 
100 µg/ml streptomycin, 30 mg collagenase (Sigma C2139), 0.8 mg DNase I 
(Sigma DN25) and 15 mg Dispase II (Sigma D4693)) at 37°C, 250 rpm for 30 
minutes, and vortexed vigorously for 20s at the start, middle and end of 
incubation. Lamina propria cells were passed through a 70 μm filter, washed 
with PBS then stained for flow cytometry (see section 2.29 Flow cytometer.) 
2.20 Histology and immunohistochemistry.  
2.20.1 Haematoxylin and eosin staining 
Large bowel tissue and organs were fixed in 10% neutral buffered formalin 
(CellPath BAF-0010-10A) overnight then paraffin-embedded using a Leica 
TP1050 tissue processor and RA Lamb Blockmaster embedding center. 
Blocks were sectioned at 5 μm onto SuperFrost® Plus slides (Thermo 
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Scientific) using a Leica RM2235 rotary microtome. Sections were stained on 
a Leica ST4040 linear stainer. Sections were dewaxed through 4 xylene 
stations and rehydrated through 4 graded industrial methylated spirit stations 
then water for 1 minute per station. Sections were stained in acidified VFM 
Harris’ haematoxylin (CellPath RBA-4205-00A) for 5 minutes, differentiated 
in 0.2% acid alcohol for 1 minute and stained in Eosin Y (VWR 
1.15935.1000) for 4 minutes with a running tap water wash between each 
step. Sections were dehydrated, cleared and mounted in Pertex (Leica 
3808706E).  
Colitis scoring of haematoxylin and eosin stained large bowel was performed 
blind with the 6 parameters in Table 2-3. 
2.20.2 OPTN immunohistochemistry 
The OPTN antibody (Sigma) was used to performed 
immunohistochemistry on available UCLH archival OPTNlow bowel biopsy 
samples with patient consent and a healthy control small bowel. Initial 
antibody optimisation was performed on control small bowel tissue. Sections 
underwent automated dewaxing and endogenous peroxidase was blocked 
using 3-4% (v/v) hydrogen peroxide. After preliminary optimisation where 
optimal conditions were chosen based upon the criterion of background-free 
selective cellular labelling, the antibody was used on the OPTNlow and 
healthy control small bowel samples at a dilution of 1:100 with 30 minute 
incubation at ambient temperature following heat induced epitope retrieval for 
20 minutes using an EDTA-based (pH 9.0) epitope retrieval solution. Signal 
visualization using the Bond Polymer Refine Detection kit (DS9800) with 
DAB Enhancer (AR9432) was performed on the Bond-III automated staining 
platform (Leica). Cell nuclei were counterstained with haematoxylin. 
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Table 2-3 H&E colitis scoring system. 
Epithelial hyperplasia 
0 None 
1 Mild hyperplasia but retaining architecture 
2 Moderate hyperplasia with mild distortion 
3 Severe, marked, crowding of cells 
Crypt deformity/architectural distortion 
0 None 
1 Mild branching/twisting/deformity 
2 Moderate, affecting >50% 
3 Severe, marked deformity near 100% surface due to inflammation & oedema 
Ulceration 
0 None 
1 Small focal erosions 
2 Small ulcers/multiple erosions 
3 Large/deep transmural ulcers 
Variation 
0 None/no inflammation 
1 Mild variability/patchy inflammation 
2 Moderate/>50% inflammation 
3 Severe, diffuse near 100% inflammation 
Inflammatory cell infiltrate 
0 None 
1 Few multifocal mononuclear cells in lamina propria 
2 Several multifocal areas & neutrophils 
3 Multiple transmural infiltrates/crypt abscesses 
Goblet cell depletion 
0 None/normal 
1 Mild/scattered depletion 
2 Moderate/>50% depletion 
3 Severe depletion/few visible/absent 
 
2.20.3 Myeloperoxidase immunohistochemistry 
The rabbit polyclonal anti-myeloperoxidase (MPO) antibody (Dako) was 
chosen for use in this study due to its reported specificity for MPO in murine 
tissues [240] and suitability for use with formalin-fixed paraffin-embedded 
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tissues. 3 µm thick sections of naïve murine large bowel as a negative 
control and bone marrow cells as a positive control were used for antibody 
optimisation on the Bond-III automated staining platform (Leica). Sections 
underwent automated dewaxing and endogenous peroxidase was blocked 
using 3-4% (v/v) hydrogen peroxide. After preliminary optimisation where 
optimal conditions were chosen based upon the criterion of background-free 
selective cellular labelling, the antibody was used on the Citrobacter infected 
large bowel samples at 1:1,000 with 30 minute incubation at ambient 
temperature following heat induced epitope retrieval for 20 minutes using an 
EDTA-based (pH 9.0) epitope retrieval solution. Prior to signal visualization 
using the Bond Polymer Refine Detection kit (Leica DS9800) with DAB 
Enhancer (Leica AR9432) a 10% block of normal goat serum (Sigma G9023) 
was applied at ambient temperature for 30 minutes to reduce non-specific 
binding of the polymer. Cell nuclei were counterstained with haematoxylin. 
2.20.4 Steiner Silver stain 
Slides were deparaffinised in xylene for 10 minutes then hydrated through an 
alcohol gradient (100%, 100%, 90%, 70%, 50%) to dH2O at 30 s per gradient. 
Slides were then incubated in preheated 1% uranyl nitrate at 60°C for 15 
minutes in plastic coplin jars and rinsed in three changes of hot 60°C dH2O. 
Slides were then incubated in preheated 1% silver nitrate at 60°C for 1.5 
hours, rinsed in three changes of hot 60°C dH2O, two changes of room 
temperature 95% ethanol and 2 changes of room temperature absolute 
ethanol. Slides were placed in room temperature 2.5% gum mastic for 5 
minutes and allowed to air dry. Slides were then incubated in reducing 
solution at 45°C for 20 minutes then allowed to stand in the reducing solution 
at room temperature until desired degree of black staining for 1 to 2 minutes 
and rinsed in three changes of room temperature dH2O. Slides were 
dehydrated through the alcohol gradient, cleared in xylene and mounted in 
DPX Mountant (Sigma 44581).  
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2.21 Killing assay 
Cells were plated at 2.5×105/well in a 24-well plate in their respective culture 
media containing penicillin and streptomycin and incubated overnight to allow 
cells to adhere to plate. Cells were washed once in 1 ml PBS and incubated 
overnight in media with no antibiotics to allow washing out of the antibiotics. 
Cells were washed once in 1 ml PBS and incubated with E. coli in media 
containing no antibiotics at an MOI of 20 for 2 hours at 37 °C, 5% CO2 to 
facilitate adequate phagocytosis of E. coli.  
After 2 hours, the cells were washed once in 1 ml PBS to remove 
bacteria and incubated in media containing 300 μg/ml gentamicin for 1 hour 
to kill extracellular E. coli. Cells were washed once in PBS to remove 
gentamicin and lysed for the 1 hour time point in PBS containing 1% Triton 
X-100 (BDH 306324N). Remaining cells were also washed in PBS and 
incubated in media containing 100 μg/ml gentamicin for further time points. 
Neat and three 1:10 serial dilutions of lysed cells in PBS was plated on LB 
agar plates and bacterial CFUs were counted the next day. 
2.22 Phagocytosis assay 
2.22.1 Preparation of FITC-labelled HkEc 
HkEc was labelled with fluorescein isothiocyanate (FITC) (Invitrogen F1906). 
1×109 HkEc was washed three times in 20 ml then resuspended in 1 ml of 
0.1 M sodium bicarbonate. 10 μl of 10 mg/ml FITC dye in DMSO was added 
to the HkEc and incubated at 1400 rpm, 4 °C for 30 minutes on an Eppendorf 
Thermomixer comfort incubator. 100 μl of 1.5 M hydroxylamine pH 8.5 
(Sigma 159417) was added to terminate the reaction. HkEc was washed 3 
times in PBS and stored at -20 °C. Trypan blue (Merck FN1072132) was 
made up at 2.5 mg/ml in dH2O and filtered with a Nalgene 0.45µm filter 
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(Thermo Scientific 190-2545) to remove undissolved residue and stored at 
room temperature.  
 
2.22.2 Phagocytosis of FITC-HkEc 
1×105 cells were plated onto Corning 96-well special optics plates (Sigma 
CLS3720) and incubated overnight to allow cells to adhere to the bottom of 
the plate. 100 μl of FITC-HkEc at an MOI of 20 was added to each well. 10 μl 
of 2.5 mg/ml Trypan blue was added to each well to quench the FITC at 
different time points. Fluorescence intensity was measured at an excitation 
wavelength of 485 nm and read at an emission wavelength of 520 nm using 
a FLUOstar Omega microplate reader (BMG LABTECH). 
 
2.23 Autophagy assay 
Optn+/+ and Optn-/- whole cell lysates from BMDM stimulated with HkEc at 
time points up to 24 hours were immunoblotted for LC3B (Sigma) to 
investigate autophagy in BMDM.  
 
2.24 Endoplasmic reticulum stress assays 
Optn+/+ and Optn-/- BMDM stimulated with HkEc for 4 hours were assessed 
for the unfolded protein response and were immunoblotted for CHOP (Affinity 
BioReagents), GRP78/BiP (Santa Cruz) and GRP94 (Santa Cruz). 
Additionally, BMDM were stimulated for 4 hours with 2 μM of 10mM 
Thapsigargin (Sigma T9033) in DMSO, 2 μg/ml of 1 mg/ml Tunicamycin 
(Sigma T7765) and 200 nM Bafilomycin A (Sigma) for mRNA. Total RNA was 
harvested and converted to cDNA as described above. PCR was performed 
on cDNA samples and digested with PstI (Promega) restriction enzyme. 
Samples were run on a 2% high performance MetaPhor™ Agarose (Lonza 
50181) gel, made as per manufacturer’s instructions and run at 4 °C to 
separate the bands. 
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2.25 Subcutaneous HkEc injection 
Nine to twelve week old Optn+/+ and Optn-/- female mice were anaesthetised 
with Halothane and their backs were shaved. Serial dilutions of HkEc were 
made up to 1×1010, 1×109, 1×108, 1×107, 1×106 per ml in PBS and 100 μl was 
injected subcutaneously in two areas over both scapulae for a dose response 
experiment. Injection was performed by tenting up the skin to ensure 
insertion of the 26 G needle into the subcutaneous space. Mice were 
weighed daily and size of the injection site was measured using Vernier 
callipers. Skin and serum was harvested for histology. 1×108 HkEc was used 
and injected into Optn+/+ and Optn-/- mice as described above. 
2.26 Confocal immunofluorescence microscopy 
2.26.1 Specimen preparation and staining 
Cells were plated onto methanol cleaned 13 mm diameter 0.13 mm thick 
pure white, hydrolytic class 1 round borosilicate glass coverslips (VWR 631-
0149) at 50,000 cells/coverslip overnight. Cells were fixed in 500 μl of 4% 
formaldehyde for 10 minutes then washed with 1 ml of PBS. The aldehydes 
were quenched in 500 μl of 50 mM NH4Cl for 10 minutes then washed with 1 
ml PBS and then permeabilised in 500 μl of 0.01% Triton X-100 for 10 
minutes then blocked in 500 μl of 100 µg/ml desalted human IgG (CSL 
Behring) in confocal buffer (see section 2.6 Reagents) for 15 minutes.  
Cells were then stained with primary antibody in confocal buffer for 30 
minutes. After 3 washes with 2 ml of confocal buffer per wash, cells were 
stained with secondary antibody and 300 nM DAPI (Invitrogen) for 30 
minutes. Cells were washed 3 times with 2 ml of confocal buffer and 
reblocked with 500 μl of 100 µg/ml desalted human IgG for 15 minutes. Cells 
were then stained in second primary antibody for 30 minutes, washed 3 
times and stained with secondary antibody. Cells were washed in 2 ml 
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confocal buffer, 2 ml dH2O and then 1 ml of dH2O to remove traces of PBS 
salts. 
Coverslips were gently lifted with a straight needle probe and then 
gripped with a pair of sharp pointed straight dissection forceps. Slides were 
mounted cells facing down in 12 μl of Mowiol® (Calbiochem), dried overnight 
in the dark at room temperature then stored at -20ºC. 8 bit, 0.5 µm thick 
single or z-stack, sequential images were taken using a Leica 40×/1.15 or 
63×/1.30 oil CS apochromatic objective on a Leica TCS SPE confocal 
microscope with LAS AF Version 2.3.6. 
2.26.2 Colocalisation analysis 
Colocalisation analysis was performed using ImageJ (National 
Institutes of Health). Individual BMDM were selected and thresholds were set 
for TNF, EEA1 and GM130 to visualise vesicles and the Golgi complex. The 
image calculator function was used with the AND operator to generate an 
image of colocalised pixels for each z-stack, then the histogram function was 
used to quantify the total number of TNF, EEA1, GM130 and colocalised 
pixels in each z-stack.  
Vesicle colocalisation in MDM was quantified by counting the number 
of double positive and single positive staining vesicles using Leica’s LAS AF 
Lite viewing program. 
2.27 Electron microscopy 
Cells were plated onto methanol cleaned 13 mm diameter glass coverslips at 
100,000 cells/coverslip overnight then stimulated with HkEc at a MOI of 20 
for 4 hours. Cells were fixed in fresh 2% paraformaldehyde/1.5% 
glutaraldehyde (Agar scientific) in 0.1 M sodium cacodylate buffer pH 7.3 
(BDH) for 1 hour. Cells were washed in 0.1 M cacodylate buffer for 5 min 
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twice then post fixed in 1% osmium tetraoxide (OsO4) (Agar Scientific)/1.5% 
potassium ferrocyanine (K4Fe(CN)6) (BDH) in 0.1 M cacodylate buffer pH 7.3 
for 1 hour at 4°C in the dark.  Cells were washed in 0.1 M cacodylate buffer, 
then in 1% tannic acid in 0.05 M cacodylate buffer for 5 min, a further wash in 
0.1 M cacodylate buffer and finally in dH2O for 5min. After rinsing with dH2O, 
specimens were dehydrated in a graded ethanol-water series and infiltrated 
with Agar 100 resin. Serial 1 μm sections were cut and stained with 1% 
toluidine blue in dH2O for light microscopy. At the correct position ultrathin 
sections were cut at 70-80 nm using a diamond knife on a Reichert ultracut 
microtome. Sections were collected on a 300 mesh copper grid, stained with 
uranyl acetate (BDH) and lead citrate (BDH) then viewed in a Joel 1010 
transition electron microscope and images recorded with a Gatan Orius 
camera. 
2.28 Cell Viability Assay 
2.28.1 MTT Assay 
Cells were plated at 105/well in a 96-well plate and stimulated with bacteria. 
After 4 hours, supernatants were removed and cell viability was assessed 
using the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrozolium bromide, 
tetrazolium salt) assay (Sigma). 30 μl of 2 mg/ml MTT in PBS was added to 
100 μl of media/well and incubated for 4 hours at 37 °C. Media was tipped off 
and 100 μl of MTT lysis solution was added to each well. Absorbance was 
measured on a FLUOstar Omega microplate reader (BMG LABTECH) at 563 
nm after complete cell lysis and formazan solubilisation occurred. 
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2.29 Flow cytometry  
2.29.1 Cell preparation and staining 
Cells (blood, bone marrow and peritoneal cells) were washed in FACS buffer 
(PBS containing 1% BSA, 0.01% azide), centrifuged at 500 g for 5 minutes at 
4 °C and resuspended in 200 μl of FACS buffer containing 2.0 µg/ml anti-
CD16/CD32 Fc block (eBioscience) for 20 minutes. Cells were washed in 1 
ml of FACS buffer then stained in 100 μl FACS buffer containing 0.5 µg/ml 
CD11b V450 (BD), 0.25 µg/ml Gr1 PE (BD), 0.25 µg/ml CD3 PE-Cy™7 (BD), 
0.25 µg/ml CD19 PerCP-Cy™5.5 (BD), 0.25 µg/ml Ly-6C APC (BD) and 0.5 
µg/ml F4/80 FITC (eBioscience) antibodies for 30 minutes in the dark at room 
temperature then fixed in 1% formaldehyde in PBS for 10 minutes.  
Lamina propria cells in PBS were incubated in the dark with 1 μl of the 
LIVE/DEAD® stain (Invitrogen) for 30 minutes following the manufacturer’s 
instructions.  Cells were washed in 1 ml of PBS then blocked in 2.0 µg/ml 
CD16/CD32 antibody in FACS buffer prior to staining at 0.5 µg/ml of each 
antibody above in combination with 1.0 µg/ml CD45 PerCP-Cy™5.5 (BD) 
and either 0.5 µg/ml CD19 PE (BD) or 0.5 µg/ml Gr1 PE (BD). 
2.29.2 Compensation particle preparation and flow cytometry 
Compensation particles (BD 552845) were prepared by adding each 
antibody above to 100 µl of FACS buffer containing 1 drop of positive 
particles (~60 µl) and 1 drop of negative particles (~60 µl) to the same final 
concentration of antibodies. Particles were incubated in the dark at room 
temperature for 20 minutes then washed with 1 ml FACS buffer, centrifuged 
at 500 g for 5 minutes and resuspended in 300 µl of FACS buffer. Cells were 
run on a BD LSRFortessa (blood, bone marrow and peritoneal cells) or LSR 
II (lamina propria cells) after compensation with antibody labelled particles 
and analysed with FlowJo (Tree Star, Inc). 
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2.30 Cytokine assay 
2.30.1 ELISA and MSD® immunoassay 
Cells were cultured in FALCON® 96-well tissue culture plates at 1 × 105 
cells/well for cytokine secretion assays. After removal of supernatants for 
storage at -80 °C, cell viability was assessed using the MTT (3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyl tetrozolium bromide, tetrazolium salt) assay 
(Sigma).  
Serum TNF levels from Optn+/+ and Optn-/- intraperitoneal E. coli 
infected mice were measured using the murine TNF-α ELISA kit (Peprotech 
900-K54) as per manufacturer’s instructions and read on a FLUOstar Omega 
microplate reader (BMG LABTECH) at 405 nm. TNF, IL6, IL10 and CXCL1 
levels in C. rodentium colitis serum and BMDM supernatants from Optn+/+ 
and Optn-/- mice were measured using the Mouse Pro-Inflammatory 7-plex 
Ultrasensitive plate (Meso Scale Discovery K15012C) and read on a 
SECTOR® Imager 6000 (Meso Scale Discovery). 
2.30.2 Proteome Profiler™ Array 
106 BMDM were stimulated with HkEc at an MOI of 20 in 6-well plates for 4 
hours. Cells were lysed in cold TBS containing 0.1% NP-40 and protease 
inhibitors, sonicated for 3× 3 s bursts on ice and then interrogated with the 
Mouse Cytokine Proteome Profiler™ Array Panel A (R&D ARY006), as per 
manufacturer’s instructions. Processed arrays were exposed to X-ray film 
and imaged. 
2.31 Statistical analysis 
All data are presented as mean ± SEM using GraphPad Prism 4.03 
(GraphPad Software, Inc). Statistical significance was calculated using 
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paired or unpaired two-tailed Student’s t-test, logrank test or Fisher’s exact 
test.  Mean differences were considered significant when p<0.05. 
2.32 Ethics 
This human study was approved by the Joint University College London 
(UCL)/University College London Hospitals (UCLH) Committee for the Ethics 
of Human Research (project numbers 02/0324) and the NHS National 
Research Ethics Service, London-Surrey Borders Committee (project 
number 10/H0806/115). Ethics committee approved consent forms were 
signed by all participants. 
Animal studies were performed in accordance with guidelines of 
University College London’s Biological Sciences Unit and licensed by the 
Animals (Scientific Procedures) Act 1986 and European Directive 
2010/63/EU on the protection of animals used for scientific purposes. All 
mice were euthanised humanely under Schedule 1 of the Animals (Scientific 
Procedures) Act 1986 by CO2 asphyxiation and confirmed with dislocation of 
the neck. 
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Chapter 3 Optineurin in macrophages of Crohn’s 
disease patients 
3.1 Introduction 
Macrophages are specialised cells of the innate immune system that are 
equipped with a wide range of pattern recognition receptors to detect, 
phagocytose and kill microbes in diverse tissue locations. Others in our 
research group previously showed defective neutrophil accumulation in the 
bowel of CD patients compared to HC at sites of trauma, by quantifying 
neutrophils in bowel biopsy and re-biopsy at the exact same location after six 
hours [107]. More recently, our group found that patients with CD mounted a 
poorer acute inflammatory response with impaired blood flow to sites of E. 
coli injection on the forearm and delayed accumulation of radioactively 
labelled autologous neutrophils to the site of infection [187]. This delayed 
neutrophil accumulation was associated with reduced clearance of 
radioactively labelled killed E. coli from forearm of CD patients.  
 To investigate this impaired neutrophil recruitment, our group 
performed transcriptomic analysis on human monocyte-derived 
macrophages from CD patients and HC, with UC patients as an inflammatory 
disease control. We identified defective proinflammatory cytokine secretion in 
macrophages from CD patients but not in HC and UC patients [187]. Anti-
inflammatory and chemokine levels were not different. Further analysis 
identified an enrichment of abnormally expressed genes associated with 
vesicle trafficking and cytoskeletal organisation in CD patients. Outlier 
analysis of macrophage gene transcription by myself and others in our group 
identified low macrophage expression of optineurin in seven out of 58 CD 
patients but none in HC or UC patients, as recently published [191]. 
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3.2 Results 
3.2.1 Low OPTN expression is replicated in 10% of CD patient 
In order to verify the previously reported link between low OPTN expression 
and CD (batch 1) [191], an additional 47 CD patients and 33 healthy controls 
(HC) were recruited into a replication cohort (batch 2). Outlier analysis of 
macrophage gene expression in this replication cohort identified a further 
four CD patients with low OPTN (OPTNlow) expression, replicating the 
previously reported link (Figure 3.1).   
 
Figure 3.1 Outlier analysis of macrophage OPTN expression on microarray 
identified 11 OPTNlow CD patients. A primary cohort (left) identified seven 
and a subsequent replication cohort (right) identified four CD patients with 
low OPTN expression on outlier analysis. p value was set at a threshold of 
p<0.005 and a minimum fold change of 1.5 compared to the mean 
expression in HC. Data collection and analysis in the primary (left) and 
replication cohort (right) was performed by myself and others in our group. 
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To validate the microarray results and establish the level of OPTN 
under expression, qPCR was performed (Figure 3.2). Three out of four 
OPTNlow CD patients in the replication cohort that were available for retesting 
demonstrated on average a three-and-a-half fold reduction in OPTN 
transcript levels (p<0.01), replicating the qPCR validation in the initial seven 
OPTNlow CD patients identified [191]. Immunoblot of OPTN in MDM from four 
OPTNlow CD patients confirmed reduced OPTN protein expression compared 
to HC (Figure 3.3). 
 
Figure 3.2 qPCR verification of OPTN expression in macrophages confirms 
reduced expression in three OPTNlow Crohn’s disease patients. Results 
shown are mean ± SEM (ns, non-significant; **p<0.01; two-tailed, unpaired t 
test). qPCR of the three OPTNlow CD from the replication cohort was 
performed by myself whilst qPCR of the HC and CD patients were performed 
by others in our group. 
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 Figure 3.3 Immunoblot of OPTN confirmed low OPTN protein levels in 
macrophages from four OPTNlow CD patients. The OPTN protein levels were 
significantly lower than four HC tested. Results shown are mean ± SEM 
(*p<0.05; two-tailed, unpaired t test). All four OPTNlow CD patients and the 
four randomly selected HCs from our research group were all part of the 
primary cohort. Immunoblotting was performed by myself and others in our 
group. 
Of the 105 CD patients in total from both cohorts, 11 (10.5%) were 
identified as expressing OPTN at a level significantly below the range found 
in the HC population (n=75). By contrast, patients with the other major 
inflammatory bowel disease (IBD) phenotype, UC (n=49), demonstrated 
normal OPTN expression (p=0.0029 and p=0.0172 for difference from HC 
and UC respectively) (Table 3-1).  
Table 3-1 Outlier analysis of monocyte-derived macrophage gene 
expression identified a statistically significant cohort of OPTNlow CD patients. 
HC, healthy controls; CD, Crohn’s disease; UC, ulcerative colitis. 
Group Batch 1 Batch 2 Combined 
  OPTNnormal OPTNlow OPTNnormal OPTNlow OPTNnormal OPTNlow 
HC 42 0 33 0 75 0 
CD 51 7*/# 43 4 94 11**/# 
UC 49 0 - - 49 0 
CD vs HC *p<0.05, **p<0.01; CD vs UC #p<0.05, Fisher's exact test 
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3.2.2 Low OPTN expression in CD shows a potential male sex bias 
Having established a link with CD, demographic data, smoking status, 
medication and Montreal classification of Crohn’s disease of all the CD 
patients were collected and analysed to look for any association with low 
OPTN expression. A weak association was found between low OPTN 
expression and male CD patients (p=0.011) but otherwise no association 
was found with age, medication or smoking status (Table 3-2 and Figure 
3.4). The whole cohort of CD patients consisted of 47 males and 58 females 
of which 9 males and 2 females had low OPTN expression. These results 
suggest a potential sex bias in OPTN expression within the CD population. 
Separating OPTN expression by disease and sex revealed a lower 
expression in CD males compared to CD females (Figure 3.5), but the 
numbers were too small to come to definitive conclusions. This sex 
difference in the CD population was not replicated in either the HC or UC 
cohorts.  
Phenotypically, all of the OPTNlow males had ileal involvement 
comprising four with ileal (L1) and five with ileocolonic (L3) disease (Table 
3-3). To further investigate the role of OPTN in ileal disease in males, a 
recently published online dataset (GSE16879) was interrogated, which 
contains biopsy material from 6 (3M, 3F) controls and 18 (9M, 9F) CD 
patients both before and after infliximab anti-TNF treatment (Figure 3.6) 
[241]. Ileal OPTN expression was significantly lower in the male CD patients 
before treatment compared to male controls (p=0.006) and female CD 
patients (p=0.004). Interestingly, female CD patients demonstrated no 
reduction in OPTN in the terminal ileum compared to female controls and 
infliximab treatment had minimal effect on the expression of OPTN in both 
sexes (Figure 3.7). Further work is needed to confirm an association 
between reduced OPTN expression and male CD patients.  
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Table 3-2 Demographic data for healthy controls, Crohn’s disease patients 
and 11 OPTNlow CD patients show a potential enrichment of males. 
  Healthy controls 
Crohn’s 
disease OPTN
low p-value# 
n= 75 94 11  
Gender, n (M:F) 40:35 38:56 9:2 0.011 
Mean age ± standard deviation 39.7 ± 11.6 39.3 ± 13.8   45.3 ± 17.0 0.185 
Age range 22 - 69 20 - 70 23 - 65  
     
Smokers, n (%)  11 (12.1) 2 (18.2) 0.629 
Non smokers  80 (87.9) 9 (81.8)  
     
Medication, n (%)     
 Nil  23 (24.5) 2 (18.2) 1.000 
 Budesonide/Prednisolone 5mg  1 (1.1) 1 (9.1) 0.200 
 5-aminosalicylates  52 (55.3) 4 (36.4) 0.340 
 Immunomodulators  26 (27.7) 4 (36.4) 0.506 
 Anti-TNF  11 (11.7) 1 (9.1) 1.000 
     
Montreal classification for Crohn's disease, n (%)     
Age onset A1: ≤16  19 (20.2) 3 (27.3) 0.695 
 A2: 17 - 40  62 (66.0) 5 (45.4) 0.200 
 A3: >40  13 (13.8) 3 (27.3) 0.367 
Location L1: ileal  29 (30.9) 5 (45.5) 0.329 
 L2: colonic  22 (23.4) 1 (9.0) 0.449 
 L3: ileocolonic  41 (43.6) 5 (45.5) 1.000 
 L4: upper GI  10 (10.6)* 1 (9.0)† 1.000 
Behaviour B1: non-stricturing, non-penetrating  52 (55.3) 4 (36.4) 0.340 
 B2: stricturing  23 (24.5) 5 (45.5) 0.158 
 B3: penetrating  27 (28.7) 6 (54.5) 0.096 
 p: perianal  24 (25.5) 4 (36.4) 0.479 
#p-values shown are comparisons between OPTNlow and Crohn's disease  
*Two patients have purely upper GI disease; †patient also has lower GI disease 
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Figure 3.4 Crohn’s disease and OPTNlow patients by sex, medication and Montreal classification. Outer donut charts 
represents the 94 CD patients whilst the inner pie chart represents the 11 OPTNlow CD patients. Charts depict 
proportion by sex (top left), active medication (top right), Montreal classification for CD parameter for age of disease 
onset (bottom left), location (bottom middle) and behaviour of disease (bottom right).
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Figure 3.5 OPTN expression in macrophages was significantly lower in male 
CD patients compared to female CD patients.  Results shown are mean ± 
SEM (ns, non-significant; *p<0.05; two-tailed, unpaired t test). OPTN 
expression was calculated as a % mean of all HC for each cohort. 
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Figure 3.6 OPTN expression in the ileum was significantly lower in male CD 
patients compared to controls and female CD patients. The lower OPTN 
levels were minimally altered with infliximab anti-TNF treatment. Data from 
GSE 16879, de Bruyn et al. 2014. Results shown are mean ± SEM (*p<0.05 
and **p<0.01; two-tailed, unpaired and paired t test). 
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Figure 3.7 OPTN expression in the ileum is variably affected by IFX 
treatment. Data from GSE 16879, de Bruyn et al. 2014. 
 
Table 3-3 Demographic data, Montreal classification of Crohn's disease, 
drug treatment and smoking status in the 11 OPTNlow CD patients show an 
enrichment of ileal involved disease.  
  Age Sex Montreal classification Treatment  Smoking status 
      Age onset Location Behaviour (when MDM grown)   
1 23 M A1 (10) L3 B2 + B3p Azathioprine, Adalimumab  Non smoker 
2 23 M A1 (11) L1 B2 + B3p Methotrexate Non smoker 
3 26 M A1 (13) L1 + L4 B1 5-aminosalicylate Non smoker 
4 34 M A2 (29) L3 B1 5-aminosalicylate Non smoker 
5 36 M A2 (21) L3 B2 + B3p Nil Non smoker 
6 50 M A2 (20) L1 B2 Azathioprine Non smoker 
7 58 M A3 (42) L3 B3p Methotrexate Non smoker 
8 60 M A2 (23) L1 B3 Prednisolone 5mg Non smoker 
9 61 F A2 (40) L1 B2 + B3 Nil Smoker 
10 62 F A3 (60) L2 B1 5-aminosalicylate Non smoker 
11 65 M A3 (52) L3 B1 5-aminosalicylate Smoker 
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 3.2.3 OPTN expression is associated with inheritance of a minor SNP 
 To investigate the deficient OPTN expression identified in this subset 
of CD patients, all exons, exon-flanking regions and 2 kilobase regions up 
and downstream of the OPTN gene was sequenced in seven OPTNlow CD 
patients [191]. None of the commonly published glaucoma and amyotrophic 
lateral sclerosis variants were identified in these seven OPTNlow CD patients. 
However, five of the OPTNlow CD patients were homozygous and two were 
heterozygous for the rs12415716 minor allele that is located in the intronic 
region downstream of the last exon. To determine if the haplotype was 
associated with macrophage OPTN expression, 66 HCs and 76 CD patients 
including the newly identified OPTNlow CD patients from our microarray 
cohort were genotyped for the rs12415716 single nucleotide polymorphism 
(SNP). Low OPTN expression in macrophages, was found to be associated 
with inheritance of the minor allele at rs12415716 (Figure 3.8), which was 
exaggerated by CD. 
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Figure 3.8 Low OPTN expression is driven by inheritance of the minor SNP 
at rs12415716, which is exaggerated by CD. Results shown are mean ± 
SEM (*p<0.05, **p<0.01 and ***p<0.001; two-tailed, unpaired t test). 
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 3.2.4 OPTN is expressed in monocytes, lymphocytes and 
macrophages but not neutrophils 
In order to ascertain which cells types express OPTN, we isolated peripheral 
blood monocytes, lymphocytes, neutrophils and monocyte-derived 
macrophages (MDM) (Figure 3.9). Immunoblotting demonstrated that OPTN 
is expressed in monocytes, lymphocytes and MDM but not neutrophils in 
both a HC and OPTNlow individual.  
Ileal biopsies from four OPTNlow CD patients were stained for OPTN 
protein expression and compared against control small bowel (Figure 3.10).  
All OPTNlow patients tested demonstrated lower levels of OPTN expression in 
the lamina propria tissue-resident cells.  
 
 
Figure 3.9 Immunoblot of OPTN showing that OPTN is expressed in human 
monocytes, lymphocytes and macrophages but not in neutrophils. The 
immunoblot also shows reduced OPTN expression in the monocytes, 
lymphocytes and macrophages of an OPTNlow individual compared to the 
healthy control. Mo, monocytes; Ly, lymphocytes; Mφ, macrophages; Ne, 
neutrophils. 
 
 
119 
 
  
Figure 3.10 OPTN immunohistochemistry in the small bowel shows weaker 
staining in the lamina propria cells of an OPTNlow CD patient compared to a 
healthy control. (Upper panels 10× magnification, scale bar 400 µm; middle 
40×, 100 µm; lower 100×, 40 µm). Staining was performed by UCL-Advanced 
Diagnostics. 
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 3.3 Discussion 
In this chapter, microarray transcriptomic profiling of human MDM from 
patients with CD, HC and UC patients as an inflammatory disease control 
was performed to investigate the phenotype of impaired proinflammatory 
cytokine secretion and defective neutrophil recruitment in CD. The first cohort 
investigated identified significantly reduced OPTN expression in around 10% 
of CD patients but none amongst HC or patients with UC [191]. This second 
replication cohort reproduced our earlier findings and out of 105 CD patients 
in total, 11 (10.5%) had low MDM OPTN expression but none in the 75 HC or 
49 UC patients recruited.  
The same microarray outlier analysis in MDM also identified reduced 
expression of ADAM-like, decysin 1 (ADAMDEC1), an ADAMs related 
metalloprotease in around 10% CD patients.  Absence of ADAMDEC1 
results in exaggerated DSS and Citrobacter colitis in experimental mice, 
further verifying the outlier analysis employed to identify genes of 
significance in CD macrophages that render increased susceptibility to colitis 
[242]. This work is the subject of another PhD. 
OPTN was not identified in GWAS of CD. This is because GWAS 
works on a common disease, common variant hypothesis that may fail to 
identify rarer variants of stronger effect [134]. This is sited as a potential 
reason why only 23% of the heritability of CD has been identified through 
GWAS [99]. For example, there were no GWAS loci identified in X-linked 
inhibitor of apoptosis protein (XIAP), which has been shown to be a risk 
factor for CD and supports an immunodeficient pathogenesis in CD [243]. 
Alternatively, the association of OPTN with CD may be limited to 
macrophages requiring a transcriptomic approach to identifying the 
association. 
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  Nine out of eleven of the OPTNlow CD patients were males. Separation 
of OPTN expression in MDM according to sex in HC, CD and UC patients 
revealed significantly lower OPTN expression in males compared to females 
in CD (Figure 3.5). The sex bias is not seen in HC and UC patients. The 
male bias in low OPTN expression is statistically significant but limited by 
small numbers, hence definitive conclusions cannot be made without further 
replication, larger numbers or functional corroboration. At this point, it is not 
clear what is causing this male bias and sex-influence on OPTN expression 
but may be due to linkage of the associated SNP with sex-linked or sex-
limited genes. 
There was also an association between low OPTN expression and 
ileal involvement in CD (Table 3-2). Ten out of eleven (~91%) of the OPTNlow 
CD patients has ileal involved CD with only one female patient having pure 
colonic CD. This is in contrast to widely published data on the distribution of 
CD with upto a third having pure colonic disease and only two-thirds with ileal 
involvement [5]. The terminal ileum is the commonest site for CD and 
represents the area of greatest transition between the relatively sterile 
jejunum and the bacteria dense caecum, which may be exposed to refluxed 
bacteria from the caecum through the ileocaecal valve. The association of 
OPTN expression and ileal involved CD mirrors the association of NOD2 
inheritance with ileal CD and highlights the important association of bacterial 
response genes and by extrapolation intraluminal bacteria with ileal 
inflammation [244]. It is therefore plausible that low OPTN expression 
causing an abnormal bacterial response may predispose an individual to 
bacteria driven colitis. 
 Interrogation of a recently published online dataset (GSE16879) [241] 
found that OPTN expression from ileal biopsies was significantly lower in 
male CD patients compared to male HC and females with CD (Figure 3.6). 
This verifies our finding of reduced OPTN expression in CD patients and the 
potential male bias. It also implicates the ileum as a site of potential 
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 importance in the association of low OPTN expression and CD. The use of 
the anti-TNF IFX only marginally altered OPTN expression, which suggests 
that IFX is unlikely to be affecting the expression of OPTN in our cohort. 
What remains unclear from this data is whether CD disease activity may be 
driving down the expression of OPTN in the ileum since there was little 
difference in ileal inflammation and OPTN remained unchanged before and 
after IFX treatment in this cohort of patients with active CD. By contrast, 
patients that were recruited to our study had quiescent CD. 
 There was no significant difference in age, smoking status, drug 
treatment, age of onset or behaviour of CD in the OPTNlow cohort. There may 
be a trend towards more aggressive disease with a greater proportion of 
OPTNlow CD patients with stricturing and fistulating disease. However, the 
small numbers of OPTNlow CD patients is again a limiting factor in identifying 
any association between disease behaviour and OPTN expression.  
 Although none of the widely published variants associated with 
glaucoma and ALS were identified (Figure 1.7), an expression quantitative 
trait locus (eQTL) was found at SNP position rs12415716, which lies in an 
intronic region downstream of the last OPTN exon. Inheritance of the minor 
allele, with an allele frequency of 0.18 was associated with reduced OPTN 
expression. Gene expression and hence eQTL analysis is highly tissue 
specific. eQTL analysis using Genevar (GENe Expression VARiation) 
software [245] also identified rs17512962 as a proxy SNP in linkage 
disequilibrium with rs12415716, which is in eQTL with OPTN expression in 
fibroblasts [246]. The rs17512962 interaction with OPTN expression was 
more recently replicated in peripheral blood [247]. 
 Up to 88% of disease associated SNPs are intergenic (43%) or 
intronic (45%) [248]. This SNP is unlikely to be the sole cause of impaired 
OPTN expression as the minor allele is necessary but not sufficient to fully 
account for the altered expression, since the expression of OPTN influenced 
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 by inheritance of this minor allele was exaggerated in CD patients. It is likely 
that this SNP is in linkage disequilibrium with other yet unidentified variant or 
variants that either individually or collectively reduce OPTN expression in 
CD. The penetrance of this minor allele in OPTN expression is incomplete, 
which is unsurprising since the penetrance of the most strongly associated 
gene with CD, NOD2 is only 4.9% in homozygotes/compound heterozygotes 
[249]. 
MDM, monocytes, neutrophils and lymphocytes were isolated to 
investigate the expression of OPTN in these various leukocytes cells types. 
Interestingly, while OPTN was expressed in monocytes, lymphocytes and 
macrophages, OPTN was undetectable in neutrophils by immunoblotting. It is 
unclear why OPTN is not expressed in neutrophils since autophagic 
processes and cytokine secretion have been reported in neutrophils [250, 
251]. It is possible that neutrophils have evolved such efficient killing 
mechanisms that autophagy of ubiquitinated cytosolic bacteria via 
autophagosomes are redundant and autophagy merely serves the purpose 
of recycling organelles in neutrophils. Additionally, TNF is not secreted by 
neutrophils [251] and cytokines that are secreted by neutrophils occurs 
independent of OPTN.  
Immunohistochemistry for OPTN in small bowel specimens from HC and 
OPTNlow CD patients revealed reduced staining for OPTN In lamina propria 
cells in the OPTNlow CD patients. Costaining with macrophage or B cell 
markers was not performed due to limited biopsy specimens but the OPTN 
staining lamina propria cells were morphological identical to macrophages 
and B cells according to our GI Histopathologist. Whilst this is by no means 
conclusive in proving that the lamina propria macrophages have reduced 
OPTN levels in the OPTNlow CD patient small bowel specimens, the sections 
were all treated simultaneously under the same conditions and concentration 
of antibodies that verifies the reduced OPTN expression reported in ileal 
biopsies [241]. What remains unclear despite these two pieces of evidence is 
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 the contribution of CD itself to the expression of OPTN in the ileum as 
discussed above. 
Whilst these findings are noteworthy, the association between altered 
OPTN expression and CD is incomplete without the further functional studies 
in the next few chapters that link the role of OPTN with the CD phenotype of 
impaired neutrophil recruitment and severe colitis. 
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 Chapter 4 Intracellular location and function of 
optineurin in macrophages  
4.1 Introduction  
Low OPTN expression in MDM was identified in 10% of CD patients, as 
demonstrated in Chapter 3. OPTN was a good candidate for further 
investigation in CD due to its role in post-Golgi protein trafficking and 
autophagy.  However, most published work on OPTN was in non-immune 
cells including work on autophagy, in HeLa cells [125].  
 OPTN’s role in protein trafficking is via its role as an intracytoplasmic 
adaptor protein that forms complexes with Rab8, myosin VI and HTT. OPTN 
and myosin VI together were localised to the Golgi complex and were shown 
to have a role in maintaining the structure of the Golgi in HeLa cells [201]. 
Additionally, OPTN in complex with myosin VI and Rab8 has a role in post-
Golgi membrane trafficking since OPTN RNAi resulted in reduced transport 
from the Golgi to the plasma membrane in nonpolarised HeLa cells and to 
the basolateral domain in polarised MDCK kidney epithelial cells [203]. 
OPTN and myosin VI depletion was also found to reduce secretory vesicle 
fusion events at the plasma membrane in HeLa cells [205]. OPTN was also 
colocalised with huntingtin (HTT) to the Golgi complex in rat striatal cells 
[206]. RNAi of wildtype Htt resulted in impaired post-Golgi trafficking to 
lysosomes, which was dependent on the expression of wildtype Rab8 and 
OPTN and resulted in the accumulation of the lysosome bound mannose-6-
phosphate receptor at the TGN and reduced lysosomal function in 
proteolysis. 
The LC3-interacting region (LIR) in OPTN (Figure 1.7) was mapped to 
amino acids 169 to 209 [125]. Phosphorylation of OPTN within the LIR at 
serine-177 by TANK binding kinase 1 (TBK1) enhanced binding of OPTN to 
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 LC3 and autophagic clearance of ubiquitin-coated cytosolic Salmonella 
enterica. Conversely, OPTN with ubiquitin and LC3 binding domain 
mutations as well as silencing of OPTN or TBK1 resulted in impaired 
Salmonella autophagy and intracellular bacterial proliferation. 
Here I investigate the intracellular location and role of OPTN in 
macrophages in the context of inflammation and bacterial infection. 
4.2 Results 
4.2.1 Intracellular location of OPTN in human monocytes and 
macrophages 
Previous studies have localised OPTN to multiple intracellular locations [201, 
205]. Subcellular fractionation was performed on HkEc stimulated THP-1 
cells to determine the intracellular location of OPTN (Figure 4.1). The 
majority of OPTN was localised to the cytoplasmic fractions, 1 to 3 and also 
to a lesser extent, the Golgi enriched fraction 5. There was minimal overlap 
between OPTN and LAMP1 positive fractions, which suggest that OPTN is 
not localised to lysosomal vesicles.  
Immunoprecipitation (IP) of OPTN was performed on THP-1 cells, 
verified by immunoblotting (Figure 4.2) and co-precipitated proteins were 
identified using shotgun proteomics (Table 4-1). The strongest signal in the 
OPTN IP associated with the myosin complex was the unconventional 
myosin 18A (MYO18A), which has been shown to apply a tensile force to the 
trans-Golgi membrane, participating in the process of vesicle budding in 
anterograde trafficking [252]. Additionally, OPTN’s binding partner myosin VI 
was also pulled down in the IP. 
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Figure 4.1 Subcellular fractionation of HkEc stimulated THP-1 cells show 
OPTN localised to the cytoplasm and fractions containing Golgi membranes 
but not lysosomes. Immunoblots for the Golgi markers golgin-245 and 
GM130, LAMP1, OPTN and GAPDH on sucrose density gradient separated 
subcellular fractions show that OPTN is in the cytoplasmic (fractions 1 to 3) 
and Golgi fractions (fraction 5) but not in LAMP1 vesicle fractions (fractions 6 
to 9) in THP-1 cells.  
 
Figure 4.2 Immunoblot of OPTN after immunoprecipitation confirms 
successful pull down of OPTN. Immunoblot of OPTN on OPTN IP sample 
confirms the pull down of OPTN with minimal OPTN staining in the post IP 
lysate and the absence of OPTN in the beads alone control. 
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 Table 4-1 Proteins identified in the OPTN IP on mass spectrometry localise OPTN to the Golgi*. 
Protein  Symbol Mascot Protein  Mascot Expect Value Peptides Identified Protein Coverage % 
Complement C4-B  C4B 1240 3.70E-120 22 18.4 
Isoform 2 of Unconventional myosin-XVIIIa  MYO18A 1182 2.50E-114 20 18.6 
Isoform 2 of Unconventional myosin-Ic MYO1C 924 1.50E-88 17 27 
Isoform 2 of Fibrinogen alpha chain  FGA 854 1.70E-81 15 32.1 
Isoform 2 of Optineurin OPTN 822 2.60E-78 14 32.7 
High affinity immunoglobulin gamma Fc receptor I  FCGR1A 625 1.30E-58 11 28.9 
Actin, cytoplasmic 2  ACTG1 633 1.80E-59 10 41.9 
Isoform 2 of Myosin-10   MYH10 601 3.10E-56 10 5.7 
Structural maintenance of chromosomes protein 4   SMC4 597 8.00E-56 10 11.3 
Apolipoprotein B-100   APOB 428 5.70E-39 10 2.9 
Isoform 6 of Unconventional myosin-VI   MYO6 546 9.70E-51 9 10.1 
Isoform 2 of Myosin-14   MYH14 538 6.30E-50 9 4.5 
Isoform Beta-1 of DNA topoisomerase 2-beta   TOP2B 401 3.50E-36 8 6.3 
Complement factor H   CFH 389 4.80E-35 8 8.9 
Valine--tRNA ligase   VARS 453 2.00E-41 6 8.5 
Protein S100-A8   S100A8 311 2.90E-27 6 49.5 
Isoform 2 of Programmed cell death 6-interacting protein PDCD6IP 302 2.30E-26 6 8.4 
Isoform 2 of Clusterin   CLU 300 4.20E-26 6 15.8 
Protein-glutamine gamma-glutamyltransferase K   TGM1 277 8.50E-24 6 10.2 
Isoform 1 of Protein POF1B   POF1B 260 4.50E-22 6 11.4 
Unconventional myosin-If   MYO1F 333 2.10E-29 5 6.3 
Protein S100-A9   S100A9 317 8.30E-28 5 51.8 
Isoform 2 of Caprin-1   CAPRIN1 298 6.20E-26 5 8.4 
Pentatricopeptide repeat domain-containing protein 3, mitochondrial PTCD3 297 8.80E-26 5 9.1 
Engulfment and cell motility protein 1   ELMO1 294 1.60E-25 5 11.1 
Caspase-14   CASP14 285 1.40E-24 5 21.9 
Coatomer subunit delta   ARCN1 257 8.50E-22 5 14.1 
Isoform 2 of Protein flightless-1 homolog   FLII 255 1.20E-21 5 7.4 
Structural maintenance of chromosomes protein 3   SMC3 249 5.40E-21 5 7.1 
DNA replication licensing factor MCM4   MCM4 245 1.10E-20 5 8 
*Only proteins that have been identified with five or more peptides, which are not found in the control sample are included. 
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 Table 4-2 Gene Ontology analysis of proteins identified in the OPTN IP shows association with intracellular vesicles and the 
cytoskeleton. 
GO Term Go Term Name Count % p value Benjamini Genes 
GO:0016459 myosin complex 6 20.0 0.00000018 0.00003065 MYO6, MYO1C, MYO1F, MYH14, MYO18A, MYH10 
GO:0015629 actin cytoskeleton 7 23.3 0.00001328 0.00115430 ACTG1, MYO6, MYO1C, MYO1F, MYH14, MYO18A, MYH10 
GO:0043232 intracellular non-membrane-bounded organelle 16 53.3 0.00003096 0.00179392 MYO6, MYO1C, S100A9, MYO1F, MCM4, SMC3, SMC4, ELMO1 
      ACTG1, TGM1, FLII, MYH14, PDCD6IP, TOP2B, MYO18A,  
      MYH10 
GO:0043228 non-membrane-bounded organelle 16 53.3 0.00003096 0.00179392 MYO6, MYO1C, S100A9, MYO1F, MCM4, SMC3, SMC4, ELMO1, 
      ACTG1, TGM1, FLII, MYH14, PDCD6IP, TOP2B, MYO18A,  
      MYH10 
GO:0005856 cytoskeleton 12 40.0 0.00003727 0.00162012 ACTG1, MYO6, MYO1C, TGM1, FLII, MYO1F, MYH14, PDCD6IP, 
      MYO18A, SMC3, MYH10, ELMO1 
GO:0016461 unconventional myosin complex 3 10.0 0.00008303 0.00288549 MYO6, MYO1C, MYO1F 
GO:0031941 filamentous actin 3 10.0 0.00041103 0.01185145 MYO6, MYO1C, MYO1F 
GO:0044430 cytoskeletal part 9 30.0 0.00042766 0.01057625 MYO6, MYO1C, FLII, MYO1F, MYH14, PDCD6IP, MYO18A, 
 
     SMC3, MYH10 
GO:0044433 cytoplasmic vesicle part 5 16.7 0.00051546 0.01115140 APOB, MYO6, FGA, ARCN1, CLU 
GO:0016023 cytoplasmic membrane-bounded vesicle 7 23.3 0.00068045 0.01307366 APOB, MYO6, FGA, ARCN1, CLU, PDCD6IP, OPTN 
GO:0031988 membrane-bounded vesicle 7 23.3 0.00080607 0.01393329 APOB, MYO6, FGA, ARCN1, CLU, PDCD6IP, OPTN 
GO:0031410 cytoplasmic vesicle 7 23.3 0.00152299 0.02382103 APOB, MYO6, FGA, ARCN1, CLU, PDCD6IP, OPTN 
GO:0031982 vesicle 7 23.3 0.00189513 0.02713060 APOB, MYO6, FGA, ARCN1, CLU, PDCD6IP, OPTN 
GO:0043233 organelle lumen 11 36.7 0.00200579 0.02651576 APOB, MYO6, MYO1C, FGA, CLU, S100A9, FLII, TOP2B, 
      MYO18A, MCM4, SMC3 
GO:0031974 membrane-enclosed lumen 11 36.7 0.00233124 0.02859114 APOB, MYO6, MYO1C, FGA, CLU, S100A9, FLII, TOP2B, 
       MYO18A, MCM4, SMC3 
GO:0005884 actin filament 3 10.0 0.00310731 0.03545710 MYO6, MYO1C, MYO1F 
GO:0005938 cell cortex 4 13.3 0.00313077 0.03352562 ACTG1, MYO6, MYO1F, MYH10 
GO:0031983 vesicle lumen 3 10.0 0.00389765 0.03918319 APOB, FGA, CLU 
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 Proteins that were co-precipitated with OPTN were subjected to Gene 
Ontology (GO) analysis (Table 4-2). GO analysis resulted in the identification 
of GO-terms primarily associated with intracellular vesicles, organelles and 
the cytoskeleton, in keeping with known functions of OPTN.  
In order to confirm the subcellular localisation of OPTN, confocal 
microscopy was performed on HkEc stimulated MDM. HkEc stimulated MDM 
were fixed and co-stained for OPTN and the Golgi marker, GM130 (Figure 
4.3). There was evidence of a strong overlap between OPTN and GM130 
confirming the Golgi localisation of OPTN in stimulated MDM. OPTN positive 
staining was also present within the cytoplasm of MDM.   
4.2.2 OPTN and TNF in human monocytes and macrophages 
RNAi of OPTN in THP-1 cells was shown to result in reduced TNF and IL6 
secretion [191]. Therefore, it was important to investigate whether TNF and 
OPTN are co-localised in the cell. Confocal images of HkEc stimulated MDM 
clearly demonstrate a high degree of overlap between OPTN and TNF within 
the Golgi complex (Figure 4.4 and Figure 4.5). A number of vesicles stained 
positively for TNF or OPTN in MDM after stimulation, but only 12% of TNF 
positive vesicles also stained positively for OPTN (Figure 4.7).  
Previous studies have shown that TNF is trafficked from the Golgi 
complex to the plasma membrane through an endosomal pathway in murine 
RAW293 macrophages [171]. Human MDM were also found to traffic TNF 
predominantly through the endosomal pathway (Figure 4.6 and Figure 4.7). 
We calculated that 70% of TNF positive vesicles also expressed the 
endosomal marker, early endosome antigen 1 (EEA1) demonstrating that 
human and mouse macrophages secrete TNF along a similar pathway. 
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Figure 4.3 Confocal microscopy in monocyte-derived macrophages show 
colocalisation of OPTN with GM130 in the Golgi complex. MDM (white 
outline) show colocalisation of OPTN (ii) with GM130 (i) in the Golgi complex, 
next to the DAPI stained nucleus in blue (iii). Single stained GM130 Golgi 
complex (white arrows) and double stained OPTN and GM130 (pink arrows) 
are visible in the enlarged area of the pink box (iv) (image i, ii, iii at 63×, scale 
bar 20 µm). 
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Figure 4.4 Confocal microscopy in monocyte-derived macrophages show 
colocalisation of OPTN with TNF in the Golgi complex. MDM (white outline) 
show colocalisation of OPTN (ii) with TNF (i) in the Golgi complex, next to the 
DAPI stained nucleus in blue (iii). Single stained OPTN vesicles (pink arrows) 
and TNF vesicles (white arrows) are visible in the enlarged area of the pink 
box (iv) (image i, ii, iii at 63×, scale bar 20 µm). 
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Figure 4.5 Confocal microscopy in monocyte-derived macrophages show 
colocalisation of the trans-Golgi marker Golgin-245 with TNF. MDM (white 
outline) show colocalisation of the trans-Golgi marker Golgin-245/p230 (ii) 
with TNF (i), next to DAPI stained nucleus in blue (iii). Double positive 
Golgin-245 and TNF staining (white arrows) in enlarged area of the pink box 
(iv) are shown (image i, ii, iii at 63×, scale bar 20 µm).   
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Figure 4.6 Confocal microscopy in monocyte-derived macrophages show 
colocalisation of TNF and early endosome antigen 1. MDM (white outline) 
show colocalisation of TNF (i) and early endosome antigen 1 (EEA1) (ii) in 
peripheral vesicles. Double positive vesicles (pink arrows) and single positive 
TNF vesicles (white arrows) in enlarged area of the pink box (iv) are shown 
(image i, ii, iii at 63×, scale bar 20 µm). 
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Figure 4.7 TNF is predominantly trafficked in EEA1+ endosomes. 
Quantification of colocalisation in TNF vesicles shows that only ~12% of TNF 
vesicles contain colocalised OPTN whereas ~70% TNF vesicles colocalise 
with EEA1 (n=8-16 cells/person, 2 persons performed). 
 
4.2.3 OPTN is upregulated on bacterial stimulation 
OPTN was upregulated at both the transcriptional and protein levels in MDM 
after stimulation with bacteria and microbial ligands (Figure 4.8 and Figure 
4.9). Gram negative heat-killed E. coli (HkEc) and lipopolysaccharide (LPS) 
were the most potent inducers of OPTN transcription and resulted in the 
highest levels of intracellular protein whereas the Toll-like receptor 2 (TLR2) 
ligand, Pam3, and NOD2 ligand, muramyl dipeptide (MDP) were less potent 
inducers.  
 OPTN was similarly upregulated at the protein level in THP-1 cells 
after stimulation with bacteria and microbial ligands (Figure 4.10). HkEc and 
LPS again resulted in the most statistically significant increase in OPTN in 
contrast to Pam3 and MDP. The upregulation of OPTN is fastest with HkEc 
then Pam3 and MDP and continues to rise till 24 hours (Figure 4.11). 
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Figure 4.8 OPTN gene transcription in MDM is significantly upregulated after 
HkEc, TLR2 and TLR4 stimulation with Pam3 and LPS. Gene transcription 
was measured at four hours. Results shown are mean ± SEM; n=10-
23/group, over 2 independent experiments (***p<0.001; two-tailed, paired t 
test). 
 
Figure 4.9 OPTN protein expression in MDM are also significantly 
upregulated after HkEc, TLR2, TLR4 and NOD2 stimulation with MDP. 
Protein expression was measured at 24 hours. Results shown are mean ± 
SEM, all immunoblots are normalised to actin; n=4, over 4 independent 
experiments (*p<0.05 and **p<0.01; two-tailed, paired t test). 
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Figure 4.10 OPTN protein expression in THP-1 (human acute monocytic 
leukaemia) cells is upregulated after HkEc, TLR2, TLR4 and NOD2 
stimulation with Pam3, LPS and MDP. Protein expression was measured at 
24 hours. Results shown are mean ± SEM, all immunoblots are normalised 
to actin; n=5, over 5 independent experiments (**p<0.01 and ***p<0.001; 
two-tailed, paired t test). 
 
Figure 4.11 Upregulation of OPTN protein expression in THP-1 cells occurs 
with MDP and Pam3 stimulation but is fastest with HkEc stimulation. Results 
shown are mean ± SEM, all immunoblots are normalised to actin; n=3/group, 
over 3 independent experiments. 
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 4.2.4 Optn-/- mouse generation and charaterisation 
To investigate the effect of deleting the OPTN gene on inflammation and 
cytokine secretion in vivo, Optn-/- mice that had been generated on a 
C57BL/6 background by insertion of a promoter-driven Neo targeting 
cassette upstream of exon 3 were studied (Figure 4.12) [230]. To exclude off-
target effects of the Neo cassette, qRT-PCR of Mcm10 and Ccdc3 that flank 
Optn on chromosome 2 was performed in bone marrow-derived 
macrophages (BMDM), which demonstrated no difference in expression 
between Optn+/+ and Optn-/- cells (Figure 4.13).  
Genotyping of Optn+/+ and Optn-/- mice was performed on ear clip 
genomic DNA (Figure 4.14), using recommended primers (Figure 4.12 and 
Appendix 1). RT-PCR of Optn-/- macrophage total RNA identified a 115 bp 
larger amplicon compared to Optn+/+ cells (Figure 4.15). Sequencing of this 
Optn-SA amplicon identified a 115 bp splice acceptor (SA) insert between 
exon 2 and 3, which causes a frameshift and multiple predicted premature 
termination codons (Figure 4.16).  
Flow cytometry of peripheral blood (Figure 4.17) and bone marrow 
cells (Figure 4.18) from Optn+/+ and Optn-/- mice did not show a difference in 
the percentage of CD19+ B cells, CD3+ T cells, CD11b+ Gr1+ neutrophils and 
CD11b+ Ly6C+ monocytes. Additionally, naïve Optn+/+ and Optn-/- organs 
such as large and small bowel, spleen, bone marrow, thymus, stomach, liver, 
kidney, heart and brain were reviewed by a Histopathologist (see 
Acknowledgements) and not found to be histologically different on H&E 
staining (Figure 4.19).  
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Figure 4.12 Generation of Optn-/- mice. The exon-intron layout of the murine 
Optn gene on chromosome 2, structure of the L1/L2 human β-actin promoter 
driven neoR targeting cassette with a PGK backbone and the Optn locus 
after homologous recombination. Positions of primers used for genotyping 
and RT-PCR are depicted (widths of exons, introns and targeting cassette 
are proportional to sequence length). Data from Wellcome Trust Sanger 
Institute. 
 
Figure 4.13 qRT-PCR of Mcm10 and Ccdc3 that flank Optn on chromosome 
2 show no difference in expression between Optn+/+ and Optn-/- mice. qRT-
PCR on total RNA was performed on BMDM stimulated with HkEc for four 
hours.  
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 GGACAGCCCTTGTGAGACCCCAGGAAATGGACCCTCCAATATGGTT
CACCCCAGCCTGGACACATTCACCCCTGAGGAGCTGCTGCAGCAA
ATGAAGGAACTCCTGGTTGAGAACCACCAGCTGAAAGGTCCCAGGT
CCCGAAAACCAAAGAAGAAGAACCCTAACAAAGAGGACAAGCGGC
CTCGCACAGCCTTCACTGCTGAGCAGCTCCAGAGGCTCAAGGCTG
AGTTTCAGACCAACAGAAGCCATGAAGCTAAATAATCAAGCTATGAA
AGGGCGATTTGAGGAGCTGTCCGCCTGGACAGAGAAGCAGAAGGA
AGAGCGCCTGTTGTTTGAGATGCAAAGCAAAGAGGTTAAGGAGCGC
CTTAAGGCCCTGACTCATGAAAATGAGAGGCTGAAGGAAGAGCTTG
GAAAATTCAAAGAGAAATCAGAAAAGCCATTGGAAGACCTCAC 
D S P C E T P G N G P S N M V H P S L D T F T P E E L L Q Q M K E L 
L V E N H Q L K G P R S R K P K K K N P N K E D K R P R T A F T A E 
Q L Q R L K A E F Q T N R S H E A K Stop S S Y E R A I Stop G A V R 
L D R E A E G R A P V V Stop D A K Q R G Stop G A P Stop G P D S 
Stop K Stop E A E G R A W K I Q R E I R K A I G R P H 
 
Figure 4.14 Genotyping of Optn+/+ and Optn-/- mice. Genotyping was 
performed by PCR of gDNA isolated from ear clips amplified with Optn gene-
specific primers, producing a 238 bp knockout amplicon and a 435 bp native 
amplicon. 
 
Figure 4.15 RT-PCR of Optn in Optn+/+ and Optn-/- bone marrow-derived 
macrophages. RT-PCR produced a 115 bp larger Optn-SA amplicon from the 
Optn-/- mouse, which was absent in the Optn+/+ mouse. 
Figure 4.16 Sequencing of the Optn-SA amplicon from Optn-/- macrophages 
identified a 115 bp splice acceptor (SA) insert between exon 2 and 3. The SA 
insert results in multiple premature termination codons. Sequence is shown 
above, amino acid translation below; exon 2 in yellow, SA insert in green and 
exon 3 in pink.  
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Figure 4.17 Flow cytometry of naïve Optn+/+ and Optn-/- peripheral blood 
showed no difference in the percentage of CD19+ B cells, CD3+ T cells, Gr1+ 
neutrophils or Ly6C+ monocytes. Results shown are mean ± SEM; n=14-25 
mice/genotype, over 4 independent experiments (two-tailed, unpaired t test). 
 
Figure 4.18 Flow cytometry of naïve Optn+/+ and Optn-/- bone marrow cells 
showed no difference in the percentage of CD19+ B cells, CD3+ T cells, Gr1+ 
neutrophils or Ly6C+ monocytes. Results shown are mean ± SEM; n=7 
mice/genotype, over 3 independent experiments (two-tailed, unpaired t test).
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 Figure 4.19 Naïve Optn+/+ and Optn-/- organs were not histologically different 
on H&E staining. Magnification and scale bar of large bowel 20× 200 µm, 
small bowel 20× 200 µm, spleen 5× 800 µm, bone marrow 15× 250 µm, 
thymus 10× 400 µm, stomach 20× 200 µm, liver 5× 800 µm, kidney 5× 800 
µm, heart 5× 800 µm and brain 1× 4 mm. 
4.2.5 Thioglycollate-induced peritoneal macrophages  
Thioglycollate-induced peritoneal macrophages (TiPM) were collected and 
stimulated with MDP, Pam3 and HkEc for 24 hours (Figure 4.20). Immunoblot 
of OPTN in TiPM whole cell lysates confirmed the lack of the OPTN protein 
in Optn-/- cells (Figure 4.20). 
As has previously been shown with human MDM (Figure 4.8), HkEc 
was the most potent inducer of OPTN, which resulted in a significant 
increase in intracellular OPTN relative to unstimulated TiPM compared to 
Pam3 and MDP, which only caused a two-fold increase (Figure 4.20). 
 
Figure 4.20 OPTN protein is absent in Optn-/- thioglycollate-induced 
peritoneal macrophages and upregulated in Optn+/+ cells on stimulation with 
MDP, Pam3 and HkEc. Immunoblot of OPTN in Optn+/+ and Optn-/- TiPM, 
shown with β-actin loading control. 
 
In view of the previous finding of decreased proinflammatory TNF 
secretion from OPTN siRNA knockdown THP-1 cells [191], a dose response 
and time course stimulation of Optn+/+ and Optn-/- TiPM with bacteria and 
microbial ligands was performed (Figure 4.21). As expected, increasing 
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 doses of Pam3, LPS and HkEc resulted in increasing secretion of TNF from 
TiPM but there was no difference between Optn+/+ and Optn-/- cells at all 
doses tested. Over time, stimulation with Pam3, LPS and HkEc resulted in 
rapid release of TNF from TiPM by four hours reaching maximal secretion by 
eight hours with LPS and HkEc, but a slower rise to a maximum at 24 hours 
with Pam3 but no difference between Optn+/+ and Optn-/- cells were found. 
These kinetic findings of TNF release in TiPM are similar to what was 
previously seen in human MDM. 
OPTN has been shown to play a role in the autophagic clearance of 
Salmonella in HeLa cells [125]. To exclude the possibility that the lack of a 
difference in TNF secretion could be due to alterations in uptake and 
handling of E. coli in Optn-/- TiPM, phagocytosis and killing experiments were 
performed (Figure 4.22).  Phagocytosis of FITC-labelled HkEc resulted in the 
gradual increase of intracellular fluorescence in TiPM at 1, 3 and 24 hours 
but was not different between Optn+/+ and Optn-/- cells. Similarly, killing of 
intracellular E. coli by TiPM after three hours of bacterial incubation was no 
different between Optn+/+ and Optn-/- cells. 
OPTN was previously reported to be involved with myosin VI in the 
maintenance of Golgi structure [201]. To investigate the effect of OPTN 
deficiency on the Golgi complex, electron microscopy of naïve and HkEc 
stimulated TiPM was done (Figure 4.23). Multiple large vacuoles were found 
within Optn+/+ and Optn-/- TiPM that likely contain phagocytosed 
thioglycollate. The ER and Golgi complex structures within these TiPM were 
no different between Optn+/+ and Optn-/- cells but the effects of these large 
vacuoles on cellular function and vesicle trafficking is uncertain despite 
retaining its ability to phagocytose HkEc.   
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Figure 4.21 TNF secretion from stimulated Optn+/+ and Optn-/- thioglycollate-induced peritoneal macrophages was 
no different. Dose response (above) and time course (below) curves in TiPM stimulated with Pam3CSK4, 
lipopolysaccharide (LPS) and heat-killed E. coli (HkEc) are shown. Results shown are mean ± SEM (two-tailed, 
unpaired t test). 
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Figure 4.22 Thioglycollate-induced peritoneal macrophage phagocytosis and 
killing of E. coli was not different between Optn+/+ and Optn-/- mice. 
Phagocytosis of FITC-labelled HkEc (left) and killing of E. coli (right) are 
shown. Results shown are mean ± SEM; n=12-13 and n=14-15 
mice/genotype for phagocytosis and killing, over 6 independent experiments 
(two-tailed, unpaired t test). 
 
Figure 4.23 Thioglycollate-induced peritoneal macrophages were found to 
have multiple vacuoles on electron microscopy. The TiPM contained multiple 
vacuoles (white arrows, left) that are presumed to contain thioglycollate 
(8,000×, scale bar 2 µm). Macrophages were still able to phagocytose E. coli, 
visible at higher magnification (pink arrows, right) (20,000×, scale bar 1 µm). 
Slides prepared by Mr Mark Turmaine, UCL Biosciences. 
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 4.2.6 Bone marrow-derived macrophages 
In view of the discovery of multiple large vacuoles in TiPM and the potential 
of these vacuoles interfering with vesicle trafficking, bone marrow-derived 
macrophages (BMDM) were studied. Culture of bone marrow cells for five 
days with M-CSF resulted in a 96% to 97% enriched population of adherent 
CD11b+ F4/80+ macrophages in both Optn+/+ and Optn-/- mice (Figure 4.24). 
 
Figure 4.24 Bone marrow cells after 5 days of culture with M-CSF produce 
equal numbers of CD11b+F4/80+ macrophages in Optn-/- and Optn+/+ mice. 
Flow cytometry analysis show that the populations are 96-97% enriched for 
CD11b+F4/80+ macrophages in culture. Representative flow cytometry plots 
shown (n=2 mice/genotype, over 2 independent experiments). 
 Transmission electron microscopy (TEM) of HkEc stimulated Optn+/+ 
and Optn-/- BMDM did not show any of the large vacuoles found in TiPMs 
(Figure 4.25). Similar to TiPM, HkEc within phagosomes were visible in both 
Optn+/+ and Optn-/- cells. 
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Figure 4.25 Transmission electron microscopy of HkEc stimulated Optn-/- and Optn+/+ bone marrow derived 
macrophages. Unstimulated BMDM (8,000×, scale bar 2 µm) and HkEc fed BMDM (20,000×, scale bar 1 µm) did not 
show any large vacuoles that were seen in TiPMs. Phagosomes containing HkEc (arrowheads) were visible in equal 
numbers in both Optn-/- and Optn+/+ macrophages (20,000×, scale bar 1 µm). Slides prepared by Mr Mark Turmaine, 
UCL Biosciences.
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 Phagocytosis of FITC-labelled HkEc showed an expected rise in 
intracellular fluorescence with bacterial uptake at 1, 4 and 24 hours, which 
was not statistically different between Optn+/+ and Optn-/- BMDM at each time 
point (Figure 4.26). Killing of live E. coli was also not significantly different 
between BMDM genotypes after 3 hours of bacterial incubation.  
In view of the role of OPTN in autophagy, the induction of autophagy 
in the Optn-/- BMDM was assessed. Baseline autophagic flux was 
investigated using bafilomycin A, the vacuolar-type H+-ATPase (V-ATPase) 
inhibitor that blocks fusion of autophagosomes with lysosomes. Immunoblot 
for LC3 in Optn+/+ and Optn-/- BMDM stimulated with bafilomycin A 
demonstrated an equal upregulation in the autophagosome-bound LC3-II in 
both genotypes indicating a normal baseline autophagic flux occurs in the 
absence of OPTN (Figure 4.27).  
 
Figure 4.26 Bone marrow-derived macrophage phagocytosis and killing of E. 
coli was not different between Optn+/+ and Optn-/- mice. Phagocytosis of 
FITC-labelled HkEc (left) and killing of E. coli (right) are shown. Results 
shown are mean ± SEM, n=5 and n=3 mice/genotype for phagocytosis and 
killing over 3 independent experiments (two-tailed, unpaired t test). 
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Figure 4.27 Basal autophagic flux in Optn+/+ and Optn-/- bone marrow derived 
macrophages is not different. Immunoblot of LC3 in bafilomycin A treated 
Optn+/+ and Optn-/- BMDM shows no difference in the accumulation of LC3-II, 
shown with β-actin loading control. Bafilomycin A, a V-ATPase inhibitor 
blocks fusion of autophagosome with lysosomes and hence LC3-II 
degradation.  
 
 
Figure 4.28 Induction of autophagy in Optn+/+ and Optn-/- bone marrow 
derived macrophages by heat-killed E. coli was no different. Immunoblot for 
LC3-I and LC3-II in HkEc stimulated BMDM showed an equal rise then 
gradual fall in autophagosome-bound LC3-II in Optn+/+ and Optn-/- BMDM but 
minimal change in cytoplasmic LC3-I. Results shown are mean ± SEM, all 
immunoblots are normalised to actin, n=6 mice/genotype, over 6 independent 
experiments (two-tailed, paired t test). 
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 The induction of autophagy by HkEc was also investigated in BMDM 
(Figure 4.28). Optn+/+ and Optn-/- BMDM were exposed to HkEc at a 
multiplicity of infection (MOI) of 20 to look at LC3-II induction at various time 
points. The LC3-II autophagosome-bound LC3 was marginally higher at four 
hours but subsequently decreased thereafter to 24 hours. There was no 
difference in LC3-II levels between Optn+/+ and Optn-/- cells, and cytoplasmic 
LC-I levels remained low and unaltered through that 24 hours period. 
 OPTN siRNA knockdown resulted in reduced proinflammatory TNF 
and IL6 release from human MDM, hence the effect of the lack of OPTN was 
investigated [191]. Similar to the OPTN siRNA knockdown experiments, 
secretion of the proinflammatory cytokines TNF and IL6 was significantly 
reduced in Optn-/- BMDM compared to Optn+/+ cells (Figure 4.29). By 
contrast, anti-inflammatory cytokine IL10 and chemokine CXCL1 was 
elevated in the OPTN deficient BMDM. To investigate if this was related to 
abnormal gene transcription, qRT-PCR was performed to quantify the 
expression of Tnf, Il6, Il10 and Cxcl1 in HkEc stimulated HkEc. Similar to our 
previous findings in human MDM, gene transcription was equal between 
Optn+/+ and Optn-/- BMDM (Figure 4.29). 
To ensure that this cytokine defect was not due to differences in cell 
death, cell viability in the HkEc stimulated Optn+/+ and Optn-/- BMDM was 
evaluated using the MTT assay (Figure 4.30). In this assay the MTT salt, 3-
[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrozolium bromide, is taken up by 
viable cells and reduced into insoluble purple formazan that is colorimetrically 
measured. Purple formazan formation as a measure of cell viability in HkEc 
stimulated Optn+/+ and Optn-/- BMDM rose at four hours, peaked at eight 
hours but was lower at 24 hours. However, there was no difference between 
Optn+/+ and Optn-/- BMDM at all time points measured. 
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Figure 4.29 Stimulation of bone marrow derived macrophages with heat-
killed E. coli resulted in equal cytokine gene transcription but significantly 
lower secretion of proinflammatory TNF and IL6 and higher IL10 and CXCL1 
in Optn-/- cells. Upper panel shows gene transcription whilst the lower panel 
shows cytokine secretion. Results shown are mean ± SEM; n=5 
mice/genotype, over 5 independent experiments (*p<0.05, and **p<0.01; 
two-tailed, unpaired t test). 
 
Figure 4.30 Cell viability of HkEc stimulated Optn+/+ and Optn-/- bone 
marrow-derived macrophage was not different. Cell viability assay was 
measured using the MTT assay. Results shown are mean ± SEM, n=2 
mice/genotype (two-tailed, unpaired t test). 
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  In light of the normal cell viability, ER stress in the HkEc stimulated 
BMDM was assessed to investigate if in the absence of OPTN and potential 
cytokine mistrafficking, unfolded proteins may accumulate and result in 
diminished proinflammatory cytokine secretion. The unfolded protein 
response (UPR) is a highly conserved cellular stress response to the 
presence of misfolded proteins in the endoplasmic reticulum and the aim of 
the UPR is to stop protein translation, degrade the misfolded proteins and 
upregulate chaperone molecules that fold proteins. 
 To study ER stress in the HkEc stimulated BMDM, whole cell lysates 
were immunoblotted for two of the ER stress molecular chaperones, glucose-
regulated protein, 78kDa (GRP78) that is also known as binding 
immunoglobulin protein (BiP), glucose-regulated protein, 94kDa (GRP94) 
and CCAAT-enhancer binding protein homologous protein (CHOP). GRP78 
and GRP94 are upregulated in ER stress and functions as a molecular 
chaperone and inducer of further ER stress pathways whilst CHOP drives a 
pro-apoptotic signal in ER stress at the mitochondria. Immunoblot of GRP94, 
GRP78 and CHOP did not reveal a difference in induction of these proteins 
over time between the Optn+/+ and Optn-/- BMDM (Figure 4.31). 
 Additionally, Xbp1 splicing is associated with induction of ER stress. 
RT-PCR of total RNA from BMDM stimulated with HkEc and the ER stress 
inducers tunicamycin, thapsigargin and bafilomycin A which are then 
restriction enzyme digested did not reveal a difference in concentration of 
spliced Xbp1 transcripts between Optn+/+ and Optn-/- BMDM (Figure 4.32). 
Collectively, this indicates that ER stress was not different between BMDM of 
each genotype. 
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Figure 4.31 ER stress protein induction in Optn+/+ and Optn-/- bone marrow 
derived macrophages stimulated with HkEc was not different over time. 
Immunoblot of ER stress proteins GRP94, GRP78/BiP and CHOP in a HkEc 
stimulated BMDM time course did not show a difference in ER stress 
between Optn+/+ and Optn-/- cells, shown with β-actin loading control. 
 
 
 
 
Figure 4.32 Xbp1 splicing as a marker of ER stress in Optn+/+ and Optn-/- 
bone marrow-derived macrophages stimulated with HkEc was not different 
over time.    Metaphor™ agarose gel electrophoresis of PstI digested Xbp1 
RT-PCR of BMDM stimulated for four hours and 24 hours of HkEc, four 
hours of tunicamycin (TM), thapsigargin (TG) or bafilomycin A (BafA) 
demonstrated no difference in Xbp1 splicing. US, unstimulated. 
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 To investigate if the reduced intracellular TNF was due to defective 
protein translation in Optn-/- BMDM, brefeldin A, a potent inhibitor of protein 
transport from the endoplasmic reticulum to the Golgi was used. Intracellular 
TNF has previously been shown to exist as a membrane bound 26-kDa 
precursor and a 17-kDa secreted form [161]. Stimulation of BMDM with HkEc 
in the presence of brefeldin A resulted in elevation of the 26-kDa precursor 
TNF and loss of the 17-kDa secreted form to similar levels in both Optn+/+ 
and Optn-/- BMDM (Figure 4.33) demonstrating that TNF is translated 
normally in the absence of OPTN.  
By contrast, the inclusion of bafilomycin A, an inhibitor of vacuolar 
type H+-ATPase that blocks fusion between autophagosome and lysosomes 
produced a greater increase in intracellular levels of the 17-kDa secreted 
form (p=0.041) in the Optn-/- compared with Optn+/+ BMDM (Figure 4.33). 
There was no difference in the 26-kDa precursor TNF form, indicating that in 
the absence of OPTN, a greater proportion of the secreted form of TNF is 
trafficked through a bafilomycin A sensitive intracellular compartment in 
BMDM. 
Inhibition of lysosomal proteases has been shown to increase 
intracellular cytokine levels in HkEc stimulated human MDM [187]. Therefore, 
the role of the lysosome in intracellular TNF trafficking was investigated with 
the inclusion of monensin, chloroquine and NH4Cl in mouse BMDM. 
Chloroquine and NH4Cl partition into acidic compartments and elevate the 
lysosomal pH, whereas monensin is a proton ionophore with similar but more 
potent effects [253-255]. In HkEc-stimulated BMDM, all three inhibitors of 
lysosomal degradation increased intracellular levels of TNF to equal levels in 
Optn-/- and Optn+/+ cells when compared with HkEc stimulation alone (Figure 
4.34), indicating that a greater proportion of intracellular TNF is directed to 
lysosomal degradation in the absence of OPTN. 
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Figure 4.33 Brefeldin A results in undetectable levels of 17kDa secreted TNF 
but bafilomycin A results in significantly higher levels of 17kDa secreted TNF 
in Optn-/- BMDM. Representative immunoblot of TNF (above) with β-actin 
loading control and quantification of 26kDa precursor and 17kDa secreted 
TNF (below). Results shown are mean ± SEM, all immunoblots are 
normalised to actin; n=3-5 mice/genotype over 3-5 independent experiments 
(*p<0.05; two-tailed, unpaired t test). 
157 
 
  
Figure 4.34 The TNF secretory defect is associated with significantly less 
intracellular 26kDa precursor TNF on immunoblot, which is normalised to 
wildtype levels on addition of lysosomal function inhibitors monensin, NH4Cl 
and chloroquine. Representative immunoblot of TNF (above) showing 26kDa 
precursor TNF band and 17kDa secreted TNF band with β-actin loading 
control and quantification of TNF immunoblot (below). Results shown are 
mean ± SEM, all immunoblots are normalised to actin; n=3-8 mice/genotype 
over 4 independent experiments (*p<0.05; two-tailed, unpaired t test). 
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 TNF trafficking in macrophages has been shown to occur via the 
endosomal compartment [162, 171]. Confocal immunofluorescence 
microscopy was used to investigate TNF trafficking in BMDM, which 
demonstrated reduced levels of intracellular TNF (Figure 4.35 and Figure 
4.36) and replicated the immunoblot findings above (Figure 4.34). 
Additionally, significantly less colocalisation of TNF positive vesicles with 
EEA1 in Optn-/- BMDM was found (Figure 4.35). Similar to human MDM, TNF 
in BMDM were present in vesicles but also colocalised with the pan-Golgi 
marker GM130 (Figure 4.36). 
The previous OPTN siRNA knockdown in HkEc stimulated THP-1 
cells resulted in reduced TNF and IL6 release [191]. To investigate if any 
other cytokines were altered, a cytokine profiler array was used to measure 
intracellular cytokine levels in HkEc stimulated BMDM. Optn-/- BMDM had 
lower intracellular IL6 levels but higher CXCL13, IL16 and TIMP-1 levels. The 
significance of these findings would require further study.   
The cytokine release defect in BMDM is specific to the lack of OPTN 
since there was no defect in TNF release in the absence of OPTN’s binding 
partner myosin VI. Myo6+/+ and Myo6-/- BMDM stimulated with Pam3, LPS 
and HkEc did not secrete different levels of TNF (Figure 4.38). 
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Figure 4.35 Confocal microscopy in HkEc stimulated Optn+/+ and Optn-/- 
bone marrow derived macrophages show decreased colocalisation of TNF 
with early endosome antigen 1 in Optn-/- cells. Quantification showed 
significantly less intracellular TNF and colocalisation of TNF with EEA1 in 
Optn-/- BMDM (images at 63×, scale bar 20 µm; n=63-66 cells/genotype, over 
2 independent experiments; results shown are mean ± SEM; *p<0.05, and 
**p<0.01; two-tailed, unpaired t test). 
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Figure 4.36 Confocal microscopy in HkEc stimulated Optn+/+ and Optn-/- 
bone marrow derived macrophages show equal colocalisation of TNF with 
the Golgi marker GM130. Quantification showed no difference in 
colocalisation of TNF (i) with the Golgi marker GM130 (ii) in Optn-/- and 
Optn+/+ BMDM (white outline) (image i, ii, iii at 63×, scale bar 20 µm; n= 35 
cells/genotype; ns, non-significant; results shown are mean ± SEM, two-
tailed, unpaired t test). 
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Figure 4.37 Stimulation of Optn+/+ and Optn-/- bone marrow-derived 
macrophages with HkEc resulted in reduced levels of intracellular IL6 and 
elevated levels of CXCL13, IL16 and TIMP1 in Optn-/- cells. Intracellular 
cytokine levels were measured in HkEc stimulated Optn+/+ and Optn-/- BMDM 
at four hours using a cytokine proteome profiler array. The cytokine array 
map (above) and cytokine array profiles (below) are shown (n=2 
mice/genotype). 
 
Figure 4.38 TNF secretion in Myo6+/+ and Myo6-/- bone marrow-derived 
macrophages stimulated with Pam3, LPS and HkEc for four hours was not 
different (n=2 mice/genotype). Experiments were performed by Dr Andrew 
Smith. 
162 
 
 4.3 Discussion 
In the previous chapter, low OPTN expression was discovered in MDM 
from CD patients but not in HC or UC patients. This low OPTN expression 
was associated with inheritance of a minor allele in a SNP downstream of the 
last OPTN exon. 
In this chapter, the intracellular function of OPTN in macrophages was 
further elucidated. Subcellular fractionation of HkEc stimulated THP-1 cells 
and subsequent immunoblotting localised OPTN to the cytoplasmic and 
Golgi membrane containing but not lysosomal fractions. This is not surprising 
since OPTN has been widely shown to localise to the Golgi complex in other 
cell types [201]. Notably, OPTN is not localised to lysosomes, which we had 
previously showed to be the target of misdirected proinflammatory cytokines 
in human CD MDM. THP-1 cells are monocytic cells and not macrophages 
and as such may not truly reflect the subcellular localisation of proteins in 
macrophages. However, bacteria or LPS-stimulated THP-1 cells, become 
adherent and take on a ‘macrophage-like’ phenotype, which have been 
shown to be comparable to MDM functionally and in its expression of 
activation markers [256].  
For decades, all tissue resident macrophages were widely accepted as 
originating from circulating blood monocytes [151]. More recently, fate 
mapping studies in mice have shown that brain macrophages/microglial cells 
originate from yolk sac macrophages that are set down during development 
and undergo clonal expansion during inflammation that is independent of 
circulating monocytes whilst skin macrophages/Langerhans cells are derived 
from yolk sac and foetal liver derived monocytes [154, 155]. Importantly, 
lamina propria macrophages have been shown to originate from recruited 
Ly6C+ peripheral monocytes during inflammation [153, 257, 258]. As such, 
‘THP-1 macrophages’ and MDM should be representative of lamina propria 
macrophages in view of its monocytic origins.  
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 To confirm OPTN’s binding partners, IP of OPTN and shotgun proteomics 
of immunoprecipitated proteins was performed in THP-1 cells. This identified 
known binding partners of OPTN such as myosin VI and myosin 18A, which 
localised OPTN to the Golgi complex. Gene ontology analysis of co-
precipitated proteins with OPTN identified vesicles, organelles and the 
cytoskeleton as key roles for these proteins. This verified the antibody that 
was used but also the localisation of OPTN to the Golgi complex 
demonstrated with subcellular fractionation. This focused attention on the 
Golgi complex as the place where OPTN likely functions in MDM. Although 
mass spectrometry allows good global protein identification, peptides from 
different proteins may share similar fragmentation spectra or when 
alternatively spliced may result in misidentification of proteins. This was 
minimised by setting the threshold of identification of proteins at 5 peptides. 
However, the identification of myosin VI and 18A as well as gene ontology 
analysis provides good evidence of successful shotgun proteomics. 
Others in our research group previously showed that CD was associated 
with the phenotype of reduced proinflammatory TNF secretion from 
macrophages that results in impaired neutrophil recruitment and bacterial 
clearance [187]. TNF is secreted via endosomes in mouse RAW264.7 
macrophages [171]. Confocal microscopy in MDM localised TNF to OPTN at 
the Golgi complex but not in peripheral vesicles where TNF localises to 
endosomes. These findings strengthen the subcellular localisation of OPTN 
to the Golgi complex in macrophages but also suggest a role for OPTN in the 
trafficking of TNF at the Golgi complex in contrast to peripheral vesicles or 
the plasma membrane. These findings are limited by the permeabilisation of 
macrophages prior to confocal staining that diminishes the staining of OPTN 
in the cytoplasm that was seen in subcellular fractionation. However, the 
localisation of OPTN to the Golgi has been widely seen in other non-immune 
cells and has been shown to be similar in human macrophages for the first 
time here.   
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  OPTN expression was significantly upregulated when MDM were 
exposed to HkEc, the TLR ligands LPS and Pam3 as well as the NOD2-
ligand MDP. OPTN gene and protein induction was not equal between 
different stimuli and also between MDM and THP-1 cells. LPS and HkEc 
were the strongest or most significant stimulus of OPTN in MDM and THP-1 
cells in contrast to Pam3 and MDP. The rise in OPTN protein expression was 
fastest with HkEc in contrast to Pam3 and MDP in THP-1 cells but resulted in 
comparable levels at 24 hours. Kinetic studies of OPTN expression in MDM 
was not performed due to limited numbers that are obtained from cell culture. 
OPTN protein stimulation in MDM was lower with Pam3 and MDP in contrast 
to HkEc and LPS at 24 hours. This difference at 24 hours is possibly due to 
actual differences in stimulation of OPTN in MDM since the kinetics of OPTN 
induction in MDM is likely identical to THP-1 cells in view of the similarities 
between MDM and THP-1 cells when activated. However, this cannot be 
conclusively proven without actual kinetic studies into OPTN induction in 
MDM. 
An additional consideration is what the baseline levels of OPTN may 
be in tissue resident macrophages in healthy bowel and CD. Lamina propria 
macrophages are potentially exposed to higher levels of intraluminal TLR 
and NLR ligands but conversely may be strongly influence by anti-
inflammatory factors in their immediate environment. Functional studies 
remain difficult due to the extensive digestion required in the extraction 
process of lamina propria macrophages but is a potential avenue to explore 
coupled with FACS sorting. An alternative is to perform intravital studies in 
mice. 
 To investigate the role of OPTN in macrophages, a knockout mouse 
was obtained. The Optn-/- compared to their Optn+/+ littermates exhibited 
normal litter sizes, lived a normal lifespan, did not develop spontaneous 
colitis and did not show gross differences in organ histology or percentage of 
B cells, T cells, neutrophils and monocytes in the peripheral blood and bone 
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 marrow. This was not surprising since NOD2, the strongest associated gene 
with CD when knocked out, the Nod2-/- mouse does not develop a 
spontaneous colitis or phenotype. This supports our understanding of CD as 
a syndrome where different defects of modest effect for example impaired 
bacterial handling with OPTN or defective autophagy with ATG16L1 result in 
a similar phenotype of colitis, namely CD.  
Peritoneal macrophages are often used as a source of macrophages due 
to accessibility and ease of harvest. Naïve peritoneal macrophages can be 
harvested from the peritoneum but to increase the numbers harvested a 
sterile inflammation is set up using sterile thioglycollate broth that results in 
an early neutrophil then late macrophage migration into the peritoneal cavity 
as first described by Gallily et al in 1964 as a modification of Barski’s method 
[259, 260]. Similar to human macrophages, OPTN is upregulated in mouse 
peritoneal macrophages upon stimulation with HkEc, Pam3 and MDP. TNF 
release in peritoneal macrophages showed a dose dependent increase in 
keeping with what we previously found in human macrophages, which occurs 
early with the greatest rise at 4 hours that plateaus at 8 hours to 24 hours. 
Importantly OPTN deficiency did not affect TNF release in peritoneal 
macrophages.  
Macrophage phagocytosis and killing also did not reveal any difference 
between wildtype and knockout cells. This was surprising since, it was 
hypothesised that since OPTN was involved in autophagy of bacteria its 
absence might result in defective killing. However, autophagic mechanisms 
involved in intracellular bacterial killing are thought to be switched on to 
bacteria such as Salmonella that escape the phagosome that are then 
engulfed in double membrane autophagosomes [125]. As such, the lack of 
difference may be due to the E. coli used, which are readily killed in 
phagosomes. However, a previous study has shown that thioglycollate 
induction itself can result in defective bacterial killing in peritoneal 
macrophages [261]. Electron microscopy of the peritoneal macrophages 
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 found multiple large vacuoles that may result from phagocytosis of the 
thioglycollate broth. The presence of multiple large vacuoles may potentially 
affect the normal trafficking of cytokines and phagocytosis of bacteria, 
abolishing any difference due to the absence of OPTN. 
In order to circumvent the problem of preactivation in the thioglycollate 
induced peritoneal macrophages, M-CSF induced bone marrow derived 
macrophages were obtained, which are more immature and quiescent [262]. 
Electron microscopy of unstimulated and HkEc fed BMDM did not show any 
of the large vacuoles seen in TiPM and the presence of HkEc phagosome in 
Optn-/- and Optn+/+ cells. Previously, other groups have reported that 
knockdown of OPTN resulted in fragmentation of the Golgi complex in HeLa 
cells [201]. In view of the thin sections obtained and the arrangement of the 
Golgi complex, Golgi fragmentation is difficult to identify on electron 
microscopy. However, Golgi complex staining on confocal microscopy did not 
show obvious fragmentation of the Golgi in Optn-/- BMDM compared to 
wildtype cells. This raises the question that the fragmentation seen in HeLa 
cells with OPTN RNAi is either cell specific to HeLa cells or was a result of 
non-specific effects of the siRNA used on the Golgi or other proteins required 
for maintenance of the Golgi complex structure. 
Phagocytosis and killing of E. coli was no different between Optn-/- and 
Optn+/+ BMDM. The lack of a difference in the knockout cells despite use of 
BMDM would suggest that the thioglycollate vacuoles did not affect the 
physiological functions of phagocytosis or killing in these cells. Additionally, it 
would be surprising to find a difference in phagocytosis in the absence of 
OPTN when subcellular fractionation and confocal microscopy did not 
localise it to lysosomes or the plasma membrane in macrophages where 
phagosomes are formed. The argument against a defect in killing in the 
absence of OPTN is likely because E. coli is readily killed by phagosomes in 
macrophages independent of autophagosomes and OPTN. 
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 Basal autophagic flux as measured by accumulation of autophagosomal 
LC3-II in Optn+/+ and Optn-/- BMDM was not different. This is not surprising 
since OPTN has been shown to function as an adaptor in selective 
autophagy that binds to ubiquitinated bacteria and brings them to the 
autophagosome (Figure 1.3). OPTN has not been shown to play a role in the 
formation of the LC3-II bound double membrane autophagosome. When 
BMDM were stimulated with HkEc, there was a small rise then gradual fall in 
autophagosomal LC3-II levels, dropping below baseline levels, stable levels 
of cytoplasmic LC3-I and crucially, no difference in LC3-I or LC3-II levels in 
wildtype or knockout cells. This lack of difference indicates that the 
breakdown of HkEc in phagosomes within macrophages is not dependent on 
OPTN, which is unsurprising. A shortcoming of this experiment is the use of 
killed versus live E. coli since OPTN and autophagy may only be important 
when live bacteria escape the phagosome. Therefore, live Salmonella that 
escapes the phagosome may be a better bacteria to use.  
 However, HkEc stimulation of BMDM resulted in significantly lower 
levels of secreted proinflammatory TNF and IL6, with significantly higher 
levels of anti-inflammatory IL10 and the neutrophil chemokine CXCL1. 
Similar to CD macrophages, this defective proinflammatory cytokine 
secretion was occurring at the protein level since Tnf, Il6, Il10 and Cxcl1 
gene transcription was not statistically different. This defect was also not due 
to differences in cell viability measured using the MTT assay.  
 The defect in cytokine secretion was initially postulated to be due to 
an abnormal unfolded protein response or endoplasmic reticulum (ER) 
stress, which has been associated with CD [263-265]. Immunoblot for 
various ER stress molecular chaperones such as GRP78, GRP94 and CHOP 
as well as Xbp1 splicing all did not show increased ER stress in Optn-/- 
BMDM exposed to HkEc suggesting that ER stress was not accounting for 
the defect in TNF and IL6 release. 
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  Our group previously found that CD macrophages secreted lower 
levels of proinflammatory TNF due to misdirected trafficking to lysosomes for 
destruction. Similarly, when Optn-/- BMDM were stimulated with HkEc in the 
presence of lysosomal function inhibitors, intracellular TNF levels normalised 
to wildtype levels. This indicates that adequate amounts of TNF are 
synthesised by the BMDM but are misdirected and destroyed in lysosomes. 
By contrast, stimulation of Optn-/- BMDM with HkEc in the presence of 
bafilomycin A, the autophagy inhibitor TNF levels rose significantly higher 
than in the wildtype mice indicating that in the absence of OPTN, TNF is 
degraded via a bafilomycin A dependent pathway.  
In contrast to the signalling pathways of cytokine gene transcription, 
much less is known about the complex network of cytokine trafficking within 
cells and particularly macrophages. Work in mouse macrophage cell lines 
have begun to shed light on the complex pathways of cytokine vesicle 
trafficking particularly TNF. Both TNF and IL6 have been found to share a 
similar pathway via recycling endosomes where they then are secreted via 
different pathways to the extracellular space [171]. Although OPTN has 
previously been postulated to have a role in vesicle fusion at the plasma 
membrane, confocal microscopy in macrophages did not show staining at the 
plasma membrane and the fact that IL6 and TNF are trafficked separately to 
the plasma membrane but both have reduced secreted levels would argue 
against a role for OPTN at the plasma membrane in macrophage cytokine 
secretion.  
To investigate if the defective cytokine secretion was due to fusion 
defects at the plasma membrane or more proximal in the vesicle pathway at 
the Golgi complex, confocal microscopy of TNF and early endosome antigen 
1 (EEA1) was performed that showed reduced colocalisation of TNF with 
EEA1 in Optn-/- BMDM. This suggests that the defect in Optn-/- BMDM lies 
proximally at the Golgi complex since there was significantly less TNF 
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 staining, less colocalisation with EEA1 but no difference in TNF at the Golgi 
complex.  
In addition to the defective TNF and IL6 secretion, IL10, CXCL1, 
CXCL13, IL16 and TIMP1 were secreted at higher levels in Optn-/- compared 
to Optn+/+ BMDM. The fact that some cytokines were secreted at higher 
levels in the Optn-/- BMDM adds validity to the findings of reduced TNF and 
IL6 secretion and suggests that the defective secretion was genuine and not 
simply due to poorly viable cells. Little is known about cytokine trafficking 
within cells beyond TNF, IL6 and IL10, which is secreted via a different 
pathway that will make clarifying the trafficking pathways more difficult for 
CXCL1, CXCL13, IL16 and TIMP1. 
Finally, there was no difference in TNF release between HkEc 
stimulated MyoVI-/- BMDM compared to wildtype BMDM. This suggests that 
the defect in cytokine processing for secretion is specific to OPTN deficiency 
occurring during packaging of cytokines at the Golgi complex and not during 
trafficking of vesicles since myosin VI links vesicles to actin via OPTN. The 
lack of difference in TNF release in MyoVI-/- BMDM also suggests that TNF 
traffics via myosin VI independent pathways.  
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 Chapter 5 Animal Models of Inflammation 
5.1 Introduction  
Animal use in scientific research can be traced back to the 17th Century with 
William Harvey’s use of animals to study the blood circulation. However, it 
was the thalidomide tragedy that resulted in a rapid rise in the use of animals 
initially to test drug toxicity then later to develop animal models of human 
disease to better treat and understand disease pathophysiology.  
 Murine models of intestinal inflammation have provided invaluable 
insights into the pathophysiological processes that underlie CD and UC. No 
animal model can fully replicate human CD and UC. Two different induced 
colitis models were chosen, the first being the Citrobacter rodentium model of 
colitis [266], due to the similar effects of Citrobacter infection in mice bowel 
as enteropathic E. coli in humans and the association of E. coli with CD as 
discussed earlier [81]. The second model was the dextran sodium sulphate 
(DSS) chemical induced model of colitis due to its induction of a more UC-
like superficial colitis. 
 Citrobacter infection in the GI tract results in formation of attaching 
and effacing (A/E) lesions, which are characterised by the attachment of 
Citrobacter to the intestinal epithelium, effacement of the brush border 
microvilli and formation of pedestals between the bacteria and epithelial cells 
[266]. Disruption of the epithelial barrier occurs via the translocation of 
bacterial effectors into epithelial cells using Citrobacter’s type 3 secretion 
system (T3SS), resulting in the dissemination of bacteria into the lamina 
propria and recruitment of neutrophils into the bowel and clearance of 
Citrobacter [267].  
The mechanism of action of DSS in inducing colitis is not entirely clear. 
However, DSS is widely believed to be directly cytotoxic to colonic epithelial 
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 cells and result in the breakdown of epithelial integrity [268]. This allows 
intraluminal bacteria to invade into the normally sterile lamina propria layer. 
5.2 Results 
5.2.1 Zebrafish model of Salmonella infection 
To determine the importance of OPTN in antibacterial response across 
species, we utilised a zebrafish infection model involving Salmonella enterica 
[269]. Optn expression was localised to the intestinal bulb, brain and eye in 
both embryonic and larval stages of development (Figure 5.1). As previously 
shown in humans (Figure 4.8 and Figure 4.9) and mice (Figure 4.20) optn 
expression was elevated after bacterial stimulation with Salmonella via both 
an oral (immersion) infection and direct injection of bacteria into the yolk sac 
of embryos 2 days post fertilisation (dpf) (Figure 5.2).  
 
Figure 5.1 In situ hybridisation of optn in zebrafish embryos and larvae 
reveal expression in the brain/eyes and the intestinal bulb. Images are of the 
embryo (i) and larvae (ii) with arrows pointing at the brain/eyes (blue) and the 
intestinal bulb (red). Experiments were performed by Dr Stefan Oehlers and 
Professor Philip Crosier, University of Auckland. 
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Figure 5.2 Zebrafish optn expression is significantly increased both in (bath) 
immersion and injection infection of Salmonella at 24 hours. Results shown 
are mean ± SEM; n=16-19 zebrafish/group (*p<0.05 and ***p<0.001; two-
tailed, unpaired t test). Experiments were performed by Dr Stefan Oehlers 
and Professor Philip Crosier, University of Auckland. 
 
Figure 5.3 Optn knockdown in zebrafish was achieved by retention of optn 
intron 1 using an optn morpholino. RT-PCR of wildtype and optn knockdown 
in zebrafish at 7 days post fertilisation (dpf), by retention of optn intron 1 
using 1 pmol of an optn morpholino (MO) that targets the intron 1/exon 2 
junction, shown with ef1alpha loading control. Experiments were performed 
by Dr Stefan Oehlers and Professor Philip Crosier, University of Auckland. 
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 To study the functional consequence of Optn deficiency in zebrafish 
antibacterial responses, optn-specific morpholinos (MO) were used (Figure 
5.3). Optn knockdown resulted in an increased susceptibility to Salmonella 
infection compared to wildtype fish, and those treated with control 
morpholinos (Figure 5.4).  
 
 
Figure 5.4 Optn knockdown resulted in significantly greater mortality 
compared to controls in zebrafish injected with Salmonella. Results shown 
are mean; n=104–119 zebrafish/group over 2 independent experiments 
(***p<0.001, logrank test). Experiments were performed by Dr Stefan Oehlers 
and Professor Philip Crosier, University of Auckland. 
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 5.2.2 Mouse model of subcutaneous E. coli infection 
To determine the importance of OPTN in host antibacterial response, models 
of infection were employed in two evolutionarily divergent species, zebrafish 
and mice (Figure 1.6). To exclude a baseline difference in growth and weight, 
naïve 9 to 12 week old Optn+/+ and Optn-/- mice were fed standard chow, 
housed in specified pathogen free (SPF) cages and weighed daily.  The 
Optn+/+ and Optn-/- mice did not show a difference in weight over a two-week 
monitoring period (Figure 5.5).  
 
 
Figure 5.5 There was no difference in the weight gain of naïve Optn+/+ and 
Optn-/- mice. Mice were fed regular chow, housed under similar conditions 
and weighed daily over a 14 day period of monitoring. Results are mean ± 
SEM; n=8 mice/genotype (two-tailed, unpaired t test). 
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 Initial dose response experiments showed that increasing the dose of 
subcutaneous HkEc resulted in increasing weight loss in C57BL/6 wildtype 
mice (Figure 5.6). The local acute inflammatory response in the skin resulted 
in the formation of nodules that were larger with increasing dose of HkEc 
(Figure 5.6). The highest dose of 109 HkEc resulted in ulceration of the 
nodules but not the lower doses of 108 (Figure 5.7) and below (not shown). 
The ulcerated nodules in mice injected with 109 HkEc were associated with 
significant inflammatory cell infiltration at day 9 with epithelialisation of the 
ulcer in contrast to skin injected with 107 HkEc (Figure 5.8). Optn+/+ and Optn-
/- mice injected with 108 HkEc subcutaneously did not show a difference in 
weight loss or nodule size over the first six days (Figure 5.9). 
 
 
Figure 5.6 Subcutaneous HkEc back injection causes greater weight loss 
and larger injection site size at higher doses of HkEc. Dose response 
experiments shows that higher concentrations of HkEc causes greater weight 
loss at day one to two post injection (left) with larger injection site sizes 
(right). Results shown are mean ± SEM, n=2 mice/dose with 2 injection 
sites/mouse. 
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Figure 5.7 Subcutaneous HkEc back injection creates nodules that only 
ulcerate at 109 bacteria. Images show that at the highest dose of HkEc (109) 
mice developed nodules with ulceration at day 3 (pink arrow, top left), which 
at day 5 has begun to heal (pink arrow, bottom left). Mice injected with a 
lower dose (108) develop nodules but no ulceration (pink arrows, right). 
 
Figure 5.8 Subcutaneous HkEc back injection causes a large inflammatory 
cell infiltrate at 109 but not at 107 bacteria. H&E staining of skin injection sites 
shows a healing ulcer at day 9 in the highest (109 HkEc) injected dose (left) 
with a large inflammatory cell infiltration, in contrast to skin injected with a 
lower dose (107 HkEc) with minimal inflammatory cell infiltration (pink arrow, 
right) by day 9. Magnification 2.5×, scale bar 1 mm. 
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Figure 5.9 Subcutaneous HkEc back injection in Optn+/+ and Optn-/- mice did 
not show a difference in weight loss or injection site size. Optn+/+ and Optn-/- 
mice were injected with 108 HkEc and monitored over a six day period. 
Results shown are mean ± SEM, n= 18-21 mice/genotype over 3 
independent experiments (two-tailed, unpaired t test). 
5.2.3 Mouse model of intraperitoneal E. coli infection 
When peritonitis was induced in mice with live E. coli there was a dose 
dependent increase in the mortality of both Optn+/+ and Optn-/- mice (Figure 
5.10) but the Optn-/- mice appeared to be slightly more susceptible to E. coli 
inoculation. Compatible with the observed reduction of the release of TNF 
from cultured macrophages, the levels of TNF in the circulation were lower in 
Optn-/- mice (Figure 5.10). 
 The numbers of macrophages and neutrophils in the naïve peritoneum 
of Optn+/+ and Optn-/- mice were not different (Figure 5.11). 24 hours after the 
induction of an E. coli peritonitis, there was a significant reduction in the 
number of CD11b+ F4/80+ macrophages in the peritoneal washout, in both 
Optn+/+ and Optn-/- mice, with no significant differences between them. By 
contrast, Gr1+ neutrophil numbers were significantly increased at 24 hours 
after the induction of peritonitis but the elevation in Optn+/+ animals was 
significantly greater than in Optn-/- mice (p=0.007) (Figure 5.11). 
Representative FACS plots are shown with percentage Gr1+ cells.
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Figure 5.10 Live intraperitoneal E. coli caused greater mortality in Optn-/- mice with significantly lower levels of 
serum TNF. Mortality in Optn+/+ and Optn-/- mice increased with higher doses of bacteria but was significantly 
greater in Optn-/- mice at 5×107 E. coli. There was significantly less serum TNF in the Optn-/- mice at three 
different doses. Results shown are mean ± SEM; n=4-10 mice/genotype, over 4 independent experiments 
(*p<0.05, **p<0.01; two-tailed, unpaired t or logrank test). 
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Figure 5.11 Intraperitoneal E. coli injection resulted in robust recruitment of neutrophils to the peritoneum that was 
significantly impaired in Optn-/- mice. Peritoneal washouts after E. coli injection revealed no statistically significant 
difference (ns) in CD11b+ F4/80+ macrophages or Gr1+ neutrophils in the naïve peritoneum and one day after E. coli 
injection. By contrast, there was significantly less Gr1+ neutrophils recruited (p<0.01) to the Optn-/- peritoneum at day 
one. Representative flow cytometry plots with percentage of Gr1+ neutrophils at day one are shown. Results shown 
are mean (**p<0.01; two-tailed, unpaired t test).
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 5.2.4 Mouse model of Citrobacter rodentium colitis 
To investigate the antibacterial role of OPTN in the bowel, a Citrobacter 
rodentium bacteria induced colitis model was used. Following inoculation 
with Citrobacter, the Optn-/- mice demonstrated increased susceptibility in the 
first two days after Citrobacter inoculation, as evidenced by significantly 
greater weight loss (Figure 5.12) and increased mortality (Figure 5.12). This 
increased susceptibility in the Optn-/- mice was not due to a difference in 
faecal Citrobacter levels (Figure 5.13) and Citrobacter was seen to invade 
the normally sterile large bowel crypts in both Optn+/+ and Optn-/- mice 
(Figure 5.14). 
Citrobacter inoculation resulted in increased serum levels of TNF, IL6 
and CXCL1 in both Optn+/+ and Optn-/- mice at day 2 as compared with naïve 
animals (Figure 5.15). In the Optn+/+ mice, there was a further increase in the 
levels of IL6 and CXCL1 at day 9 whereas the level of TNF remained similar 
to that on day 2. Optn-/- mice released equivalent levels of CXCL1 at day 2 
but demonstrated a less pronounced increase in TNF and IL6 in comparison 
to wildtype animals. By day 9 post Citrobacter inoculation, TNF, IL6 and 
CXCL1 were all significantly lower in Optn-/- compared to Optn+/+ mice. The 
rise in serum IL6 and CXCL1 between day 2 and day 9 seen in Optn+/+ mice 
was not evident in Optn-/- animals.  
Tnf and Cxcl1 gene expression in the large bowel was elevated at day 
2 compared to naïve animals in Optn+/+ mice and further increased at day 9 
(Figure 5.16). In contrast to the diminished serum TNF and CXCL1 levels, 
Tnf and Cxcl1 expression in the Optn-/- mice was not statistically different 
compared to Optn+/+ mice at day 2 and day 9. By contrast, Il6 expression at 
day 2 and day 9 was unchanged compared to naïve mice. 
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Figure 5.12 Citrobacter rodentium induced colitis causes significantly more 
weight loss and mortality in Optn-/- mice compared to Optn+/+ mice. Results 
shown are mean ± SEM; n=29–31 mice/genotype over 5 independent 
experiments (**p<0.01 and ***p<0.001; two-tailed, unpaired t test and logrank 
test). 
 
Figure 5.13 Citrobacter rodentium levels in the faeces at day 2 and 9 were 
no different between Optn+/+ and Optn-/- mice. Results shown are mean ± 
SEM, n=10-26 mice/genotype, over 3 independent experiments (ns, non-
significant; two-tailed, unpaired t test).  
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Figure 5.14 Steiner silver staining of bacteria in the large bowel showed the 
absence of bacteria in the large bowel crypts of naïve mice but the 
abundance of infiltrating Citrobacter rodentium in the crypts of Optn+/+ and 
Optn-/- large bowels. Representative Steiner silver images shown, 20× 
magnification, scale bar 200 µm. Citrobacter rodentium is stained black. 
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Figure 5.15 Citrobacter colitis resulted in lower levels of serum TNF and IL6 
at day 2 and 9 but only at day 9 for CXCL1 in Optn-/- mice. There was no 
difference in serum TNF, IL6 or CXCL1 in naïve mice and at day 2 for 
CXCL1 between Optn-/- and Optn+/+ mice. Results shown are mean ± SEM, 
n=5 mice/group (*p<0.05; two-tailed, unpaired t test). 
 
 
 
Figure 5.16 qRT-PCR of large bowel TNF, IL6 and CXCL1 gene expression 
at day 2 and 9 of Citrobacter colitis was no different between Optn+/+ and 
Optn-/- mice. Results shown are mean ± SEM, relative to naive wildtype 
bowel expression, n=5 mice/genotype (two-tailed, unpaired t test). 
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  Naive colons of Optn+/+ and Optn-/- mice were histologically 
indistinguishable, with no evidence of inflammation (Figure 5.17). However, 9 
days after Citrobacter infection, both groups of mice had developed a colitis 
(Figure 5.17), but the colitis score was significantly higher in the Optn-/- mice, 
with evidence of greater inflammatory cell infiltration, crypt elongation, 
mucosal disruption and loss of goblet cells in Optn-/- compared to Optn+/+ 
bowel. 
To investigate the cellular composition of the inflammatory milieu, we 
performed flow cytometry of cells recovered from whole colonic tissue. Naïve 
tissue contained equivalent numbers of CD11b+ F4/80+ macrophages, CD19+ 
B cells, CD3+ T cells and CD11b+ Gr1+ neutrophils in both Optn+/+ and Optn-/- 
mice (Figure 5.18). Three days after infection with Citrobacter, there was a 
significant increase in neutrophil numbers within the Optn+/+ and Optn-/- 
colons. This early recruitment of neutrophils was significantly lower in Optn-/- 
mice (p=0.024) and the numbers subsequently equalized by day 9. There 
were no changes in the numbers of macrophages or T cells at day 3, but by 
day 9 both cell populations had significantly increased. By contrast, B cells 
were unchanged throughout the inflammatory episode. 
This early defective recruitment of neutrophils in the Optn-/- mice 
during a Citrobacter colitis was visualised using immunohistochemistry of 
myeloperoxidase as a marker for neutrophils in the large bowel (Figure 5.19). 
There were minimal neutrophils in the naïve large bowel but a significant 
number of neutrophils at day 9 of Citrobacter colitis in Optn+/+ and Optn-/- 
mice. By contrast, at day 2 there were less neutrophils in the Optn-/- 
compared to the Optn+/+ large bowel. 
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Figure 5.17 Citrobacter rodentium cause a significantly worse large bowel 
colitis at day 9 in Optn-/- mice. Naïve Optn+/+ and Optn-/- mice do not develop 
a spontaneous colitis but developed a colitis by day 9 (representative H&E 
images shown above, 20× magnification, scale bar 200 µm). Blinded colitis 
scoring (below) revealed a significantly worse colitis in the Optn-/- mice at day 
9. Results shown are mean ± SEM, n=17-20 mice/genotype, over 2 
independent experiments (*p<0.05; two-tailed, unpaired t test). 
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Figure 5.18 Citrobacter rodentium infection resulted in robust recruitment of 
neutrophils to the bowel that was significantly impaired in Optn-/- mice. 
Representative flow cytometry plots at day 3 are shown. Results shown are 
mean ± SEM, n=10-11 mice/genotype over 3 independent experiments 
(*p<0.05; two-tailed, unpaired t test). 
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Figure 5.19 Immunohistochemistry staining of myeloperoxidase for 
neutrophils shows an early defective recruitment of neutrophils in the Optn-/- 
bowel during a Citrobacter infection. Representative histology images are 
shown, magnification 20×, scale bar 200 µm, n=5-10 mice/genotype. Slides 
prepared by UCL-Advanced Diagnostics. 
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  To investigate the effect of being both NOD2 and OPTN deficient, 
Optn-/-Nod2-/- double knockout mice were generated from Optn-/- and Nod2-/- 
mice together with Optn+/+Nod2+/+ mice. Citrobacter rodentium colitis induced 
in Optn+/+Nod2+/+ and Nod2-/- mice showed minimal weight loss (Figure 5.20). 
By contrast, Optn-/-Nod2-/- double knockout mice showed more weight loss 
akin to Optn-/- mice but this was not statistically significant compared to the 
Optn+/+Nod2+/+ and Nod2-/- mice. Survival in the Optn-/-Nod2-/- and Nod2-/- 
mice were not significantly different compared to the Optn+/+Nod2+/+ mice. 
 
 
Figure 5.20 Citrobacter colitis in Nod2-/-, Optn-/-Nod2-/- and Optn+/+Nod2+/+ 
mice did not show any significant survival difference. Results shown are 
mean ± SEM, n=3-13 mice/genotype over 3 independent experiments (two-
tailed, unpaired t and logrank test). 
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 5.2.5 Mouse model of acute DSS colitis 
An acute 2% dextran sodium sulphate (DSS) colitis was used to investigate 
the role of the gut microflora in activating mucosal immunity in the absence of 
OPTN. In contrast to a Citrobacter colitis that is induced by a single 
pathogenic organism, a DSS colitis results in stripping of the epithelium and 
exposure of the Optn-/- large bowel to the whole gut microflora. 
 A 2% acute DSS colitis was chosen since it caused a maximal weight 
loss of 15% original weight in the majority of C57BL/6 wildtype mice, which 
was the cut off for culling of mice on the animal project license (Figure 5.21). 
By contrast, the higher doses of 3% and 5% DSS resulted in maximal weight 
loss of more than 15% and spontaneous death in a number of mice. 
 
Figure 5.21 Acute dextran sodium sulphate (DSS) colitis dose response 
curves shows increasing weight loss with higher doses of DSS. Results are 
mean ± SEM, n=5 mice/group. 
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  The acute DSS experiment was performed with 2% DSS in the 
drinking water of mice for the first seven days with monitoring over a total of 
three weeks. The 2% DSS did not show a difference in weight loss or 
survival in the Optn+/+ and Optn-/- mice (Figure 5.22). Additionally, clinical 
severity scores that encompassed weight loss, the presence of blood in the 
faeces and the severity of diarrhoea was not statistically different between 
Optn+/+ and Optn-/- mice (Figure 5.23). The onset of blood in the faeces on 
faecal occult blood testing was also not different between the genotypes 
(Figure 5.23). 
 Histological assessment at the peak of the colitis at day 7 and during 
the recovery phase of the colitis at day 14 did not reveal a difference in 
blinded colitis scores between Optn+/+ and Optn-/- mice (Figure 5.24). 
Unblinded review of histological specimens identified areas of 
reepithelialisation at day 14 but not at day 7 (Figure 5.24). Large bowel 
lengths measured in naïve mice were not significantly different between 
Optn+/+ and Optn-/- mice (Figure 5.25). During the 2% DSS colitis, large bowel 
length at day 7 was significantly shorter than naïve mice (p=0.035), but not at 
day 14 compared to naïve mice. Large bowel length at day 21 was 
significantly longer than day 14, 7 and naïve mice. However, large bowel 
lengths between Optn+/+ and Optn-/- mice at day 7, 14 and 21 were not 
statistically different. 
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Figure 5.22 Acute 2% DSS colitis results in similar weight loss and mortality 
in Optn-/- and Optn+/+ mice. Results shown are mean ± SEM, n=35-38 
mice/genotype, over 3 independent experiments (ns, not significant; two-
tailed, unpaired t test and logrank test). 
 
 
Figure 5.23 Acute 2% DSS colitis did not cause a significant difference in 
clinical scores or onset of blood in the faeces between Optn-/- and Optn+/+ 
mice. Clinical score (left) and % mice with bloody diarrhoea (right) are 
shown. Results shown are mean ± SEM, n=10-20 mice/genotype, over 3 
independent experiments (ns, not significant; two-tailed, unpaired t test). 
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Figure 5.24 An equally severe colitis was induced by 2% DSS in Optn-/- and 
Optn+/+ mice. Representative H&E stain of acute 2% DSS colitis in the large 
bowel (above) of Optn-/- and Optn+/+ mice. At day 7 there is widespread 
mucosal destruction, oedema and inflammatory cell infiltration. At day 14, 
there is re-epithelialisation of the mucosa. Blinded scoring at day 7 and 14 
(below) did not reveal a significant difference in large bowel colitis scores in 
Optn-/- and Optn+/+ mice. Results shown are mean ± SEM, magnification 15×, 
scale bar 200 µm, n=3-5 mice/genotype (ns, not significant; two-tailed, 
unpaired t test). 
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Figure 5.25 There is no difference in large bowel length between naive Optn-
/- and Optn+/+ mice or at day 7, 14 and 21 of an acute 2% DSS colitis. 
Representative images of Optn-/- and Optn+/+ large bowel in naïve, day 7, 14 
and 21 of DSS are shown (scale bar 20 mm). Results shown are mean ± 
SEM, n=4-10 mice/genotype (ns, not significant; two-tailed, unpaired t test). 
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  Again, to investigate the effect of being both NOD2 and OPTN 
deficient, Optn-/-Nod2-/- double knockout mice were compared with 
Optn+/+Nod2+/+ mice. Acute 2% DSS colitis induced in Optn-/-Nod2-/-, Nod2-/- 
and Optn+/+Nod2+/+ mice showed similar weight loss to 80% original weight in 
all three genotypes that were not statistically different between genotypes 
(Figure 5.26). However, the Nod2-/- mice did show a slightly slower recovery 
of weight (green line) compared to the Optn-/-Nod2-/- and Optn+/+Nod2+/+ mice 
that was not significantly different. Survival in the Optn-/-Nod2-/-, Nod2-/- and 
Optn+/+Nod2+/+ mice were also not significantly different between genotypes. 
 
Figure 5.26 Acute 2% DSS colitis results in similar weight loss and mortality 
in Optn-/-Nod2-/-, Optn+/+Nod2+/+ and Nod2-/- mice. Results shown are mean ± 
SEM, n=7-13 mice/genotype, over 3 independent experiments (ns, not 
significant; two-tailed, unpaired t test and logrank test). 
 
5.2.6 Mouse model of chronic DSS colitis 
To assess if the slower recovery from a colitis in the Nod2-/- mice was 
important and had a bearing on further episodes of colitis in the Nod2-/- mice 
as well as the Optn-/-, Optn-/-Nod2-/- and Optn+/+ mice, a chronic 2% DSS 
colitis was performed.  
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 Mice were exposed to 7 days of 2% DSS then exposed to 2% DSS for 
a further 7 days after 14 days of recovery. The initial colitis proved to be 
protective and as a result the 2nd exposure to DSS only resulted in minimal 
weight loss (Figure 5.27). Extending the recovery to 28 days after the 2nd 
exposure to DSS resulted in similar weight loss in the 3rd exposure of DSS as 
experienced in the 1st exposure.  
 Weight loss in the Optn-/-Nod2-/- mice was similar compared to the 
Optn+/+ mice but the Nod2-/- mice exhibited significantly reduced weight 
during the recovery phase after the 1st exposure to DSS, which did not fully 
recover thereafter in the 2nd and 3rd exposure periods. 
 
 
Figure 5.27 Chronic 2% DSS colitis did not cause a difference in weight loss 
of Optn+/+, Optn-/-, Nod2-/- and Optn-/-Nod2-/- mice but may cause a difference 
in weight recovery in Nod2-/- mice. Chronic 2% DSS was performed with DSS 
given at day 0 to 7, 21 to 28 and 56 to 63 (dotted vertical lines). Recovery 
from DSS to 100% original weight (horizontal solid line) was slowest in the 
Nod2-/- mice whilst the Optn-/-Nod2-/- was intermediate compared to Optn+/+ 
mice. Results shown are mean ± SEM, n=5-15 mice/genotype. 
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 5.3 Discussion 
In Chapter 3, low OPTN expression in macrophages from CD patients 
was identified and was associated with inheritance of a minor allele in a SNP 
downstream of the last OPTN exon. In Chapter 4, OPTN was localised to the 
Golgi complex in macrophages, and the absence of OPTN was associated 
with reduced proinflammatory TNF and IL6 secretion due to mistrafficking via 
a bafilomycin A dependent pathway to lysosomes. In this chapter, in vivo 
studies were performed to look at the effect of OPTN knockdown or knockout 
on bacterial handling and specifically colitis. 
In situ hybridisation in zebrafish embryos and larvae localised optn to the 
brain, eyes and intestinal bulb (Figure 5.1), which was upregulated when 
zebrafish were infected with Salmonella (Figure 5.2). Additionally, Salmonella 
infection resulted in significantly higher mortality in optn knockdown zebrafish 
compared to wildtype and control morpholino knockdown (Figure 5.3). This 
suggests that OPTN is localised to the gut and has an evolutionarily 
conserved function in bacterial handling and survival even in zebrafish, which 
are an evolutionarily divergent species from humans. 
A recently published paper found that zebrafish injected with OPTN-
specific translation blocking morpholinos resulted in a curved tail phenotype 
similar to zebrafish overexpression SOD1 G93A, an ALS associated variant 
[270]. There was no report of a curved tail phenotype in the zebrafish with 
the morpholino used, but a review of the literature in zebrafish identified 
different genetic knockdowns or treatments in zebrafish that resulted in 
curved tails [271-273]. This suggests that the reported curved tail phenotype 
seen with OPTN knockdown may be a non-specific outcome of morpholino 
use rather than specifically related to OPTN gene knockdown. 
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 To investigate if the absence of OPTN results in an innate immune 
defect, HkEc was injected subcutaneously, which resulted in an acute 
inflammatory response that was dose dependent but weight and injection site 
size was not different between Optn+/+ and Optn-/- mice. The study was 
limited by variability in the measurement of the injection site size as well as a 
lack of an established method to digest down the inflammatory skin site to 
assess cellular recruitment or local cytokine release. 
An intraperitoneal injection of E. coli was performed which allowed for 
assessment of mortality, serum cytokine levels as well as cellular recruitment 
to the peritoneal cavity. Notably, the phenotype of impaired TNF release and 
defective neutrophil recruitment in CD patients was replicated here in the 
Optn-/- mice. Live intraperitoneal E. coli resulted in greater mortality in the 
Optn-/- mice with increasing doses of E. coli except in the highest dose tested 
likely due to overwhelming sepsis in both the wildtype and knockout mice. 
Serum TNF levels increased with higher levels of E. coli used in the wildtype 
mice, which also rose in the Optn-/- mice but was consistently lower 
compared to wildtypes.  
 Intraperitoneal CD11b+ F4/80+ macrophages were no different in the 
naïve peritoneum and on day 1 after intraperitoneal E. coli inoculation. 
Macrophage numbers were lower on day 1 due to activation and adherence 
of macrophages to the peritoneum resulting in a reduction in macrophages 
from the intraperitoneal washout [274, 275]. Neutrophils are recruited to the 
peritoneal cavity as seen in wildtype mice [274] but importantly there was 
early defective neutrophil recruitment at day 1 in the Optn-/- peritoneal cavity. 
The defective neutrophil recruitment may be related to the impaired TNF 
secretion that has resulted in a defective intraperitoneal neutrophil 
recruitment and subsequent increased mortality in the Optn-/- mice. 
The discovery of an OPTN deficiency in CD focussed attention on the 
role of OPTN in the development of colitis. Citrobacter rodentium is an 
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 enteropathic bacteria that results in colitis in mice in a similar way to 
enteropathogenic E. coli. Optn-/- mice experienced greater weight loss and 
higher mortality in a Citrobacter colitis. This occurred despite similar levels of 
faecal Citrobacter and invasion into the normally sterile crypts in both 
wildtype and knockout mice. This occurred in the presence of reduced levels 
of serum proinflammatory TNF, IL6 and CXCL1 in the Optn-/- mice with no 
difference in Tnf, Il6 and Cxcl1 gene expression in the large bowel. The Optn-
/- mice experienced a greater colitis later at day 9, with an early defective 
recruitment of neutrophils to the large bowel at day 3. 
NOD2 is the strongest genetic risk factor for developing CD. Nod2-/- mice 
were previously found to have impaired intestinal clearance of Citrobacter 
with reduced CCL2 production and monocyte recruitment [276]. To see if the 
absence of Nod2 would result in an additive susceptibility to a bacterial 
colitis, we generated Optn-/-Nod2-/- double knockouts. The Nod2-/- mouse did 
not show a drop in weight and the Optn-/-Nod2-/- resulted in an early weight 
loss that was not statistically significant, diminishing the effect of the absence 
of OPTN. 
The dextran sodium sulphate (DSS) model of colitis is a commonly used 
model of chemical induced colitis that results in DSS induced cytotoxicity of 
the bowel epithelium that resembles human ulcerative colitis [268, 277]. An 
acute 2% DSS colitis did not result in a difference in weight loss, mortality, 
clinical score or the onset of bloody diarrhoea in the Optn-/- and Optn+/+ mice. 
Additionally there was no difference in large bowel length or colitis score at 
the peak of colitis on day 7 or during the resolution phase of the colitis on day 
14 between wildtype and OPTN deficient mice. This is not surprising since 
OPTN deficiency was not identified in UC patients but exclusively in CD 
patients and as such Optn-/- mice would not be expected to suffer a more 
severe ‘UC-type’ colitis. We hypothesise that the lack of difference is due to 
mucosal exposure to colonising microflora in both the wildtype and knockout 
bowel that is independent of OPTN in contrast to the invasion of Citrobacter 
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 rodentium that is OPTN dependent and results in an exaggerated bacteria 
induced colitis. 
Nod2-/- mice did not experience increased weight loss or mortality in the 
acute 2% DSS colitis compared to wildtype mice but did show reduced 
recovery of weight that did not reach statistical significance (Figure 5.26). By 
contrast, Optn-/-Nod2-/- double knockout mice experience weight loss that 
was indistinguishable from wildtype mice. Initial studies did not show an 
increased susceptibility to an acute DSS colitis in Nod2-/- mice [278] but later 
studies have shown increased susceptibility in Nod2-/- mice [279, 280]. It is 
not clear why these differences in response exist, possible explanations 
include the small numbers of mice used in some of the experiments, 
differences in gut microflora in different animal units or subtle genetic 
differences that exist among inbred C57BL/6 mice [281]. 
When Nod2-/- mice were subject to repeated exposure to DSS in a 
chronic DSS model of colitis, Nod2-/- mice were slow to regain weight with 
repeated exposure to DSS in contrast to Optn-/-Nod2-/- and Optn-/- mice that 
were no different from wildtype mice (Figure 5.27). Whilst inheritance of 
NOD2 variants is associated with an increased risk of CD, it has protective 
effects in UC [100]. It is therefore not surprising that the absence of NOD2 
results in a defect in a UC-like model of colitis. The impaired recovery in 
weight with each subsequent DSS insult likely renders mice incapable of an 
adequate responds to further insults that may provide insights into the 
pathogenesis of UC. This interesting discovery warrants further investigation. 
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 Chapter 6 General Discussion 
6.1 Summary of investigations conducted and novel findings 
CD is a complex, multifaceted disease that predominantly manifests in the GI 
tract with patchy transmural inflammation and granulomas. We previously 
showed that CD is characterised by impaired neutrophil recruitment and 
defective bacterial clearance from sites of inoculation [107]. The phenotype 
of CD was associated with decreased proinflammatory TNF cytokine release 
from macrophages of CD patients when stimulated with HkEc [187]. 
Differential gene expression analysis in CD macrophages on microarray 
identified genes involved in vesicle trafficking. This defective TNF secretion 
by CD macrophages on bacterial stimulation has been replicated by others 
[282, 283]. 
6.2 Discussion of findings, implications and study limitations 
The cause of defective cytokine secretion in CD is still elusive. To 
identify potential candidate genes involved in defective cytokine secretion we 
analysed the transcriptome of macrophages. The identification of reduced 
OPTN expression in approximately a tenth of our CD patients provided 
evidence that it may play a role in the cytokine secretion defect observed, 
underpinned by its established role in vesicle trafficking and secretion [201, 
204]. 
Our initial studies demonstrated that upon depletion of OPTN using 
siRNA knockdown, proinflammatory cytokine secretion was reduced [191]. 
We have now expanded these initial findings and identified a major in vivo 
role for OPTN in the inflammatory response in the bowel. The loss of OPTN 
in knockout mice and diminished levels in CD patients did not result in 
complete loss of cytokine secretion, pointing to redundancy in the regulation 
of these secretory pathways. However, partial impairment of the secretion of 
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 proinflammatory cytokines may be pathologically relevant when the host is 
exposed to a large quantity of bacteria requiring an immediate, robust 
inflammatory response.  
This type of defect is highly relevant in the case of CD where we have 
previously demonstrated a dose dependent immune deficiency in these 
individuals [187, 284]. A breach in the mucosal wall could result in the 
exposure of the underlying tissue to an enormous bacterial challenge, which 
will need rapid containment and clearance. This may be particularly relevant 
in the terminal ileum where there is the greatest transition from a relatively 
low level of bacteria in the small bowel to the caecum where this is a high 
concentration of bacteria. Ten out of eleven of our OPTNlow CD patients had 
ileal involvement of their CD. Reduced OPTN expression, inheritance of 
NOD2, ATG16L1 variants or congenital monogenic innate 
immunodeficiencies will impact directly on the efficiency of this response, 
failure of which could result in inadequate clearance of foreign material and 
the development of chronic inflammation. 
The role of OPTN in intracellular trafficking in non-immune cells has 
been well characterised. OPTN has been shown to localise to the Golgi 
complex and play an important role in vesicle trafficking through the 
formation of macromolecular complexes, which include numerous binding 
partners such as Rab8, HTT and myosin VI. The role and composition of the 
OPTN containing complex in vesicle trafficking is only partially elucidated. 
Previous studies have provided evidence of a role in protein sorting within 
the Golgi complex and trafficking to the plasma membrane [201]. 
Replacement of OPTN’s binding partner HTT with a 111Q polyglutamine 
mutant resulted in reduced localization of OPTN to the Golgi complex and 
impaired post-Golgi trafficking in striatal cells [206]. Depletion of OPTN with 
siRNA in HeLa cells also resulted in dramatically reduced exocytosis.  
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 However, these studies did not look at the role of OPTN in the context 
of bacterial or TLR stimulation that is relevant in the context of CD. More 
recently, a mouse in which wild-type OPTN was replaced by the polyubiquitin 
binding-defective OPTN mutant, demonstrated an abrogated response to 
LPS in BMDM due to impaired activation of TANK-binding kinase 1 [200]. 
This was associated with defective interferon-β release but TNF and IL6 
secretion was described as normal in these mice [213]. This is in contrast to 
our findings of defective cytokine secretion, which indicates that TNF and IL6 
secretion is partially dependent on the expression of OPTN but independent 
of its ability to bind ubiquitin in BMDM. 
Cytokine trafficking in macrophages is complex and only partially 
understood. Previous work has shown that TNF and IL6 share a common 
pathway of secretion from the trans-Golgi network to endosomes where they 
are then dynamically segregated [162, 171].  In contrast, IL10 is secreted via 
both endosome-dependent and independent pathways [172]. Others have 
also shown that OPTN only minimally colocalises to the endosomal 
compartment [214]. BMDM that lack OPTN demonstrate a reduced overlap 
between TNF and the endosomal compartment. These findings would 
indicate that the role of OPTN in the defective release of TNF and IL6 in 
BMDM lies in its role in sorting proteins for transport at the Golgi complex.   
Inclusion of a range of protein trafficking inhibitors results in increasing 
the level of TNF within the cells. The reduction in secreted protein coupled 
with the generation of equivalent levels of intracellular protein after bacterial 
stimulation provides evidence to support our previous findings in CD patients 
of cytokine mistrafficking. Inclusion of bafilomycin A an inhibitor of vacuolar 
H+-ATPases (V-ATPases), results in a greater intracellular build-up of the 17 
kDa secreted form of TNF in OPTN deficient BMDM than wildtypes. These 
findings suggest that in the absence of OPTN a greater proportion of TNF is 
trafficked through a V-ATPase dependent compartment and degraded 
instead of being released at the plasma membrane (Figure 6.1). It has also 
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 been demonstrated that OPTN can function at the plasma membrane and 
facilitate the final fusion event of vesicle trafficking. We cannot completely 
rule out a role for OPTN at the plasma membrane in BMDM, but our results 
suggest that it does not play a major role in TNF secretion. In fibroblasts, 
knocking down OPTN, which is required for the final step in the vesicle 
plasma membrane fusion results in a dramatic increase in the number of 
docked vesicles at the cell surface. This causes a build-up of vesicle cargo 
protein within these cells. BMDM devoid of OPTN demonstrate no such 
build-up at the plasma membrane or within the cell, which argues against the 
same process occurring in these cells.  
Reduced TNF and IL6 release was shown to coincide with defective 
neutrophil recruitment after bacterial induced inflammation in both the bowel 
and peritoneum of OPTN deficient mice. In both inflammatory models an 
increased systemic response was recorded and this contributed to an 
increased colitis and greater mortality. Alterations in cytokine levels can have 
profound effects on the outcome of infections and inflammatory episodes. 
Previous studies have demonstrated an elevation in inflammation resulting 
from a deficiency in TNF expression [285]. TNF knockout mice are more 
susceptible to bacterial infection and generate a more severe colitis than 
control mice [286, 287].  
204 
 
  
Figure 6.1 TNF trafficking in macrophages. TNF is packaged at the Golgi 
apparatus by OPTN to be secreted via the recycling endosome. The absence 
of OPTN results in degradation of TNF via a bafilomycin A dependent 
pathway involving lysosomes. As a result, inhibition of lysosomal function 
results in normalisation of TNF whilst bafilomycin A results in significantly 
higher TNF levels in the Optn-/- compared to Optn+/+ macrophage. AP, 
autophagosome; APL, autophagolysosome; Ly, lysosome; EE, early 
endosome; LE, late endosome; RE, recycling endosome; EL, endolysosome.  
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 Additionally, patients with ankylosing spondylitis and juvenile arthritis 
treated with etanercept, a fusion protein made up of the TNF-receptor II 
extracellular domain fused with the Fc fragment of IgG1 were reported to 
develop CD [53-61]. The association of etanercept with CD is not seen with 
the other anti-TNF agents infliximab and adalimumab. This difference may be 
explained by infliximab’s apoptotic action (via binding to transmembrane 
TNF) on T cells, which etanercept lacks in contrast to binding and 
neutralisation of soluble TNF [62].   These findings provide evidence that 
TNF has a protective role in the acute phase of an inflammatory response 
and the release of suboptimal TNF levels could result in the development of 
chronic inflammation.  
Noteworthy is the lack of a difference in weight loss or mortality in the 
mice treated with DSS. We hypothesise that the lack of an effect may be 
related to the fact that DSS mimics a more UC type colitis that starts distally 
in the large bowel whereas the Citrobacter model more closely mimics a 
proximal colitis as the inoculated bacteria transitions from the small bowel to 
the caecum and large bowel. Additionally, the difference may be explained 
by an invasion of the bowel with a single pathogen that is in the mouse akin 
to enteroinvasive E. coli is to humans, which resembles CD more and that 
the chemically induced stripping and subsequent exposure of the gut mucosa 
to all the resident gut flora does not require OPTN in immune cells. 
6.3 Future directions 
The work presented in this thesis has highlighted further experiments and 
new exciting areas for future research, such as: 
• Further human work, in the eleven OPTNlow CD patients such as 
staining of bowel tissue for macrophage, B and T cell markers to 
characterise the lamina propria cells with low OPTN expression, to 
look at proinflammatory cytokine secretion from these OPTNlow MDM 
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 on HkEc stimulation, in vivo neutrophil recruitment, bacterial clearance 
studies and OPTN expression in bowel biopsies especially the ileum.  
• An interesting study may be to identify families that express low OPTN 
and inherit the associated SNP to see if ileal and colonic OPTN 
expression is attenuated especially family members who may not yet 
have CD but have altered OPTN levels, to look at proinflammatory 
cytokine secretion in their MDM. 
• To study autophagy using Salmonella in Optn-/- BMDM to see if there 
is a defect in the induction of autophagy when BMDM are infected with 
Salmonella that evade phagosomes and autophagy is required. 
• Bone marrow transfer experiments in the Citrobacter colitis model to 
see if the neutrophil recruitment defect can be reproduced in wildtype 
mice grafted with Optn-/- bone marrow cells and if defective neutrophil 
recruitment can be reversed in Optn-/- mice grafted with wildtype bone 
marrow.  
• Alternatively, to see if the defect in neutrophil recruitment is due to 
reduced proinflammatory TNF secretion, administration of TNF to the 
Optn-/- mice infected with Citrobacter may then reverse the defective 
neutrophil recruitment. However, these experiments may be limited by 
incorrect doses and mode of TNF administration used.  
• To investigate if there are differences in the gut microflora of Optn+/+ 
and Optn-/- mice that may account for the differences in response to 
Citrobacter infection and whether co-housing mice may alter the 
response to Citrobacter. 
6.4 Conclusion 
The present results demonstrate a role for OPTN in macrophage cytokine 
secretion, neutrophil recruitment to sites of bacterial infection and bowel 
inflammation in vivo. Bacterial exposure upregulates OPTN expression in 
human and murine macrophages, which is associated with the secretion of 
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 proinflammatory cytokines and subsequent recruitment of neutrophils into 
inflamed tissue. OPTN deficiency results in increased susceptibility to 
bacterial infection and the development of exaggerated inflammation in the 
bowel. The phenotype identified in mice mirrors our findings in CD patients, 
reinforcing the suggestion that the reduced expression of OPTN could play 
an important role in the development of bowel inflammation in humans.     
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 Appendix 1 Primers, probes and morpholinos used 
Mouse primers used 
Gene Primer pair Primer sequence Size (bp) 
Mouse genotyping primers 
 Wildtype Optn Optn_47570 F 5'-ACCACACGATGGCTCACAAC-3' 435 
 Optn_47570 R 5'-GTGTCTCAAAACAACAAATTCTCCC-3'  
Mutant Optn Optn_47570 F 5'-ACCACACGATGGCTCACAAC-3' 238 
 CAS_R1_Term x 5'-TCGTGGTATCGTTATGCGCC-3'  
Wildtype Nod2 oIMR4112 F 5'-ACAGAGATGCCGACACCATACTG-3' 370 
 oIMR4113 R 5'-TGGAGAAGGTTGAAGAGCAGAGTC-3'  
Mutant Nod2 oIMR4114 F 5'-TGACTGTGGCTAATGTCCTTTGTG-3' 1000 
 oIMR6955 R 5'-TTCTATCGCCTTCTTGACGAGTTC-3'  
 Mouse qRT-PCR primers 
Optn mOptn2 F 5'-GAGCAGCTGGCCTTGCA-3' 73 
 mOptn2 R 5'-ACTGTCTACTGCCTCCCTCTTCA-3'  
Tnf mTnf F 5'-CTGAACTTCGGGGTGATCGG-3' 122 
 mTnf R 5'-GGCTTGTCACTCGAATTTTGAGA-3'  
Cxcl1 mCxcl1 F 5'-ACTGCACCCAAACCGAAGTC-3' 114 
 mCxcl1 R 5'-TGGGGACACCTTTTAGCATCTT-3'  
Il6 mIL6 F 5'-CGCTATGAAGTTCCTCTCTGCAA-3' 64 
 mIL6 R 5'-CACCAGCATCAGTCCCAAGAA-3'  
Il10 mIL10 F 5'-GCTGGACAACATACTGCTAACC-3' 78 
 mIL10 R 5'-ATTTCCGATAAGGCTTGGCAA-3'  
Ppia mPpia F 5'-GGGCCGCGTCTCCTTT-3' 86 
 mPpia R 5'-ATCCTTTCTCTCCAGTGCTCAGA-3'  
Mcm10 mMcm10 F 5'-TCCCAGCCAAGAGAAAACCA-3' 115 
 mMcm10 R 5'-CCCTGGAGGCTGTTTAATTG-3'  
Ccdc3 mCcdc3 F 5'-CTACTTCTCCTGCCACTCCC-3' 93 
  mCcdc3 R 5'-CCGTGTGGCAAGAGATTGTA-3'   
Mouse RT-PCR primers 
Optn mOptn ex2-4 F 5'-CTGACTGAGAAGGGGGACAG-3' 367 
  mOptn ex2-4 R 5'-ACCTGTAGCCACCTGTGAGG-3'   
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 Zebrafish primers, probes and morpholinos used 
Gene Primer pair Primer sequence Size (bp) 
Zebrafish in situ hybridisation probe 
optn optineurin Fw455 5'-GCCAGAACCAGACTGAACACTATGG-3' - 
  optineurin Rv1736 5'-GGACTTCCCCACATTTAGGACAAG-3'   
Zebrafish morpholinos (MO) 
optn optn MO 5'-AGAGCCTCTGTGGGATGCATATAAT-3' - 
control control MO 5'-CCTCTTACCTCAGTTACAATTTATA-3'   
Zebrafish qRT-PCR primers 
optn optn qFw1163 5'-TCGATGAGATGAAGATGGAACTATTC-3' 77 
 optn qRv1239 5'-TTCTGCCTGTGCCTGGAAA-3'  
ef1alpha ef1alpha qFw 5'-TGCCTTCGTCCCAATTTCAG-3' 101 
  ef1alpha qRv 5'-TACCCTCCTTGCGCTCAATC-3'   
Zebrafish RT-PCR primers 
optn optn sFw62 5'-GGCTGACTGTAACGCACCAATC-3' 360 
 optn sRv421 5'-CTCCTTCTGCTTCTCCTTCCAAG-3'  
ef1alpha ef1alpha sFw 5'-ATCTACAAATGCGGTGGAAT-3' 299 
  ef1alpha sRv 5'-ATACCAGCCTCAAACTCACC-3'   
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 Appendix 2 Address of Chemical Suppliers and Equipment 
Manufacturers 
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Abbott House 
Vanwall Business Park 
Vanwall Road 
Maidenhead 
Berkshire SL6 4XE 
 
Abcam plc 
330 Cambridge Science Park 
Milton Road 
Cambridge CB4 0FL 
 
ABR Affinity BioReagents 
4620 Technology Drive 
Suite 600 
Golden, CO 
United States of America 
 
Agar Scientific/ 
Elektron Technology (UK) Ltd 
Unit 7, M11 Business Park 
Parsonage Lane 
Stansted CM24 8GF 
 
BD 
The Danby Building 
Edmund Halley Road 
Oxford Science Park 
Oxford OX4 4DQ 
 
Beckman Coulter (UK) Ltd 
Oakley Court 
Kingsmead Business Park 
London Road 
High Wycombe HP11 1JU 
 
Bioline Reagents Ltd 
16 The Edge Business Center 
Humber Road 
London NW2 6EW 
 
 
Bio-Rad Laboratories Ltd 
Bio-Rad House 
Maxted Road 
Hemel Hempstead 
Hertfordshire HP2 7DX 
 
BMG Labtech Ltd 
5 Alton House Office Park 
Gatehouse Way 
Aylesbury 
Buckinghamshire HP19 8YB 
 
Calbiochem/Merck Serono Ltd 
Bedfont Cross 
Stanwell Road 
Feltham 
Middlesex TW14 8NX 
 
Cecil Instruments Ltd 
Milton Technical Centre 
Cambridge CB24 6AZ 
 
CellPath Ltd 
Unit 80 Mochdre Enterprise Park 
Newtown 
Powys SY16 4LE 
 
Clontech/Takara Bio Europe SAS 
2 Avenue du President Kennedy 
78100 Saint-Germain-en-laye 
France 
 
CSL Behring UK Ltd 
Hayworth House 
Market Place 
Haywards Heath 
West Sussex RH16 1DB 
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 Dako UK Ltd 
Cambridge House 
St Thomas Place 
Ely 
Cambridgeshire CB7 4EX 
 
eBioscience Ltd 
2nd Floor, Titan Court 
3 Bishop Square 
Hatfield 
Hertfordshire AL10 9NA 
 
Enzo Life Sciences (UK) Ltd/ 
Alexis Biochemicals 
Palatine House 
Matford Court 
Exeter EX2 8NL 
 
Eppendorf (UK) Ltd/Innova 
Eppendorf House 
Gateway 1000 Whittle Way 
Arlington Business Park 
Stevenage SG1 2FP 
 
Eurofins Genomics 
Anzingerstr. 7a 
85560 Ebersberg 
Germany 
 
GE Healthcare Ltd/Amersham/ 
PAA Laboratories 
Amersham Place 
Little Chalfont  
Buckinghamshire HP7 9NA 
 
GraphPad Software, Inc. 
7825 Fay Avenue 
Suite 230 
La Jolla, CA 92037 
United States of America 
 
Immunostics Inc. 
1750 Brielle Ave 
Ocean, NJ 07712 
United States of America 
 
 
LEEC 
Private Road No. 7 
Colwick Industrial Estate 
Nottingham NG4 2AJ 
 
Leica Microsystems (UK) Ltd 
Larch House 
Woodlands Business Park 
Breckland 
Linford Wood 
Milton Keynes MK14 6FG 
 
Life Technologies Ltd/ 
Gibco/Invitrogen/ 
Applied Biosystems/Ambion 
3 Fountain Drive 
Inchinnan Business Park 
Paisley PA4 9RF 
 
Lonza Biologics plc/Amaxa 
Suite 3, Building A 
The Courtyard 
Severn Drive 
Tewkesbury Business Park 
Tewkesbury GL20 8GD 
 
Merck Chemicals Ltd 
Boulevard Industrial Park 
Padge Road 
Beeston  
Nottingham NG9 2JR 
 
Meso Scale Discovery 
1601 Research Boulevard 
Rockville, MD 20850-3173 
United States of America 
 
MP Biomedicals 
Wellington House 
East Road 
Cambridge CB1 1BH 
 
New England Biolabs Ltd 
75-77 Knowl Piece 
Wilbury Way 
Hitchin SG4 0TY 
 
237 
 
 Peprotech 
Peprotech House 
29 Margravine Road 
London W6 8LL 
 
Promega 
Delta House 
Southampton Science Park 
Southhampton SO16 7NS 
 
Qiagen 
Qiagen House 
Fleming Way 
Crawley 
West Sussex RH10 9NQ 
 
R&D Ltd 
19 Barton Lane 
Abingdon Science Park 
Abingdon OX14 3NB 
Santa Cruz Biotechnology, Inc. 
Bergheimer Str 89 
2 Heidelberg 
69115 Germany 
 
Sigma-Aldrich Company Ltd 
The Old Brickyard 
New Road 
Gillingham 
Dorset SP8 4XT 
 
Scientific Laboratory Supplies Ltd 
Wilford Industrial Estate 
Ruddington Lane 
Wilford 
Nottingham NG 11 7EP 
 
Thermo Fisher Scientific UK/ 
RA Lamb 
Bishop Meadow Road 
Loughborough LE11 5RG 
 
TreeStar, Inc. 
385 Williamson Way 
Ashland, OR 97520 
United States of America 
 
UVItec Ltd 
Unit 36, St John’s Innovation 
Centre 
Cowley Street 
Cambridge CB4 0WS 
 
VWR International Ltd/BDH 
Prolabo 
Hunter Boulevard 
Magna Park 
Lutterworth 
Leicester LE17 4XN 
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Disruption of macrophage pro-inflammatory cytokine release in Crohn's 
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patients. Immunology 2015. 144:45-55. 
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 Appendix 5 Presentations & Prizes 
 
Oral presentation 
12th Annual North West Gastroenterology Meeting 
Lytham St Annes, United Kingdom 2014 
  
Best Oral Communication Prize 
Gut and Liver Inflammation: A Translational Science Masterclass 
British Society of Gastroenterology Annual Conference 
Manchester, United Kingdom 2014 
 
Oral presentation 
12th Annual Bardhan Fellowship Meeting 
Sheffield, United Kingdom 2014  
 
Best digital oral poster award 
9th European Crohn’s and Colitis Organisation Congress 
Copenhagen, Denmark 2014 
 
Poster presentation 
Keystone symposia: Molecular Cell Biology of Macrophages in Human 
Diseases  
Santa Fe, United States of America 2014 
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